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EFFECT OF EURYCOMA LONGIFOLIA SUPPLEMENTATION: AN 
EVALUATION OF CELL GROWTH, EXERCISE PERFORMANCE AND 




Eurycoma longifolia is often prescribed in complementary and alternative medicine. 
The extract has gained a reputation for boosting sexual performance, mood, muscle mass, 
and strength by increasing testosterone levels in males facing low testosterone levels, 
stress, and lack of energy due to ageing. E. longifolia has demonstrated the ability to 
regulate testosterone production by affecting the hypothalamic-pituitary axis in animals, 
but this phenomenon has not been thoroughly examined in humans. Even though studies 
are limited, E. longifolia supplementation has shown improvement in exercise 
performance and wellbeing. This murine and human study has four primary aims: (1) to 
examine the cytotoxicity of E. longifolia on skeletal muscle cells; (2) to elucidate the 
effect of E. longifolia supplementation in terms of selected reproductive hormonal 
changes; (3) to compare the short-term versus long-term effects of  E. 
longifolia supplementation on psychological mood state and sexual function among 
young participants; (4) to determine the ergogenic properties of E. longifolia with regard 
to exercise performance following supplementation among young participants.  
 
This work’s main findings show higher cytotoxicity levels in the control treatment 
(CON) treated with a differentiation medium compared to skeletal muscle cells (SMC) 
treated with E. longifolia. An increase in lactate dehydrogenase activity was observed 
from 96 to 144 hours with a 4.4, 3.8 and 3.3 (CON > 0.5 mg/ml > 1.0 mg/ml) fold increase 
and 4.4, 3.3 and 3.9 (CON > 1.0 mg/ml > 0.5 mg/ml) fold increase in passage 13 and 26, 
iv 
respectively. While findings have shown that SMC exposure to E. longifolia treatment 
did not exhibit any toxicity, there is an increase in cell viability in E. longifolia treated 
cells.   
 
With regard to hormonal changes, short-term supplementation of 600 mg/day showed 
an increase in testosterone (0.97 ng/ml, 11.1%; p = 0.004), while long-term 
supplementation showed an increase up to week 4, then a decrease (0.142 ng/ml, 2%; p > 
0.05) at week 8. Neither short nor long-term supplementation showed any significant 
changes in luteinising hormone (LH) and estradiol. Findings also show that the changes 
in testosterone are not due to the extract influencing the hypothalamic-pituitary gland 
axis. In addition, the dosage did not exhibit deleterious effects on liver functions, 
demonstrating that supplementation E. longifolia for 8 weeks is safe for consumption.  
 
When investigating duration, short-term supplementation of E. longifolia 
demonstrated an improvement in mood state domains, such as anger (5.12%) and fatigue 
(11.09%); long-term supplementation seemed to affect tension (8.19%) and anger 
(4.14%). These findings indicate that supplementation of E. longifolia improves certain 
mood state domains, indicating that this extract may be an effective remedy to improve 
daily mood states affected by daily stress. Meanwhile, the sexual function test was 
measured through self-reported data. Short-term supplementation showed improvement 
in the ejaculation domain (6.13%), and after long-term supplementation, the erection 
(25.89%) and overall satisfaction (33.33%) domains. The present study showed 
improvement in sexual function upon completing the E. longifolia supplementation 
programme, providing evidence of E. longifolia acting as an aphrodisiac, a substance that 
increases sexual desire, sexual attraction, sexual pleasure, or sexual behaviour.  
 
v 
The effect of E. longifolia following the 8-week supplementation showed no 
improvements in isokinetic strength or anaerobic power. Hence, the supplementation of 
E. longifolia alone did not exhibit any ergogenic effects among young adults, which may 
be due to the lack of changes in the circulating testosterone levels after 8-weeks of E. 
longifolia supplementation.    
 
In conclusion, the cytotoxicity test demonstrated that E. longifolia has lower lactate 
dehydrogenase activity in the SMC, suggesting low toxicity levels. While current results 
show an increase in testosterone level after short-term supplementation, findings also 
provided evidence that E. longifolia did not influence the hypothalamic-pituitary-gonadal 
(HPG) axis. Supplementation of E. longifolia improved mood state and sexual function, 
providing further evidence of the use of E. longifolia as an adaptogen and aphrodisiac.  
Results also showed 600 mg of E. longifolia alone, the highest dose permitted at present, 
does not have any ergogenic effects on strength or power.  
  








KESAN SUPPLEMENTASI EURYCOMA LONGIFOLIA: PENILAIAN 
PERTUMBUHAN SEL, PRESTASI LATIHAN DAN KESEJAHTERAAN 
DALAM KALANGAN LELAKI DEWASA 
ABSTRAK 
Eurycoma longifolia sering dijadikan sebagai komplementari dan ubat alternatif. 
Ekstrak mempunyai reputasi dalam memperbaiki prestasi seksual, mood, jisim otot, dan 
menambah kekuatan dengan meningkatkan paras testosteron pada individu lelaki yang 
menghadapi paras testosterone yang rendah, tekanan, dan kekurangan tenaga. E. 
longifolia mempunyai keupayaan untuk mengawal pengeluaran testosteron dengan 
mempengaruhi paksi hipotalamus pituitari aksis pada haiwan, tetapi fenomena ini belum 
dikajisecara teliti pada manusia. Walaupun kajian adalah terhad, suplemen E. longifolia 
menunjukkan peningkatan prestasi fizikal aktiviti dan kesejahteraan. Terdapat empat 
objektif utama: (1) Untuk mengkaji kesitotoksikan E. longifolia pada sel otot skeletal  
tikus; (2) Untuk mangkaji mekanisma yang mempengaruhi perubahan hormon 
reproduktif disebabkan oleh pengambilan E. longifolia; (3) Untuk membandingkan kesan 
jangka pendek dengan jangka panjang pengambilan suplemen E. longifolia terhadap 
mood psikologi dan fungsi seksual di kalangan individu muda; (4) Untuk mengkaji sifat 
ergogenik E. longifolia terhadap prestasi latihan di kalangan individu muda.  
 
Penemuan utama dari penyelidikan ini menunjukkan tahap sitotoksisiti yang lebih 
tinggi dalam rawatan kawalan (CON) berbanding dengan sel otot rangka (SMC) yang 
dirawat dengan E. longifolia. Peningkatan aktiviti laktat dehidrogenasi (LDH) 
diperhatikan dari jam 96 hingga 144 dengan peningkata kali ganda sebanyak 4.4, 3.8 dan 
3.3 (CON > 0.5 mg/ml> 1.0 mg/ml) dan 4.4, 3.3 dan 3.9 (CON > 1.0 mg/ml > 0.5 mg/ml) 
bagi passage 13 dan 26 masing-masing. Walaupun penemuan menunjukkan bahawa 
vii 
pendedahan SMC terhadap rawatan E. longifolia tidak menunjukkan ketoksikan, 
pertumbuhan myotube diperhatikan. 
 
Berkenaan dengan perubahan hormon, suplemen jangka pendek 600 mg/hari 
menunjukkan peningkatan testosteron (0.97 ng / ml, 11.1%; p = 0.004)), sementara 
suplemen jangka panjang menunjukkan peningkatan hingga minggu ke-4, kemudian 
menurun ( 0.142 ng/ml, 2%; p > 0.05) pada minggu ke-8. Kedua-dua suplemen jangka 
pendek dan jangka panjang tidak menunjukkan perubahan ketara dalam LH dan estradiol. 
Walaupun suplemen E. longifolia jangka pendek menunjukkan kesan yang baik dalam 
meningkatkan tahap testosteron, penemuan juga menunjukkan bahawa perubahan dalam 
testosteron bukan disebabkan oleh ekstrak yang mempengaruhi paksi hipotalamik-
pituitari-gonadal (HPG). Di samping itu, dos tidak menunjukkan kesan buruk pada fungsi 
hati, menunjukkan bahawa E. longifolia selamat untuk dimakan. 
 
Semasa mengkaji jangka masa suplementasi, suplemen jangka pendek E. longifolia 
menunjukkan peningkatan dalam domain keadaan mood seperti kemarahan (5.12%) dan 
keletihan (11.09%), jangka panjang mempengaruhi ketegangan (8.19%) dan kemarahan 
(4.14%). Penemuan ini menunjukkan bahawa suplemen E. longifolia meningkatkan 
domain keadaan mood tertentu, menunjukkan bahawa ekstrak ini mungkin berupaya 
untuk memperbaiki keadaan mood harian yang dipengaruhi oleh tekanan harian. 
Sementara itu, untuk ujian fungsi seksual, suplemen jangka pendek menunjukkan 
peningkatan dalam domain ejakulasi (6.13%), dan untuk jangka panjang; domain ereksi 
(25.89%) dan kepuasan keseluruhan (33.33%). Penyelidikan ini menunjukkan 
peningkatan fungsi seksual setelah selesai suplemen E. longifolia, memberikan bukti 
bahawa penggunaan E. longifolia sebagai afrodisiak. 
 
viii 
Kesan E. longifolia berikutan suplementasi 8 minggu tidak menunjukkan peningkatan 
kekuatan isokinetik dan daya anaerobik. Oleh itu, suplemen E. longifolia sahaja tidak 
menunjukkan kesan ergogenik di kalangan orang dewasa muda, yang mungkin 
disebabkan oleh kekurangan perubahan tahap testosteron selepas supplementasi E. 
longifolia selama 8 minggu. 
 
Sebagai kesimpulan, ujian sitotoksisitas menunjukkan bahawa E. longifolia 
mempunyai aktiviti dehidrogenase laktat yang lebih rendah di SMC, menunjukkan tahap 
ketoksikan yang rendah. Walaupun hasil semasa menunjukkan peningkatan tahap 
testosteron setelah suplemen jangka pendek, hasil penemuan juga memberikan bukti 
bahawa E. longifolia tidak mempengaruhi paksi HPG. Tambahan pula, E. longifolia 
meningkatkan keadaan mood dan seksual, memberikan bukti bahawa penggunaan E. 
longifolia sebagai adaptogen dan afrodisiak. Hasil kajian juga menunjukkan suplementasi 
600 mg E. longifolia sahaja adalah dos tertinggi pada masa ini tidak mempunyai kesan 
ergogenik terhadap kekuatan otot dan daya anaerobik. 
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 According to the World Health Organisation (WHO), herbal medicine includes herbs, 
herbal preparations, herbal materials, and all finished herbal products that contain parts 
of plants, or other plant materials or combinations, as active ingredients.  To date, 
approximately 80 percent of people worldwide use herbal medicine as one of the 
alternatives for their health care needs due to the naturally occurring substances known 
as ‘phytochemicals’. The phystochemicals could exert medicinal or therapeutic properties 
and enhance general health status, along with preventing or treat illnesses (WHO, 2002; 
Firenzuoli & Gori, 2007; Gunnels & Bloomer, 2014). Herbal medicines are credited with 
many health benefits and are widely used. However, many of the herbs remain untested, 
and their usage has not been monitored (WHO, 2002).  
 
  Eurycoma longifolia Jack (E. longifolia), commonly known in Malaysia as 'Tongkat 
Ali', often prescribed in complementary or alternative medicine or herbal therapy, is well-
known in Asia and Western countries (Rehman, Choe & Yoo, 2016). E. longifolia has 
gained its reputation due to its ability to alleviate various illnesses, such as aches, 
intermittent fever, sexual insufficiency, dysentery, glandular swelling and fatigue, based 
on a limited number of positive scientific findings (Ang & Sim, 1998; Ang & Cheang, 
2001; Ang, Lee & Kiyoshi, 2004; Tambi & Imran, 2010; Zanoli, Zavatti, Montanari & 
Baraldi, 2009; Wahab, Mokhtar, Halim & Das, 2010; Bhat & Karim, 2010; Low, Choi, 
Wahab, Das, & Chan, 2013a; Li et al., 2013), which have led to a higher demand for E. 
longifolia globally.  
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 E. longifolia is one of the four species of the plant commonly known as 'Tongkat Ali'. 
The other three species are known as Eurycoma apiculata, Polyathia bullata, 
and Goniothalamus sp. (Aziz, Sarmidi, Kumaresan, Taher, & Foo, 2003; Athimulam, 
Kumaresan, Foo, Sarmidi & Aziz, 2006; Hassan et al., 2012). E. longifolia is a tall, 
slender, shrubby tree that grows as tall as 15 to 18 metres in sandy soil and grows up 2 to 
3 cm long green fruit when mature (Figure 1.1). Almost all the parts of the plant, including 
the roots, stems, and bark are used as remedies to improve health and wellness.  
 
 
Figure 1.1 Eurycoma longifolia (Source: Bhat & Karim, 2010) 
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 Apart from herbal supplements, such as ginseng, Tribulus terrestris, fenugreek and 
many more, the root extract of E. longifolia is also available in the market (Bhat & Karim, 
2010). The extract is used commonly to treat sexual dysfunction, malaria, cancer, 
diabetes, anxiety, aches, constipation, fever, leukaemia, osteoporosis, stress, syphilis, and 
glandular swelling. However, most of these claims remain to be verified via randomized 
controlled trial. It is also used to improve exercise recovery and increase energy and 
strength (Darise, Kohda, Mizutani & Tanaka, 1982; Chan, Lee, Sam & Han, 1989; Grieco 
and Morre, 1998; Kuo, Damu, Lee & Wu, 2004; Hussein, Ibrahim & Kiong, 2006; 
Miyake, Tezukam, Awale, Li & Kadota, 2009; Fiaschetti, Grotzer, Shalaby, Castelletti & 
Arcaro, 2011). 
  
 E. longifolia may offer an attractive alternative to more mainstream products. Its wide-
ranging properties are deemed useful in increasing energy, inducing weight loss, 
promoting muscle growth or inducing other physiological or metabolic responses that 
may be conducive to enhancing exercise performance (William, 2006). An earlier study 
suggests that E. longifolia improves muscle strength post-supplementation (Hamzah & 
Yusof, 2003); however, the underlying mechanisms were not well explained. Following 
Hamzah and Yusof (2003), many have shown that the increased strength and body 
composition in older adults and young participants supplemented with E. longifolia are 
associated with increased testosterone levels. According to Talbott, Talbott, George, and 
Pugh (2013), E. longifolia is considered an extract that can restore low testosterone levels 
to normal circulating level in human and do not enhance testosterone beyond the normal 
circulating level. While the improvement in older individuals could be due the result of 
E. longifolia restoring low testosterone levels, the improvement in young individuals with 
normal testosterone level could be due to the combination of E. longifolia’s ability to 
restore or maintain circulating testosterone levels with strength training (Hamzah & 
Yusof, 2003). Strength training had the most considerable influence on the secretion of 
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testosterone and, thus, increased strength (Ahtiainen, Pakarinen, Kraemer & Hakkinen, 
2003; Ahtianen, Pakarinen, Alen, Kraemer & Hakkinen, 2005; Linnamo, Pakarinen, 
Komi, Kraemer & Hakkinen, 2005; McCaulley et al. 2009). Additional intake of E. 
longifolia may potentially lead to an increase in muscle mass and strength (Hamzah & 
Yusof, 2003; Chen et al., 2019). However, further examination in this respect is necessary 
to determine whether the muscle strength improvement is due to the strength training 
programme, a combination of strength training and E. longifolia, or E. longifolia alone. 
 
 Apart from being used to enhance physical attributes, E. longifolia is used as a folk 
medicine for anxiety; however, there has been limited research to prove this claim. There 
are three related studies; one conducted on animals while two were conducted on humans. 
These showed a significant decrease and improvement in tension, anger, confusion 
(Talbott et al., 2013), and increased vigour (George, Udani, Zainal Abidin & Yusof, 
2018).  E. longifolia may be a practical approach to shielding the body from the 
detrimental effects of day-to-day chronic stress, such as stress in planning a daily dietary 
intake to lose weight, deprivation of sleep, and exercise training (Talbott et al., 2013). 
Nevertheless, more studies are needed to substantiate the findings of previous studies.  
 
 Numerous studies have been conducted on animals and humans to investigate the 
therapeutic effectiveness of E. longifolia on male sexual dysfunction. The efficacy 
of      E. longifolia in managing male sexual health is due to the presence of the 4.3 kDa 
peptide (Sambandan, Rha, Kadir, Aminudim & Saad, 2004). The bioactive peptide (4.3 
kDa) (patented: PI 20003988, MAL: 10/362697, USA; 01920972.5, EUROPE and 2002-
522919, JAPAN) was isolated from E. longifolia is a phytoandrogen, which was reported 
to increase testosterone level in rat Leydig cells. Efforts have been put into identifying 
the mechanism involved in enhancing testosterone and how testosterone regulation via 
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the negative feedback loop is affected. Hayes, DeCruz, Seminara, Boepple, and Crowley 
(2001) proposed that luteinising hormone (LH) and follicle-stimulating hormone (FSH) 
of the pituitary gland regulate the activity of the Leydig cells which produce testosterone. 
Also, the aromatase enzyme acts by catalysing the irreversible conversion of testosterone 
to oestrogen. In an animal study by Low, Choi, Abdul Wahab, Das, and Chan (2013a), E. 
longifolia was shown to interfere with the HPG axis by inhibiting the aromatase enzyme 
and, thus, prevent the conversion of testosterone to oestrogen. Eurycomanone, a bioactive 
compound extracted from E. longifolia, is responsible for the inhibition of aromatase and 
it increases the level of testosterone circulation (Low et al., 2013a). This mechanism 
allows more testosterone to remain in the system, and the inhibition of aromatase leads to 
a lower negative feedback signal to the hypothalamus. The decline in negative feedback 
causes a stimulation of the anterior pituitary to increase LH and FSH production. LH and 
FSH’s increased secretion stimulates the Leydig and Sertoli cells to produce more 
testosterone and spermatogenesis (Bhatnagar, Müller, Schenkel, Trunet, Beh & 
Schieweck, 1992). There is a lack of supporting data in humans concerning the 
mechanism involved. The study by Low et al. (2013a) for the first time demonstrated 
that E. longifolia could increase the availability of testosterone via interference in the 
negative feedback loop mechanisms by inhibiting aromatase and thus prevent the 
conversion of testosterone to oestrogen. Hence, the increase in testosterone was 
speculated to enhance muscular strength, mood state and sexual functions in the male 
population.  
 
 The various benefits demonstrated by E. longifolia has also prompted extensive 
research into its cytotoxicity and anti-proliferative effects on human cell lines. Various 
compounds isolated from E. longifolia show cytotoxic and anti-proliferative effects 
(Rehman, Choe & Yoo, 2016) when tested on various human cell lines, as well as on 
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various solid tumours, including lung, breast, and cervical cell lines (Jiwanjinda, 
Santisopasri & Murakami, 2002; Kuo, Damu, Lee & Wu, 2004). This compound has 
demonstrated a cytotoxic response against many cancer cell types. It is said that the 
approach of killing that is induced by most anticancer agents is by apoptotic cell death. 
The anti-proliferative activity and cytotoxicity of eurycomanone have been investigated 
in cancerous cell lines (Caov-3, HeLa, Hep G2, HM3KO, and MCF-7) by triggering 
apoptotic cell death. The antiproliferative activity demonstrated by eurycomanone is due 
to the induction of apoptosis. These were determined using Tdt-mediated dUTP nick end 
labelling (TUNEL) assay with the apoptotic detection kit and further confirmed using the 
Nuclear staining assay to evaluate the morphological changes of apoptotic cells, 
chromatin condensation and formation of apoptotic bodies (Mahfudh & Azimahtol, 
2006). However, eurycomanone is relatively non-toxic on non-cancerous cell lines, and 
this was evaluated using the cell proliferation assay (Rubinstein et al., 1990; Kardano et 
al. 1991; Kuo et al., 2003; Tee & Azimahtol, 2005; Mahfudh & Azimahtol, 2006; Park et 
al., 2014; Tong et al., 2015). Hajjouli et al. (2014) have shown that the major quassinoid, 
eurycomanone and its derivative, eurycomanol are regulators of signalling pathways 
involved in proliferation, cell death, and inflammation without affecting healthy cells.  
 
1.2 Problem Statement 
 
 Eurycoma longifolia is generally marketed as a testosterone booster and is growing in 
popularity amongst the male population, based on its acclaimed benefits in alleviating 
illness, and increasing strength, physical performance, sexual function and mood state. 
Despite its extensive use in South East Asian countries and the infiltration of western 
countries as a supplement to improve health and treat and prevent diseases, the ergogenic 
properties affecting exercise performance and wellbeing among male adults and their 
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underlying mechanisms are not well explained. Due to its claim of being a putative 
replacement of testosterone, there is a risk of intramuscular injection of the extract. No 
preliminary study is examining the cytotoxicity effect of E. longifolia on skeletal muscle 
cells.  
 
 Cytotoxicity studies are commonly used as the initial step in determining potential 
toxicity of a test substance, including plant extracts or bioactive compounds isolated from 
plants. In relation to in vitro cell culture study, a substance is considered cytotoxic when 
it interferes with cells’ attachment, alters morphology, affects rate of cell growth or even 
causes cells death (McGaw et al., 2014). At present, extensive in vitro studies examining 
the cytotoxicity and anti-proliferation effect of various bioactive compounds of E. 
longifolia on numerous cancer cell lines have been conducted, and many have 
demonstrated cell death and diminished cell growth (Thu, Hussain, Mohamed & Shuid, 
2018). Two studies show no cytotoxicity and anti-proliferation in normal cells (Nurhanan, 
Azimahtol, Mohd Ilham & Mohd Shukri, 2005; Mahfudh and Pihie, 2008; Tong et al., 
2015). E. longifolia is believed to be an alternative to testosterone replacement therapy 
but yet to be verified (George & Henkel, 2014). It may have the same functionality as 
testosterone administration, which promotes hypertrophy in myoblasts (Deane et al., 
2013). However, no study has investigated the cytotoxicity effect of E. longifolia on the 
skeletal muscle cell line to date. Thus far, only oral supplementation of E. 
longifolia shows enhanced testosterone levels and improved muscular strength in young 
and old individual with or without low circulating testosterone levels, but these changes 
have not been investigated at the cellular level, particularly in myoblasts. 
  
 On the other hand, two animal studies have attempted to explain the mechanism behind 
the increase production of testosterone following supplementation of E. longifolia. It is 
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suggested that the increase in testosterone is due to the inhibition of the aromatase 
enzyme, which converts testosterone to oestrogen (Low et al., 2013a; Low, Das & Chan, 
2013b). In humans, E. longifolia supplementation has been shown to improve 
testosterone production in older participants with low testosterone levels (Tambi et al., 
2012; Talbott et al., 2013) and young, healthy men with normal testosterone levels 
(Ismail et al., 2012; Chen et al., 2014; Chen et al., 2019). However, the regulation of all 
the hormones (testosterone, free testosterone, LH, FSH, sexual hormone-binding 
globulin, and oestrogen) involved in the negative feedback has not been examined. 
Though a plausible mechanism has been shown in rats (Low et al., 2013a and 2013b), no 
studies have demonstrated this in humans.  
 
In their pilot study, Hamzah and Yusof (2003) showed an increase in muscular strength 
after a combination of a period of strength training and E. longifolia supplementation. 
However, no study has been conducted to examine young men’s muscular strength using 
only E. longifolia supplementation. Whether supplementation of E. longifolia alone, 
without strength training, augment muscle mass and strength in men with normal 
circulating testosterone levels is still unknown. Similarly, the effects of E. longifolia on 
psychological mood state and sexual function have been studied using animal models, but 
research on the effectiveness of E. longifolia in humans is still scarce (Talbott et al., 2013; 
George et al., 2018).  
 
      The present thesis examines the hormonal changes in humans to understand the 
mechanism involved in testosterone regulation and how the interference of the feedback 
loop will improve the said benefits. The findings will also allow a better understanding 
of the reputed ergogenic properties of E. longifolia, especially in terms of muscular 
strength and power.  
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1.3 Research Aim and Objectives 
 
The research’s primary aim was to examine the effect of E. longifolia in skeletal muscle 
cell growth, wellbeing and exercise performance in adult males.  
 
The primary aim would be realised by addressing the following objectives in the four 
study chapters:  
(i) to examine the cytotoxicity of E. longifolia on the murine skeletal muscle cells 
(SMC). 
(ii) to elucidate the changes in selected reproductive hormone due to E. 
longifolia supplementation. 
(iii) to compare the short-term versus long-term effects of E. 
longifolia supplementation on psychological mood state and sexual function 
among healthy young adults. 
(iv) to determine the ergogenic properties of E. longifolia with regard to physical 
measures (muscular strength and power) following supplementation among 
healthy young adults. 
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1.4 Research hypothesis 
1.4.1 Murine skeletal muscle (C2C12) cells treated with E. longifolia significantly 
increase cytotoxicity compared to untreated C2C12 (control). 
1.4.2 Supplementation of 600 mg/day of  E.longifolia for 2 and 8 weeks would 
significantly increase the hormonal concentrations such as testosterone, free 
testosterone, luteinising hormone, follicle-stimulating hormone, and decreased 
oestrogen concentration compared to placebo (maltodextrin) consumption.    
1.4.3 Supplementation of 600 mg/day of E. longifolia for 2 and 8 weeks improve 
participant's psychological mood such as anger, confusion, depression, tension, 
fatigue, and vigour compared to placebo (maltodextrin) consumption.  
1.4.4 Supplementation of 600 mg/day of E. longifolia for 2 and 8 weeks would 
significantly improve participant's sexual function, such as sexual drive, 
erection, ejaculation, problem assessment, and overall satisfaction compared to 
placebo (maltodextrin) consumption. 
1.4.5 Supplementation of 600 mg/day of E. longifolia for 8 weeks would significantly 
increase muscular strength and anaerobic capacity compared to placebo 
(maltodextrin) consumption.  
 
 
1.5 Significance of the Study 
 
 This present study will add considerably to the body of literature pertinent to the usage 
of E. longifolia among male individuals globally. These studies’ findings can facilitate 
professionals or other health care practitioners to conduct consistent, safe, and effective E. 
longifolia supplementation to all individuals in Malaysia, and even to individuals from 
the west.  Once the efficacy of E. longifolia is established, the mode of action, potential 
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adverse reactions, contraindications and interactions with existing pharmaceutical drugs 
can be determined in future studies to promote safe and rational use of the extract. 
Since E. longifolia is said to be an alternative treatment to exogenous testosterone, it can 
be used as a natural supplement to slow down age-related muscle loss. The present 
findings will provide preliminary information regarding whether E. longifolia intake will 
alter the endogenous steroid profile similar to exogenous testosterone consumption.  
 
 A cytotoxicity test is performed to predict potential toxicity by using cultured cells. 
These tests involve short-term exposure of cultured cells to test substances to detect how 
cultured cells may be affected by E. longifolia extract. Thus, the cytotoxicity test in the 
present study can determine the potential toxicity of E. longifolia towards SMCs prior to 
performing efficacy and safety studies in humans. 
 
  The fundamental data from this study may indicate future research directions. It can 
stimulate multiple research ideas, especially molecular physiology and interventional 
studies of populations with or without disease or populations involved in sport. This study 
may also be relevant for the public, the authorities, researchers, health care practitioners, 
care service providers, coaches, athletes, and family members in garnering a shared effort 
for the wellbeing of an individual with health issues and individuals that want to improve 
their sporting performance and health benefits. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 Introduction to literature  
 
Eurycoma longifolia is native to Southeast Asia countries such as Malaysia, Indonesia, 
Thailand, Philipines and Vietnam. E. longifolia has known by many for its medicinal 
properties since ancient times, particularly in South East Asia. E. longifolia is popular for 
its aphrodisiac properties, a substance that increases sexual desire, sexual attraction, 
sexual pleasure or sexual behaviour. Also, every single part of the plant is used for the 
preparation of traditional remedies to treat various illnesses such as aches, intermittent 
fever, sexual insufficiency, dysentery, glandular swelling and fatigue (Ang & Sim, 1998; 
Ang & Cheang, 2001; Ang, Lee & Kiyoshi, 2004; Zanoli, Zavatti, Montanari & Baraldi, 
2009; Tambi & Imran, 2010; Wahab, Mokhtar, Halim & Das, 2010; Bhat & Karim, 2010; 
Low, Choi, Wahab, Das, & Chan, 2013a; Li et al., 2013). An aphrodisiac is a substance 
that can increase sexual desire, sexual attraction, or sexual pleasure. Despite being known 
for the extensive variety of traditional uses, E. longifolia is most well-known for its 
aphrodisiac properties and is highly sought after in the western world for its potential in 
enhancing sexual performance (Norhidayah et al., 2015). Hence, E. longifolia with its 
many bioactive compounds capable of improving general wellbeing and most 
importantly, enhancing testosterone production, was chosen in this study.  
 
A study by Ab Rahman et al. (2011) found that 40 percent of the 1331 male 
participants aged 40 years and above used E. longifolia as part of their treatment of sexual 
problems because they believed that its testosterone-enhancing abilities contributed to the 
aphrodisiac properties. Approximately 8,550 out of 20,211 E. longifolia products from 
local manufacturers in Malaysia are produced locally. Any imported products must be 
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registered with the Drug Control Authority. These products are sold in the market in 
various forms, such as capsule, polls, liquid formulation, pre-mixed coffee and canned 
processed drinks (Ang & Lee, 2007; Ang et al., 2004; Effendy et al., 2012) and can be 
found and purchased easily from any pharmacies. Due to its ubiquity, extensive animal 
and human clinical evaluations have been performed (Tambi, 2009); however, findings 
related to cytotoxicity on SMCs, how E. longifolia works and its efficacy concerning 
reproductive hormones, mood, sexual function and muscular strength in humans are still 
scarce. 
 
2.2 Bioactive phytochemicals of E. longifolia 
  
 The major bioactive compounds isolated from parts of E. longifolia are presented in 
Table 2.1. All the bioactive compounds are compiled from studies spanning more than 
three decades and provided findings related cancer cell lines’ effectiveness. The 
compounds are categorised into: quassinoids, alkaloids, squalene derivatives, triterpene 
type tirucallane, and many more (Mahfudh & Pihie, 2008; Ang, Cheang & Yusof, 2000; 
Kuo et al., 2004; Miyake et al., 2009; Tran et al., 2014).  
 
 According to Rehman et al. (2016) and Fiaschetti, Grotzer, Shalaby, Castelletti, and 
Arcaro (2011), quassinoids are the main bioactive compounds of E. longifolia, found 
especially in the root of the plant. Quassinoids are a group of nortriterpenoids that have 
numerous pharmacological properties. Quassinoids such as eurycomanone, 
eurycomalactone, trihydoxyklaineanone, laurycolactones, eurycomalactone, 
eurycomalides, longilactone, and eurycolactone derivatives have mostly been isolated 
from the roots and leaves of the E. longifolia plant (Morita, Kishi, Takeya & Itokawa, 
1992; Mitsunaga et al., 1994; Jiwajinda et al., 2002). While quassinoids are mostly 
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isolated from the roots, alkaloids, squalene derivatives and tirucallane-type triterpenes are 
mainly found in the herbal plant’s bark, stem, and roots. The successful isolation and 
characterisation of over 150 quassinoids have prompted numerous in vitro and in 
vivo studies using bioactive compounds (Fiaschetti et al., 2011).  
 
2.2.1 Bioavailability, pharmacokinetics and pharmacodynamics of E. longifolia 
 
While there are few animal studies examining the bioavailability, pharmacokinetics 
and pharmacodynamics of E. longifolia, none were conducted on humans (Han et al., 
2015; Low et al., 2005; Pan et al., 2014). Bioavailability was conducted to measure the 
transport of an active ingredient to its site of action to cause the predicted effects (Ahmad 
et al., 2018). Previous studies conducted by Low et al. (2005), Ahmad et al. (2018) and 
Ma et al. (2015) demonstrated poor absorption after oral administration and low 
bioavailability. However, the authors also demonstrate that the plasma volume 
distribution of E. longifolia is high, which suggests that they are distributed in various 
tissues, slow elimination rate and does not show inhibitory effects on cytochrome P450 
isoenzymes (Thu et al., 2018). In vitro assessment of the effect of eurycomanone on 
cytochrome P450 (CYP) isoforms CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, 
CYP2E1 and CYP3A4 demonstrated eurycomanone did not inhibit any of the 
investigated isoforms (Pan et al., 2014; Han et al., 2015). Hence, the purported 
mechanism suggested by Low et al. (2013) that E. longifolia inhibit aromatase and 
prevent the conversion of testosterone to oestrogen may not be true. 
 
E. longifolia’s exhibit various pharmacodynamic response against various animal and 
human diseases such as male fertility enhancement (Low et al., 2013a, 2013b), 
antimalarial (Chan et al., 1986; Kardono et al., 1991; Ang et al., 1995; Kuo et al., 2004; 
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Wernsdorfer et al., 2009; Low et al., 2011), cytotoxic (Kuo et al., 2004; Kardono et al., 
1991; Rehman et al., 2016), antiproliferative (Wong et al., 2012; Hajjouli et al., 2014), 
and antiulcer (Tada et al., 1991), anti-osteoporotic (Shuid et al., 2011; Saadiah et al., 
2012; Tambi & Henkel, 2012; Mirza & Canalis, 2015), sexual function (Tambi et al., 
2012; Ismail et al., 2012; Udani et al., 2014; George & Henkel, 2014; Henkel et al., 2014) 
effects, are generally accredited to the quassinoids, specifically eurycomanone. Studies 
haven shown that eurycomanone is the compound responsible for the reported activities 
using in vitro and in vivo studies on rats and cell lines. To date, there are in vivo and 
human clinical studies which have explored the effectiveness of E. longifolia in the 
management of male sexual dysfunction, but mostly on older, hypogonadic, infertile 
individuals (Tambi et al., 2012l; Udani et al., 2014; George & Henkel, 2014; Henkel et 
al., 2014).  
 
2.3 Cytotoxicity effects of E. longifolia extract 
 
Many extensive investigations using animal and human cell lines have been performed 
related to the cytotoxicity effect of E longifolia (Table 2.2. and Table 2.3). While most 
studies used methanol to extract the E. longifolia, later it was partitioned using 
chloroform and butanol before compounds were isolated through various 
chromatographic resin and isolation techniques (Park et al., 2014; Kuo et al., 2003; 
Mahfudh & Azimahtol, 2008). Results from water extract E. longifolia to examine the 
cytotoxicity effect on cell lines are limited (Table 2.3). E. longifolia's active 
phytochemicals, such as quassinoids, alkaloids, squalene derivatives, and tirucallane-type 




Cytotoxicity and anti-proliferative test are commonly used in in vitro toxicology 
studies to detect cytotoxicity or cell viability and the inhibition of cell growth following 
exposure to toxic substances (Fotakis & Timbrell, 2006). The cytotoxicity test is also 
known as a means of assessing the loss of membrane integrity, membrane metabolic 
activity, the loss of monolayer adherence, and the arrest of cells in various stages of the 
cell cycle.   
 
The most common cytotoxicity and anti-proliferation test used to test E.longifolia are 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and 
Sulforhodamine B (SRB) assay. Apart from these assays, the Lactate dehydrogenase 
(LDH) assay is also known for its reliability, speed and simple evaluation characteristics 
(Decker & Lohmann-Matthes, 1988). However, the LDH assay has never been used in 
examining the cytotoxicity effect of E. longifolia on cell lines. This assay is considered 
more reliable compared to the MTT assay, aquabluer, and neutral red assays. It has also 
been suggested that the LDH assay can be useful in screening herbal medicine (Specian et 
al., 2016). The cytotoxicity effect of E. longifolia extract on various cell lines is presented 




Table 2.1: Bioactive compound isolated from E. longifolia from its various plant parts 
 




Roots Kuo et al. (2004); Darise et al. (1982); Tran et al. (2014); Park et al. (2014); Chan et al. (1998); 
Udani et al. (2014); Chan et al. (1986); Kardono et al. (1991); Low et al. (2011); Wernsdorfer et 
al. (2009); Ang et al. (1995a); Low et al. (2005); Ang et al. (1995b); Darise et al. (1983); Wong 
et al. (2012) 
Eurycomanol derivatives Roots Kuo et al. (2004); Darise et al. (1982); Chan et al. (1991); Meng et al. (2014); Chan et al. (1998); 
Udani et al. (2014); Chan et al. (1986); Ang et al. (1995a); Ang et al. (1995b); Darise et al. (1983) 
Trihydroxyklaineanone 
derivatives 
Leaves,    Roots Jiwajinda et al. (2001); Kuo et al. (2004); Tran et al. (2014); Chan et al. (1998); Park et al. (2014); 
Chan et al. (1998); Itokawa et al. (1993) 
Laurycolactones A and B Roots Miyake et al. (2009); Itokawa et al. (1993) 
Eurycomalactone Roots Kuo et al. (2004); Tran et al. (2014); Chan et al. (1992); Park et al. (2014); Chan et al. (1998); 
Udani et al. (2014); Kardono et al. (1991); Itokawa et al. (1993); Ang and Lee (2002) 
Eurycomalides derivatives Roots Kuo et al. (2004); Miyake et al. (2009); Tran et al. (2014) 
Longilactone derivatives Leaves, Roots Kuo et al. (2004); Miyake et al. (2009); Tran et al. (2014); Chan et al. (1998); Itokawa et al. 
(1993); Morita et al. (1993); Jiwajinda et al. (2002) 
Eurycolactone  derivatives Roots Miyake et al. (2009); Ang et al. (2000); Tran et al. (2014); Park et al. (2014); Ang et al. (2002); 
Kuo et al. (2004); Tada et al. (1991) 
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Table 2.1: Bioactive compound isolated from E. longifolia from its various plant parts (Continued) 
 
Chemical compounds  Parts References 
Alkaloids 
Alkaloids derivatives Bark, Stem, Roots Kuo et al. (2004); Tran et al. (2014); Low et al. (2011); Itokawa et al. 1993); Kuo et al. (2003); 
Miyake et al. (2010); Lin et al. (2001); Souza-Almeida et al. (2011); Donkwe et al. (2012); Jiang 
and Zhou (2008); Mitsunaga et al. (1994); Kardono et al. (1991); Varghese et al. (2013); Kuo et 
al. (2003); Siregar et al. (2009); Siregar et al. (2004); Maziah and Rosli (2009) 
Squalene 






episapelin A, melianone, 
hispidone 




Table 2.2: Summary of investigation implementing isolated bioactive compounds on numerous cell lines. 
 
Model Dose Toxicity Outcome variable References 
MCF-7, colon, 
HT1080, A-549, 
melanoma, KB and P-
388 
7 - 5000 
ng/ml 
ED50 : 2.0 - 12.0 μg/mL Cytotoxic against all cell lines except for P-
388 
Kardono et al. (1991) 
A-549 cell line 
MCF-7 cell line 
NA ED50:  < 2.5 μg/mL Significant cytotoxicity against cell lines Kuo et al. (2004) 
A-549 cell line 
MCF-7 
NA ED50:  < 2.5 μg/mL -4.2 μg/mL Significant cytotoxicity against cell lines Kuo et al. (2003) 
MCF-7 cell line 2.5 μg/ml EC50: 2.2 ± 0.18 μg/ml Anti-proliferative against cell line Chuen and Pihie (2004) 
A-549 cell line 5 - 20 
μg/ml 
GI50: 5.1 μg/ml Inhibited proliferation in a dose dependent 
manner 
Wong et al. (2012) 
Caov-3, HeLa, HepG2, 
HM3KO, MCF-7 
5 μM IC50 : 2.13 ± 0.09 - 4.21 ± 0.2 
μg/ml 
Cytotoxicity effect on cell lines Mahfudh and Pihie  
(2008) 
K-562 cell line 25 ± μg/ml 
6 μg/ml 
IC50: 19 ± 3 μg/ml 
IC50: 6 ± 1 μg/ml 
Cytotoxicity effect against cell line                       
Strong anti-proliferative against a cell line 
Al-Salahi et al. (2014) 
A-549, MCF-7 
HeLa cell lines 
1 ,10 and 
100 μM 
21.01 ± 2.46 to 66.9 ± 6.67μM 
21.01% ±2.46% to 66.9% ± 6.67 
Cytotoxicity effect against cell lines Park et al. (2014) 
K562 cell line 
Jurkat cell line 
100 μM IC50: 5.7 μM 
IC50: 6.2 μM 
Inhibited cell lines viability and proliferation Hajjouli et al. (2014) 
LNCaP,RWPE-1, 
WRL-68 cell lines 
2.5 - 100 
μg/ml 
IC50: 5.97 μg/ml Selective cytotoxicity  Tong et al. (2015) 
KB, DU-145, RD, 
MCF-7, CaOV-3 cell 
lines 
0.1 - 100 
μg/ml 
IC50: 3.2μg/mL Cytotoxicity effect against cell lines Nurhanan et al. (2005) 
HepG2 5.0 μg/ml IC50: 3.8 ± 0.12 μg/ml - 45 ± 0.15 
μg/ml 
Toxicity and inhibitory effect towards cell 
line 
Zakaria et al. (2009) 
MC3T3-E1 cell line 25 μg/ml - Proliferation or growth of MC3T3-E1  Thu et al. (2017) 
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2.3.1 The cytotoxicity effect due to various dosage of E. longifolia  
 
 Cytotoxicity and anti-proliferation tests have been conducted on numerous cell lines 
and found to be toxic to the cell and prevent cell growth when exposed to E. longifolia. 
However, a small number of studies have shown reduced levels of toxicity and no 
cytotoxicity effect in healthy human cell lines. Most isolated bioactive compounds of E. 
longifolia have been used extensively to examine cytotoxicity and the anti-proliferation 
of malignant neoplasm (Rehman et al. 2016) by using various assay options, such as MTT 
and SRB (Table 2.3). A malignant neoplasm is a group of diseases involving unregulated 
cells, and these cells divide and grow uncontrollably to form a malignant tumour and then 
spread to nearby parts of the human body. Isolated alkaloids, such as 9-methoxycanthin-
6-one, 9-methoxycanthin-6-one N-oxide, 9-hydroxycanthin-6-one, and 9-
hydroxycanthin-6-one-N-oxide, has cytotoxic effects against breast, colon, fibrosarcoma, 
lung, melanoma, KB, KB-V1, and murine lymphocytic leukaemia cell lines (Kardono et 
al., 1991). Since then, Kuo et al. (2004) have isolated sixty-five compounds from E. 
longifolia,  with some of the alkaloids showing similarities to the compounds isolated by 
Kardono et al. (1991) and Kuo et al. (2003), namely 9-methoxycanthin-6-one, canthin-6-
one and canthin-6-one-9-O-β-glucopyranoside, which also showed potent cytotoxicity on 
the human lung (A-549) cell line and human breast (MCF-7) cell lines with an effective 
dose (ED50) and inhibitory concentration (IC50) ranging from 2.0 - 12.0 μg/ml.  While 
isolated bioactive compound of E. longifolia was tested on various cell lines, it has not 





 The studies discussed above confirm the cytotoxicity effect of E. longifolia in cancer 
cell lines. However, studies tested on healthy cell lines showed the methanolic extract 
of E. longifolia and eurycomanone were 95 and 30 times less toxic than imatinib, a 
medication used to treat cancer (Al-Salahi et al., 2014). Also, the studies have shown that 
healthy cells, such as peripheral blood mononuclear cells (Hajjouli et al. 2014), non-
cancerous breast cells (MCF10A) (Chuen & Pihie, 2004), normal prostate (RWPE-1), 
liver (WRL-68) cell lines (Tong et al., 2015), MDBK (bovine kidney) and Vero (African 
green monkey kidney) (Mahfudh and Azimahtol, 2008), treated with eurycomanone did 
not demonstrate high cytotoxicity levels and did not inhibit proliferation. In addition, no 
cytotoxicity was detected post 9-methoxycanthin-6-one administration on normal bovine 
kidney (MDBK) cell lines (Nurhanan et al., 2005). 
 
 One study reported that crude water extract of E. longifolia had no toxicity effect on 
non-malignant cells, such as Chang's liver and human normal skin cells (CCD11114sk) 
(Zakaria et al., 2009). Interestingly, a recent study by Thu et al. (2017) has shown that E. 
longifolia water extract promotes proliferation and osteogenic differentiation of 
osteoblastic cell lines (MC3T3-E1). A low concentration of the water extract of E. 
longifolia (5 to 50 μg/ml) that contains proteins, eurypeptide, glycosaponins, and 
eurycomanone treated on MC3T3-E1 demonstrate significant proliferation at day three 
and day six of treatment. However, with a higher concentration of 50 - 2500 μg/ml, a 
progressive decrease in proliferation consistently over time, due to the cell undergoing 
apoptosis at a higher dose, was observed (Thu et al., 2017).  
 
 Most compounds of E. longifolia isolated using the methanol extraction method 
demonstrated cytotoxicity towards human cancer cell lines. However, water extract E. 
longifolia showed lower cytotoxicity levels and even induced proliferation with a low 
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dose of E. longifolia. Thus, administration of E. longifolia in low doses may have the 
potential to be an alternative approach to testosterone replacement therapy, such as 
osteoporosis management. Based on these findings, there is an indication that a specific 
bioactive compound administered in low doses was not toxic or harmful to normal cells.  
Thus, there is a possibility that low doses of E. longifolia may enhance proliferation and 
reduce cytotoxicity in SMCs. However, no studies have indicated the dose needed to 
reduce or increase proliferation and cytotoxicity on SMCs; thus, more investigation is 
warranted.   
 
2.3.2 Cell Death 
 
 Cell death is a critical and active process that maintains tissue homeostasis and 
eliminates potentially harmful cells (Green and Llambi, 2015). Apoptosis and necrosis 
are two types of cell death (Galluzi et al., 2007). Apoptosis is the process of programmed 
cell death and often characterized by cell shrinkage, membrane blebbing, chromatin 
condensation, nuclear fragmentation, and chromosal DNA fragmentation (Kerr et al., 
1972; Green and Llambi, 2015). Apoptosis can be triggered through the intrinsic 
(mitochondrial) pathway and the extrinsic (death receptor) pathway.  Is it said that drugs 
used for chemotherapy resulted in DNA damage in cells through a p53 dependent 
apoptotic pathway (Elmore, 2007; Green and Llambi, 2015). On the other hand, necrosis 
is characterized by cell swelling and plasma membrane rupture, and a loss of organellar 
structure without chromatin condensation. Also, necrosis is referred to as the degradation 
processes that occur after cell death. This form of cell death can result from active 
signalling pathways that depend on the activity of the protein kinase RIP3 (Elmore, 2007; 
Green and Llambi, 2015). 
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 Cytotoxicity happens due to apoptosis by up-regulating p53 (apoptotic trigger) and 
down regulating Bcl-2 (the apoptosis suppressor gene) (Zakaria et al., 2009).  
Eurycomanone, the main quassinoid, was used to examine the mechanism of cytotoxicity 
or the mode of cell death.  Previous studies found that eurycomanone induced apoptosis 
through the up-regulation of p53 and Bax protein and down-regulation of Bcl-2 protein 
in the liver cell line (Mahfudh & Azimahtol, 2008; Cheun & Pihie, 2004; Zakaria et al., 
2009).  
 
2.3.2.1 Effect of E. longifolia on liver function toxicity 
 
 Based on animal studies, the oral lethal dose 50 (LD50) of the alcohol extract of E. 
longifolia is between 1500 - 2000 mg/kg, while the aqueous extract is between 3000 - 
5000 mg/kg (Satayavivad et al. 1998; Shuid et al. 2011). Effendy et al. (2012) stated that 
to extrapolate an animal dosage to humans, the normalisation of body surface area is used, 
and it shows that LD50 for E. longifolia is extrapolated to be 810 mg/kg in an adult man. 
Clinical data has demonstrated safe consumption of the water-soluble E. longifolia extract 
to be between 200 and 600 mg (Tambi, 2005). In the study by Tambi (2005), a high dose 
of E. longifolia supplementation (600 mg/day) over two months taken by twenty healthy 
males, aged from 38 to 58 years old, showed no influence on the blood profile 
(haemoglobin, red blood cell, white blood cell, platelet count) or any deleterious effects 
on measures of liver or renal functions. The quality of E. longifolia is based on its level 
of eurycomanone, which is the main active ingredient found in E. longifolia (Norhidayah 
et al., 2015). The Department of Standards Malaysia functions as the National Standards 
Body and the National Accreditation Body, which provides credible accreditation 
services to laboratories, inspections and certification bodies for greater market access and 
global recognition for technical competence and quality assurance.    
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Table 2.3: Cytotoxicity and anti-proliferative responses of various bioactive compound isolated from E. longifolia 
 
Bioactive compound Method Toxicity Cytotoxicity and anti-proliferative outcome References 
Methanol extract alkaloids                
9-Methoxycanthin-6-one,                   
9-Hydroxycanthin-6-one,                   
9-Methodoxycanthin-6-one-N-
oxide,                                         9-




                      
MTT assay      
SRB assay 
                      
ED50: 2.0 μg/mL - 
12.0 μg/mL           
IC50: 3.2 μg/mL 
                                                                                    
Cytotoxicity effect on the breast (MCF-7), colon, fibrosarcoma, 
lung (A-549), melanoma, KB, and murine lymphocytic 
leukaemia (P-388), epidermoid carcinoma (KB), prostate 
cancer (DU-145), rhabdosarcoma (RD), Ovarian cancer 
(CaOV-3).  No significant cytotoxic effect detected on bovine 
normal kidney (MDBK) cell line 
                                        
Kardono et al. (1991); Kuo et 
al. (2004); Kuo et al. (2003); 
Nurhanan et al. (2005) 
Methanol extract quassinoids 
eurycomalactone,                             
6dehydroxylongilactione,    
longilactone,                                    
14, 15β-dihydroxyklaineanone, 
pasakbumin B, C,                
eurycomanone,                            
semi-purified eurycomanone     
TAF273                                     
13,21-dihydroeurycomanone     
13α(21)-epoxyeurycomanone 
Eurycomanol         
epoxyeurycomanone 
                      




                    
ED50: < 2.5μg/mL 
EC50:2.2 ± 0.18 
μg/ml          GI50: 
5.1 μg/ml    IC50: 
3.8 μg/ml - 59.26 
μg/ml  
                                                                                            
Cytotoxicity toward A-549, MCF-7, Caov-3, HeLa, Human 
liver (HepG2), HM3KO, MCF-7  cell lines.                                                                    
Inhibited A549, HepG2, K-562, Jurkat cell line proliferation in 
a dose-dependent manner                                                                                     
Selectively cytotoxic to LNCaP prostate cancer cells, RWPE-1 
and WRL-68 cell line 
No cytotoxicity effect on MDBK and Vero, Chan's liver, and 
WLR-68 cell line                                                                        




                                              
Kuo et al. (2004)                       
Chuen and Pihie (2004)           
Wong et al. (2012)              
Mahfudh and Azimahtol 
(2008) Zakaria et al. (2009)                        
Al-Salahi et al. (2014)                  
Park et al. (2014)                   
Hajjouli et al. (2014)                  
Tong et al. (2015) 
Water Extract                                  
E. longifolia extract 
                       
MTT assay  
                       
IC50: 45 ± 0.15 
μg/ml 
                                                                                           
Higher toxicity to HepG2.                                                    
Non-malignant cells (Chang's liver and CCD11114sk) was not 
affected                                                                          
Promoting proliferation and osteogenic differentiation of 
osteoblastic cell line (MC3T3-E1) 
                                          
Zakaria et al. (2009)                
Thu et al. (2017) 
Note: MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay; SRB: Sulforhodamine B assay; ED50: median effective dose;          
IC50: Half maximal inhibitory concentration
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 The Malaysian Standard (2011), issued by the Department of Standards Malaysia, 
states that the level of eurycomanone should be from 0.8 to 1.5 w/v (%). The E. longifolia 
used in the present study reported a 1.21 w/v (%) and complied with the Malaysian 
Standard (2011). Thus, a dose of 600 mg/kg body weight (Tambi, 2005) is safe for 
consumption. 
 
2.4 Steroid hormones production pathways 
Steroid hormones are grouped into three classes by function, which is glucocorticoids 
(i.e. cortisol), mineralocorticoids (i.e. aldosterone) and sex hormones (i.e. androgen, 
oestrogen). These are synthesized in the adrenal glands. In addition, sex hormones can 
also be synthesized by the gonads and placenta (Arlt et al., 2002; Schiffer et al., 2019). 
Mineralcorticoids hormones are synthesized in the adrenal cortex known as zona 
glomerulosa to regulate the concentration of electrolytes circulating in the blood. On the 
other hand, glucocorticoids are synthesized in the zona fasciculate, which regulate the 
process of cortisol, and lastly, the sex hormones (i.e. testosterone, oestrogen) are 
synthesized in the adrenal cortex known as zona reticularis, which promote sexual 
characteristics and maturation of reproductive organs (Shier et al., 2010; Connell & 
Davies, 2005; Schiffer et al., 2019).  Steroid hormones are synthesized in the adrenal 
glands from cholesterol, a substance for the biosynthesis of pregnenolone. Pregnenolone 
is the precursor steroid in the biosynthesis of all the steroid hormones to form aldosterone, 
cortisol and androstenodione (Figure 2.1). Steroid hormones are hydrophobic, and the 
hormones are transported in the blood by albumin, corticosteroid-binding globulin and 
sex hormone-binding globulin (Schiffer et al., 2019). While the glucocorticoids and 
mineralcorticoids are beyond this review’s scope, the review will focus on the androgen 
hormone synthesizing into androstenedione, a precursor to testosterone which is produced 
by the adrenal gland and gonads. Subsequently, the precursor is converted to testosterone, 
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which then aromatized to oestrogen (King et al., 1999). Testosterone hormones are 
regulated via the HPG axis.  
2.4.1 Feedback systems involved in testosterone regulation 
 
 The production of testosterone by the Leydig cells of the testes is regulated by the HPG 
axis, forming a homeostatic testosterone negative feedback loop. The hypothalamus 
secretes the gonadotrophin-releasing hormone (GnRH) and, subsequently, stimulates the 
anterior pituitary to secrete LH and FSH, further stimulating the Leydig and Sertoli cells 
to increase the production of testosterone and spermatogenesis. However, the increase in 
testosterone level will then feeds back to the HPG to reduce the LH secretion, and this 
mechanism is called the negative feedback loop (Tilbrook & Clarke, 2001) (Figure 2.2).  
 
 The development of the negative feedback loop is essential for the homeostasis of 
circulating testosterone concentration in males (O'Hara et al., 2015). On the other hand, 
testosterone produced can be metabolised in the peripheral and neuroendocrine tissue by 
either 5α-reductase to the androgen 5α-dihydrotestosterone (DHT) or by aromatase to 
oestrogens (Bhatnagar et al., 1992). Aromatase is an enzyme responsible for the 
conversion of testosterone to estrogen (de Ronde & de Jong, 2011), but it cannot convert 
DHT to estrogen (Bhatnagar et al., 1992). Thus, testosterone and DHT are aromatisable 
and non-aromatisable androgens, respectively. The existence of 5α-reductase (Martini, 
1983) and aromatase (Naftolin et al., 1975) in the neuroendocrine system influences the 
hypothalamic-pituitary unit to maintain homeostasis has been well recognised.  Thus in 
the hypothalamic-pituitary unit, testosterone can apply its regulatory influence on 
gonadotrophin secretion by three probable mechanisms which are either directly, after 
conversion to the non-aromatisable DHT or after aromatisation to estrogens. The first two 
mechanisms which cause the secretion of gonadotrophin by the anterior pituitary through 
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the direct influence of testosterone or after conversion to DHT mechanisms are not 
affected by aromatase inhibition.  However, the third mechanism responds to aromatase 
inhibition by detecting a decline in the negative feedback signal due to a reduction of 
oestrogen, thus effecting increased gonadotrophin production. The increase in 
gonadotrophin stimulates the anterior pituitary to increase LH and FSH secretion and, 
consequently, cause an increase in testosterone production from the testes. The negative 
feedback exerted by testosterone on gonadotropin secretion is dependent on the 
aromatisation of testosterone to oestrogen (Bhatnagar et al., 1992).  
 
 While there is research on E. longifolia in animal and human models, the effect of E. 
longifolia on increasing testosterone levels in humans remains inconclusive. Further work 
is required to explore the possible mechanisms concerning the wide-ranging benefits 
claimed, especially in the changes in sex hormones due to E. longifolia supplementation. 
 
2.4.2 Effect of testosterone on skeletal muscle growth  
 
Sex hormones play an important role in the maintenance and growth of muscles. A 
gradual decrease in sex hormones such as testosterone, oestrogens and progesterone will 
cause the loss of muscular function and mass (Kim et al., 2016). Muscle hypertrophy or 
muscle growth is said to be regulated by a mechanical, hormonal and nutritional signal. 
Sex hormones responsible for muscle growth are testosterone and insulin-like growth 
factor-1 which are known to be potent anabolic agents. To enable the interaction between 
testosterone and skeletal muscle cells to enhance muscle mass, the androgen hormone 
needs to bind to androgen receptors (AR) (Hulmi et al., 2008). In addition, endogenous 
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and exogenous testosterone also enhance muscle protein synthesis (Griggs et al., 1989; 
Urban et al., 1995; Brodsky et al., 1996; Arny et al., 1998). 
While testosterone demonstrates a marked increased in muscle protein synthesis, 
muscle protein breakdown was not examined in the current study. Whether there is any 
testosterone effect on the net protein synthesis, it still remains unclear. However, 
according to Arny et al., (1998) and other studies, a continuous increase in muscle protein 
synthesis would eventually increase lean body mass, provided that protein synthesis was 
to be greater than protein breakdown over time (Bhasin et al., 1996; Brodsky et al., 1996).  
 Androgen is shown to elevate the mRNA levels of insulin-like growth factor-I (IGF-
I), which subsequently plays a role in androgen-mediated muscle growth via the IGF-I 
pathway (Urban et al., 1995; Xu et al., 2004). It is said that IGF-IEc also known as the 
mechano growth factor (MGF) exist as one of the splice variants of IGF-I mediates 
satellite cell activation. Study shows an increased proliferation in C2C12 myoblast upon 
MGF administration (Yang & Goldspink, 2002; Matheny et al., 2010). However, it is 
unknown whether that MGF is the actual effector towards the activation of satellite cells 
(Matheny et al., 2010). In addition, the circulating level of testosterone and androgen 
receptor in the blood are affected by exercise, especially performing resistance exercise. 
A single resistance exercise session (Bamman et al., 2001) and long-term strength 
training (Hameed et al., 2004) can affect the insulin-like growth factor-I (IGF-I) and MGF 
or IGF-IEa. There is a significant correlation between AR and IGF-IEa (MGF) responses 
to resistance exercise such as the anabolic effects of androgens in the muscle (Lewis et 
al., 2002; Hulmi et al., 2008). 
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Figure 2.1 Steroid hormones biosynthesis pathway
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2.5 Effect of E. longifolia on reproductive hormones 
  
 Studies have shown that E. longifolia supplementation increases testosterone 
production and strength in humans and animals (Tambi, 2009; George & Henkel, 2014) 
(Table 2.4). Animal studies are available to show the aphrodisiac and testosterone-
enhancing effects of E. longifolia extract (Ang & Sim, 1998). While in humans, a study 
that examined 76 patients with late-onset hypogonadism (LOH) (below 6 nmol 
testosterone per litre) supplemented with 200 mg of a standardised water-soluble extract 
of E. longifolia for one month showed an increase in testosterone concentration (5.66 
±1.52 to 8.31 ± 2.47 nM) (Tambi et al., 2012).  
 
 To further substantiate the findings of Tambi et al. (2012), a small number of studies 
have shown an increase in testosterone concentration following E. 
longifolia consumption (Henkel et al., 2014; Talbott et al., 2013; Udani et al., 2014). 
Talbott et al. (2013) and Henkel et al. (2014) demonstrated a significant increase in 
testosterone after consuming 200 mg/day and 400 mg/day of E. longifolia for four weeks 
and five weeks, respectively. Interestingly, testosterone concentration in female 
participants also recorded an increase in total (48.6%) and free testosterone (122%) 
(Henkel et al., 2014), which, they suggested but did not further explain, was due to a 
significant decrease in the sex hormone-binding globulin (SHBG). However, a study 
conducted by Henkel et al. (2014) comparing the effect of E. longifolia between male and 
female cyclist with no control group. Hence, the study is not able to establish a cause-
and-effect relationship of E. longifolia and the outcomes could have been confounded by 
external variables.   
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 The liver produces and secretes SHBG into the bloodstream, where it will then bind 
the androgens, such as testosterone and oestrogen with high affinity, regulating their 
bioavailability (Simό et al., 2015). SHBG drives free testosterone and bioavailable 
testosterone levels, and it is said that the hepatic production of SHBG is regulated 
positively by estradiol and negatively by testosterone. Thus, an increase in testosterone 
levels would increase free testosterone levels directly, and indirectly lower the SHBG 
levels (Brand & van der Schouw, 2010).   
 
 Another study administered a combination of E. longifolia (300 mg) and Polygonum 
minus to examine sexual performance and wellbeing in twelve men aged between 40 - 65 
years for 12 weeks. Polygonum minus is a herbal plant commonly used as a food additive, 
flavouring agent and traditionally used to treat stomach and body aches. This herbal plant 
was reported to have high antioxidant content (Christapher et al., 2015). Total 
testosterone levels increased significantly from 359.2 ng/dL to 396.4 ng/dL (p < 0.005) 
with an increase of 10.36% in total testosterone in the treatment group, and a significant 
decrease in free testosterone was recorded for the treatment group (10.73 ± 1.12 to 8.55 
± 1.07 ng/dL). The increased levels in total testosterone and decreased levels in free 
testosterone poses numerous questions regarding testosterone metabolism. E. 
longifolia might increase the production of SHBG, leading to increased metabolism and 
the breakdown of free testosterone, and a decrease in free testosterone (Udani et al., 
2014). The increase in total testosterone in the previous studies may be due to the herb 
being most effective in participants with lower baseline levels of testosterone (Tambi et 
al., 2012; Tambi et al., 2010).  
 
 While the studies reviewed reported a significant improvement in testosterone 
concentration, a study by Ismail et al. (2012) reported otherwise. Ismail et al. (2012) 
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examined the effect of E. longifolia on the improvement of quality of life and sexual 
wellbeing in males aged between aged 30 to 55 years and found no significant changes in 
testosterone, IGF-1, SHBG and dehydroepiandrosterone sulfate (DHEA-SO4). Even with 
a longer supplementation period (12 weeks), administration of 300 mg/day of E. 
longifolia did not induce any testosterone concentration change (Ismail et al., 2012). 
Another double-blind, placebo-controlled, cross-over study, examining 13 healthy male 
recreational athletes supplemented with 400 mg of E. longifolia for six weeks, also did 
not demonstrate a significant increase in testosterone: epitestosterone ratio (Chen et al., 
2014).  
 
 At present, only Low et al. (2013a & 2013b) have suggested that the eurycomanone, 
the bioactive compound in E. longifolia, may enhance the testosterone in the Leydig cells 
by inhibiting aromatase conversion of testosterone to oestrogen, thus affecting the HPG 
axis. However, this postulated mechanism of action behind the reputed effects of E. 
longifolia has only been tested on an animal model. Thus further investigation of the 
mechanism of E. longifolia is needed to rule out a possible effect of certain steroid-like 
compounds found in E. longifolia, such as eurycomanone, that are mediated by receptor 
or feedback loop regulation rather than bioconversion into steroids (Bucci, 2000).  
 
 The quality of E. longifolia was based on the level of eurycomanone (Norhidayah et 
al., 2015), and The Malaysian Standard (2011) stated that the level of eurycomanone 
should be from 0.8-1.5 w/v (%). Although it was suggested that eurycomanone, is 
responsible for the enhanced production of testosterone, studies have not reported the 
content of eurycomanon prescribed in those studies (Table 2.3). However, a few studies 
have reported that the supplement contained 22% eurypeptide which showed 
improvement in testosterone and muscular strength (Ali & Saad, 1993; Sareena & Yusof, 
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2003; Tambi, 2005). Efficacy report by Tambi (2005) showed that dosage of 200, 400 
and 600 mg of E. longifolia (22% Bioactive Eurypeptide) is not toxic to liver function, 
renal function, haematological profile, lipid profile, body electrolytes and body immune 
system as well as cancer markers such as Prostate Specific Antigen.  Thus far, the efficacy 
is only based on the assumption that all E. longifolia do consist of eurycomanone and 
eurypeptide.  
 
2.5.1 Eurycoma longifolia effects of reproductive hormones regulation 
  
 Eurycoma longifolia contains a broad mixture of bioactive compounds (Morita et al., 
1993; Ang et al., 2002; Bedir et al., 2003) and eurypeptides with a molecular weight of 
4.3 kDa known to have effects in improving energy status and sex drive in animal studies 
(Asiah et al., 2007; Zanoli et al., 2009; Ang et al., 2001). In addition, eurypeptide is a 
glycopeptide and has about 36 amino acids. These eurypeptides can activate the CYP17 
(17α-hyroxylase/17, 20 lyase) enzyme to enhance the metabolism of pregnenolone and 
progesterone to produce more dehydroepiandrosterone (DHEA), androstenedione and 
testosterone, respectively (Sambandan et al., 2006; Tambi, 2009; George and Henkel, 
2014).  
 
      Low et al. (2013a) demonstrated that E. longifolia could increase testosterone levels, 
LH, FSH, and decrease oestrogen through the stimulation of the rats’ HPG axis. The HPG 
axis regulates the circulating concentration of testosterone (Borst & Mulligan, 2007) via 
the endocrine feedback loop, with LH and FSH as the main hormonal signals (Amory & 
Bremner, 2003) (Figure 2.2).  
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Table 2.4: Studies conducted to examine the effectiveness of E. longifolia on testosterone production 
Study Dose & duration Participants/Specimen Outcome Reference 
Eurycomanone, the major 
quassinoid in Eurycoma 
longifolia root extract increases 
spermatogenesis by inhibiting 
the activity of 
phosphodiesterase and 
aromatase in steroidogenesis 
100 μL solution of 
Eurycomanone at 
0.1, 1.0 and 10 μM 
Testicular interstitial cells Significantly increased testosterone production dose-
dependently at 0.1, 1.0, and 10.0 μM (p < 0.05) at the 
Leydig cells by inhibiting aromatase conversion of 
testosterone to oestrogen.  
Low et al. 
(2013a) 
Standardised quassinoid-rich 
Eurycoma longifolia extract 
improved spermatogenesis and 




fractions of E. 
longifolia at a dose 
of 25 mg/kg body 
weight 
Male rats E. longifolia fraction (F2) and eurycomanone 
significantly increased the testosterone level from the 
Leydig cells, and the plasma LH and FSH levels were 
significantly higher than the control group. 
Low et al. 
(2013b) 
Standardized water-soluble 
extract of Eurycoma longifolia, 
Tongkat Ali, as testosterone 
booster for managing men with 
late-onset hypogonadism? 
200 mg for 1 month 76 of 320 LOH patients 
28 – 70 years 
Prior to treatment, 35.5% (n = 27) had normal 
testosterone (5.66 ± 1.51 nm) level. Post treatment, 
90.8% (n = 69) showed normal (8.31 ± 2.47 nm) 
values. 
Tambi et al. 
(2012) 
Tongkat Ali as a potential herbal 
supplement for physically active 





13 physically active male 
and 12 female 
57 - 72 years 
Significant increase in total testosterone (+15.1%) 
and free testosterone concentrations (+61.1%) 
(p<0.05) 
Henkel et al. 
(2014) 
Effect of Tongkat Ali on stress 
hormones and psychological 
mood state in moderately 
stressed subjects. 
200 mg daily 
for 4 weeks 
63 male aged 45 - 65 years 
moderately psychological 
stressed male 
Significant increase in testosterone levels in all sub-
fertile men.  




Table 2.4: Studies conducted to examine the effectiveness of E. longifolia on testosterone production (continued) 
Study Dose & duration Participants/specimens Outcome Reference 
Effect of a proprietary freeze-
dried water extract of 
Eurycoma longifolia and 
Polygonum minus on sexual 
performance and well-being in 
men: A randomised, double-
blind, placebo-controlled study 
300 mg 






30 healthy males aged 40 
- 65 years 
 
Significant increase in total testosterone from 359.2  
ng/dL to 396.4 ng/dL (p < 0.05) 
Udani et al., 
(2014) 
Randomised clinical trial on 
the use of Physta freeze-dried 
water extract of Eurycoma 
longifolia for the improvement 
of quality of life and sexual 





30 - 55 years 
No significant changes in testosterone, IGF-1, SHBG, 
and DHEASO4among the E. longifolia group or 
differences to placebo 
Ismail et al. 
(2012) 
Supplementation of Eurycoma 
longifolia Jack Extract for 6 
weeks does not affect urinary 
testosterone: epitestosterone 
ratio, liver and renal functions 




13 healthy male 
recreational athletes 
29.0 ± 5.5 years 
T: E ratio was not significantly different following 6 
weeks supplementation of either E. longifolia or placebo 
group compared with respective baseline values. 
Chen et al. 
(2014) 
Effect of Eurycoma longifolia 
extract on anabolic balance 
during endurance exercise 
100 mg/day  
24 hours 
15 male cyclist Significantly decreased cortisol levels and increased 
testosterone levels 












Figure 2.2: Hypothalamic-pituitary-gonadal axis regulates the circulating 
concentration of testosterone. 
 
 Inhibition of aromatase occurs when E. longifolia is supplemented (Low et al., 2013a). 
Rat testicular Leydig cells showed an increase in testosterone production dose-
dependently at 0.1, 1.0 and 10.0 μM compared to the non-treated group, and dosing 
eurycomanone alone on rat testicular Leydig cell-rich interstitial cells significantly 
decreased the oestrogen levels. The reduction of oestrogen levels by eurycomanone could 
be due to competition between the quassinoid and oestrogen at the oestrogen receptor, 
eventually culminating in reduced oestrogen production, or quassinoid may directly 
inhibit the aromatase enzyme that converts testosterone to oestrogen. To test the 
hypothesis, a combination of formestane (1.0, 10.0, 200 nM), an aromatase inhibitor with 
eurycomanone (1.0 μM) was administered; it showed a significant reduction in oestrogen 
(p < 0.05) compared to the group administrated with formestane alone or the control 
group. These findings indicate that eurycomanone may not react on the oestrogen 
receptor; however, the quassinoid may share the exact aromatase inhibition mechanism 
as with formestane. It is conclusive that eurycomanone acts on oestrogen production in 
the rat testicular Leydig cell by inhibiting aromatase from blocking testosterone’s 
Negative 
feedback 
Stimulates Leydig and Sertoli cells 
Hypothalamus 
Gonadotropin releasing hormone (GnRH) 
Stimulates Anterior pituitary 
Luteinizing Hormone (LH) and follicle stimulating hormone 
Testosterone levels and spermatogenesis increases 
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conversion to oestrogen and, subsequently, explains the elevation of testosterone levels 
(Figure 2.3).  
 
 
Figure 2.3: Inhibition of aromatase to prevent the conversion of testosterone to 
oestradiol 
 
 Findings by Low et al. (2013a) were further substantiated by another study conducted 
in the same year (Low et al., 2013b), where male rats were treated with bioactive fractions 
of E. longifolia at doses of 10, 25, 50 mg/kg for 48 days. There was an increase in plasma 
testosterone levels and gonadotropins, LH and FSH. The study also reported a reduction 
in plasma oestrogen levels. The authors concluded that E. longifolia treatment did indeed 
down-regulate the oestrogen-mediated feedback effect for LH and FSH secretions in the 
HPG axis. The reduction or absence of the oestrogen-mediated feedback effect and the 
low level of oestrogen allowed the pituitary gland to continuously release LH and FSH 














2.6 Effect of E. longifolia on sexual function and psychological mood state 
 
 The ability of E. longifolia to increase and maintain testosterone levels provides 
numerous benefits, such as increased muscle mass and reduced body fat, improved 
psychological vigour, such as mental or physical strength, and general wellbeing (Miller, 
2009; Grossmann, 2011). The roots of E. longifolia are typically used as an adaptogen to 
help individuals that have reduced mood levels and libido due to ageing (Adimoelja, 
2000; Cyranoski, 2005; Joseph et al., 2005; Wan Hassan, 2007; Zhari et al. 1999). 
Adaptogen is defined as a substance used in herbal medicine to increase the body’s ability 
to resist the harmful effects of stress and support or restore normal physiological 
functioning (Panossian & Wagner, 2005). Tambi and Kadir (2005) found that E. 
longifolia improved haematological and lipid profile and sexual function. Testosterone 
levels start to decrease by approximately 1 to 2% annually after the age of 30 years (Gatti 
& De Palo, 2011), thus affecting the psychological mood state and sexual wellbeing of 
individuals. E. longifolia could, therefore, be used as a supplement for testosterone 
replacement to improve psychological parameters such as mood, sense of wellbeing and 
improved sexual function in those with hypogonadism (Talbott et al., 2013; Ang & 
Cheang, 1999). 
 
2.6.1 Effect of E. longifolia on sexual functions 
   
 In three studies, the rats were obstructed by an electric grid (0.10 mA) in the electrical 
copulation cage to investigate how much an aversive stimulus (crossing the electric grid) 
the male rats were prepared to overcome to reach the oestrous receptive female rats in the 
other side of the cage. Interestingly, there was a decrease in the hesitation time in reaching 
the oestrous receptive female in the goal cage after eight weeks of E. longifolia 
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supplementation. Thus, three studies’ authors suggested that the extract improves sexual 
qualities in male rats (Ang et al., 2003a; Ang & Lee, 2002; Ang & Ngai, 2001).   
 
 Earlier, Ang et al. (2000) investigated the effects of E. longifolia on the initiation of 
the sexual performance of castrated male rats. Each male rat was supplemented with E. 
longifolia at various dosages for 50 to 80 days, and sexual performance tests were 
performed in the copulation cage after ten days of treatment. In the test, the male rats 
were introduced to the female rats. The rats were monitored for any mounting without 
intromission or vaginal intromissions. If either of these two copulatory behaviours ended 
with ejaculation, the performance test was terminated. Thus, they demonstrated a dose-
dependent increase in sexual performance of E. longifolia treated rats by eliciting an 
increase in mounting, intromission, and ejaculation.  
 
 Ang and Lee (2002) further substantiates this phenomenon by showing increases in 
orientation activities in male rats, which have been fed with E. longifolia, toward the 
receptive females (anogenital sniffing, licking and mounting), an increase in genital 
grooming of themselves and a preference for restricted movements within a particular 
area of the cage with the female rats, with decreased interest in the external environment 
(climbing, rearing, exploring).  
 
 Most studies examining the impact of E. longifolia in managing sexual dysfunction is 
via in vivo animal models (Ang & Ngai, 2001; Ang & Lee, 2002; Ang et al., 2003a; 
Ang et al., 2003b; Ang & Lee, 2004), with limited research conducted in human trials 
(Thu et al., 2017; Tambi, 2009; Tambi et al., 2012; Ismail et al., 2012; Muhammad et al., 
2010; Udani et al., 2014; Tambi & Imran, 2010). Although human studies have provided 
some significant findings, the effectiveness of E. longifolia on sexual function in human 
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has only been demonstrated in three studies, and the mechanisms behind the changes are 
still unknown. The three studies (Tambi et al., 2012; Ismail et al., 2012; Udani et al., 
2014) recruited similar age groups ranging from 30 to 65 years (Table 2.4). While Tambi 
et al. (2012) recruited participants diagnosed with hypogonadism, Ismail et al. (2012) and 
Udani et al. (2014) recruited healthy participants, along with some participants with 
chronic medical illnesses such as controlled diabetes mellitus and hypertension. 
 
 Tambi et al. (2012) in their clinical study, showed improvement in ageing male 
symptoms (AMS) among participants with hypogonadism. The AMS was used to assess 
ageing symptoms under different health conditions, evaluate the severity of symptoms, 
and measure changes post androgen replacement therapy (Heinemann et al., 2003; Badia 
& Herdman, 2001). The AMS was categorised into no complaints, a few complaints, mild 
complaints and severe complaints. Prior to the treatment, 10.5% of the patients did not 
show any complaints, but this increased to 71.1% after being treated with E. longifolia 
for four weeks. Increased testosterone concentration was observed as well (Tambi et al., 
2012). However, in Ismail et al. (2012) administration of 300 mg of E. longifolia to 109 
healthy men found significant improvements in overall erectile function, sexual libido 
and overall sexual satisfaction scores in the E. longifolia group (p < 0.001). Also, in a 
double-blind and placebo-controlled study on 30 healthy males, improvements in the 
frequency of sexual performance, penile erection and hardness, and overall sexual 
wellbeing were observed when treated with E. longifolia (Udani et al., 2014). Thus, the 
three studies’ findings demonstrated the effectiveness of E. longifolia not only on elderly 
participants diagnosed with LOH but also on healthy elderly participants in improving 
quality of life and sexual wellbeing. 
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 Despite E. longifolia's promising efficacy of improving sexual function demonstrated 
in numerous animal model studies and limited human studies (Table 2.5), more data 
related to E. longifolia and male sexual function are required to determine whether age or 
health play a role in determining the effectiveness of E. longifolia.  
 
2.6.2 Psychological mood state following E. longifolia consumption 
  
 Consumption of E. longifolia can reduce anxiety levels in animal models (Ang & 
Cheang, 1999). Ang and Cheang (1999) demonstrated an anti-anxiety effect in various 
behavioural tests, such as emotional state anxiolytic and anxiogenic drug effects in 
rodents following E. longifolia feeding. In this study as well, the E. longifolia anxiolytic 
effect was reported to be similar to that of the positive control diazepam, a controlled drug 
substance used to treat anxiety (Table 2.5). Thus the effects are thought to be due to a 
restoration of normal testosterone levels post E. longifolia supplementation.  
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Table 2.5: Studies demonstrating the potential of E. longifolia in improving male sexual function 
 
Test Subjects  Dosing regimen and 
duration 
Findings Reference 
Sexual Intercourse Attempt 
diary, Erection Hardness Scale, 
Sexual Health Inventory of Men, 
and Aging Male Symptom 
30 healthy male 
aged 40 - 65 
years 
 
300 mg daily  
6 months 
Significant improvements in all test  Udani et al. 
(2014) 
The Ageing Males’ Symptoms 
(AMS) and the serum 
testosterone concentration  
76 patient with 
LOH aged 30 - 
64 years 
200 mg daily 
1 month 
Improved AMS score, serum testosterone 
concentration. Improvement in sexual performance 
Tambi et al. 
(2012) 
International Index of Erectile 
Function (IIEF) and Sexual 
Health Questionnaires (SHQ); 
Seminal Fluid Analysis (SFA) 
109 healthy 
men aged 30 - 
55 years 
300 mg daily  
3 months 
Improved in the domain Physical Functioning, 
Erectile Function domain, sexual libido  
Ismail et al. 
(2012) 




adult male rats 
 
0.5 g/kg E. longifolia 
 
Decreased the hesitation time of noncopulator male 
rats  
Transient increase in the percentage of the male rats 
responding to the right choice  
Ang and 
Ngai (2001) 
Monitoring orientation activities  
towards the receptive females  
Adult middle-
aged  
9 months old 
and retired 
breeders 
200, 400 and 800 mg/kg 
of  E. longifolia fraction 
 
 
Increased orientation activities towards the receptive 
females (anogenital sniffing, licking and mounting), 
increased genital grooming towards themselves  
 
 
Ang et al. 
(2000) 
Electrical copulation cage during 
the dark phase of the light-dark 
cycle and in subdued light. 
Adult male rats, 
9 months old 
and retired 
breeders 
0.5 g/kg of E. longifolia 
 
control group : 3 ml/kg 
of normal saline daily 
for 12 weeks 
Enhanced sexual qualities by decreasing their 
hesitation time to controls.  
 
Ang et al. 
(2003a) 
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 The survey conducted by Talbott et al. (2013) investigated E. longifolia on stress 
hormones and the psychological mood state in a moderately stressed human subject. The 
survey assessed mood states, such as vigour, depression, anger, confusion, fatigue and 
anxiety. Significant improvements were reported in E. longifolia groups for tension (-
11%), anger (-21%), and confusion (-15%) compared to placebo. The hormone profile 
(salivary cortisol and testosterone) was also tested, and findings showed significant 
improvement post supplementation, with reduced cortisol level (- 16%) and an increase 
in testosterone (+37%), with an overall improvement in cortisol: testosterone ratio by -
36% (Table 2.6).  
 
 In a more recent randomised, double-blind and placebo-controlled study (George et 
al., 2018), 93 participants aged 25 to 65 years were supplemented with 50 mg of E. 
longifolia water extract plus multivitamins for 12 weeks, and they found an increasing 
trend in the profile of mood states scale (POMS) at week 12 and a reduction of 15% in 
physical stress. However, when the participants were subdivided according to age, those 
aged 46 to 65 showed significant improvement in the POMS-vigour (+14.1%) domain 
compared to the younger age group. The older group’s improvement was due to a 
reduction in muscle strength and endurance with age, changes in body fat percentages, 
and poor nutrition. Thus, E. longifolia supplementation improved muscles and strength 
acted in an anti-ageing capacity and enhanced vigour (George et al., 2018). According to 
the findings to date, it is suggested that this plant could be beneficial for individuals 
affected by daily chronic stress, dieting, sleep deprivation and exercise training stress. 
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Table 2.6: Selected studies on the effect of E. longifolia on psychological mood state. 
 
Study Test Dosage Outcome Reference 
Studies on the anxiolytic 
activity of E. longifolia Jack 
roots in mice.  
Inbred adult albino mice 
Supplementation twice daily 
for 5 days. 
Open-field test, elevated 




Chloroform (0.3 g/kg) 
Methanol (0.3 g/kg) 
Water (0.3 g/kg) 
Butanol (0.3 g/kg) 
Control (3 ml/kg) 
Diazepam (1 mg/kg) 
E. longifolia attenuated anxiety parameters 
in open-field and plus-maze test and 




Effect of Tongkat Ali on stress 
hormones and psychological 
mood state in moderately 
stressed subjects. 
POMS survey in 63 
moderately stress men and 
women. Supplemented for 4 
weeks 
200 mg / day  Significant improvement for Tension, 
Anger, and Confusion   
Cortisol and testosterone significantly 
improve, reduced cortisol exposure and 
increased testosterone  
Talbott et 
al. (2013) 
Efficacy and safety of 
Eurycoma longifolia (Physta) 
water extract plus multivitamins 
on quality of life, mood, and 
stress 
POMS survey in 93 subjects. 
E. longifolia plus 
multivitamins 
12 weeks 
50 mg /day Increased trend in POMS vigour domain 
Significant improvement on POMS vigour 




2.7 Effects of E. longifolia on physical strength                       
  
 Eurycoma longifolia offers the potential of improving strength and power for those 
engaged in sport and exercise (Table 2.7). There are preliminary data that support the 
claims made on E. longifolia concerning improvements in strength and body composition 
(Hamzah & Yusof, 2003; George et al., 2013). At present, only Hamzah and Yusof 
(2003) and Chen et al. (2019) have conducted studies on young men, while other studies 
recruited participants aged between 30 to 72 to examine the effectiveness of E. 
longifolia in muscular strength. In their pilot study, Hamzah and Yusof (2003), 
investigated the ergogenic effects of E. longifolia supplementation on fourteen healthy 
men by ingesting 100 mg per day of E. longifolia water extract and performing an intense 
strength training programme for five weeks. The combination of supplementation and 
strength training-induced an increase in muscle strength by 6.8% (p < 0.05). Also, the 
pilot study showed a significant increase in lean body mass, reduction in the percentage 
of body fat, and increased mean arm circumference in the E. longifolia treated group. In 
a more recent study, 40 young males were assigned into four groups: control group, E. 
longifolia group, E. longifolia combined with resistance training and resistance training. 
Participants in the E. longifolia and E. longifolia combined with training, were dosed with 
200 mg E. longifolia for eight weeks (Chen et al., 2019). This study showed that the 
combination of E. longifolia administration and resistance training, and even 
supplementation alone, improved isokinetic power and anaerobic power. Although there 
was no significant improvement in strength, there was a trend towards increased strength 
when E. longifolia was taken while resistance training was performed.       
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Table 2.7: Effect of E. longifolia supplementation in improving muscular strength 




Performed intense strength training with 
supplementation of E. longifolia water-






1RM test showed a significant increase in the 
treatment group compared to the placebo group. E. 




A total of four interval visits and 
required to performed physical testing at 











T: E ratio did not change during the 12 weeks 
supplementation period. 
Muscular strength improved significantly in the 
back and leg 
George et al. 
(2013) 
Supplementation of E. longifolia for 5 
weeks. A resting, fasting blood sample 
were collected before treatment and 
during week 3 and 5. Muscular strength 









Significant increase in total and free testosterone 
and muscular force in men and women 
Henkel et al. 
(2014) 
Resistance training with E. longifolia 
supplementation. Strength examined 
using handgrip strength. Muscle 
circumference determines using an 
ultrasound method.  
31 middle-
aged 
women,  45 
- 59 years 
12 weeks 
100 mg/day 
Increased handgrip strength and bigger quadriceps 
muscles as determined by cross-section of the 
rectus femoris muscle compared to placebo. 
Sarina et al. 
(2009) 
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 Previous studies examining the effectiveness of E. longifolia on muscular strength 
mainly recruited older participants. Ooi et al. (2015) are one of the most recent studies to 
examine the combined effects of E. longifolia and a circuit training programme on 
muscular strength and power in men aged around 46 years old. In this study, eight weeks 
of 400 mg of E. longifolia and circuit training programme was found to have improved 
muscular strength and power compared to the group that performed circuit training alone. 
However, Ooi et al. (2015) did not report any possible confounding factors such as dietary 
intakes, daily physical activities, or whether the training involved a specific target heart 
rate zone in standardizing the intensity.  
 
 In a later study conducted by Sarina et al. (2009), for the first time on women aged 45 
to 59 years, 100 mg per day of E. longifolia was supplemented for 12 weeks, and strength 
training was performed twice weekly (Sarina et al., 2009). The treatment period 
demonstrated an increase in muscle strength and a more significant increase in quadriceps 
muscle size. There followed a study by Henkel et al. (2014), which saw 12 active female 
and 13 active male recruits aged between 57 to 72 years supplemented with 400 mg E. 
longifolia daily for five weeks and demonstrating increased muscular strength while 
performing the handgrip test. Although females reported increased in strength, the 
muscular strength remained significantly lower than in the male participants. The findings 
further affirm the ergogenic benefits of E. longifolia through enhanced muscle strength 
not just in men but also in females. However, this study (Henkel et al., 2014) compared 
between male and female cyclist with no control group. In order to determine whether 
there is an effect to a treatment, a control group is needed to provide a baseline data. 
Furthermore, testosterone is not measured in females to indicate a possible relationship 
between strength and the testosterone-enhancing E. longifolia. Hence, the increase in 
strength could be due to the resistance training itself and not entirely due to E. longifolia.    
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 At present, only one randomised, double-blind, and placebo-controlled trial with 40 
male non-athletes aged between 30 to 55 years supplemented with 300 mg/day of E. 
longifolia for 14 weeks with no strength training has been carried out by George et al. 
(2013). There was a significant increase in back and leg strength in the E. 
longifolia supplemented group; however, other fitness tests did not show any changes. It 
speculated that a higher dose and longer duration of supplementation in young and older 
participants might produce better improvement in physical strength.  However, the 
effectiveness of E. longifolia alone in improving strength is still debatable, especially in 
young males. Previous studies have shown that supplementation of E. longifolia 
demonstrates an increase in testosterone. However, no study has been conducted to date 
to determine whether supplementation of E. longifolia alone will affect muscular strength 
in young, healthy males with normal testosterone concentration.  
 
2.8 Summary of literature review 
  
 Cytotoxicity tests are important steps to determine the cytotoxicity and inhibition of 
cell growth following exposure to a toxic substance. Numerous bioactive compounds 
isolated from E. longifolia have shown positive cytotoxic and anti-proliferation responses 
towards various cell lines, especially cancer cells. However, a small number of 
examinations have shown that E. longifolia is not cytotoxic on normal cell lines but 
improves normal healthy cells’ proliferation. E. longifolia has been described as a 
testosterone replacement due to its androgen characteristics, and this claim can increase 
in the usage of E. longifolia in the near future. Thus, whether the administration of E. 
longifolia on SMCs will promote hypertrophy or promote cell death are still not being 
investigated or answered.  
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 Previous studies have shown that E. longifolia can induce aromatase inhibition and, 
thus, prevent the conversion of testosterone to oestrogen, allowing more testosterone 
concentration production. This inhibition of aromatase will then cause the hypothalamus 
to sense a decline in the negative feedback signal. This inhibition will prompt the anterior 
pituitary to secrete more LH and FSH and, subsequently, produce more testosterone by 
the Leydig cells. The authors have demonstrated the mechanism of E. longifolia in their 
animal studies and suggested that similar mechanisms may happen in humans to increase 
testosterone. However, it is still unknown whether the mechanism demonstrated in their 
study (Low et al. 2013a) will be the same in humans. 
 
 The testosterone level in humans has been shown to increase in fat-free mass, muscle 
size, and strength in young, healthy men using E. longifolia supplementation with a 
combination of strength training. Physically active older men and older men with LOH 
have also demonstrated an increase in muscular strength. However, the increase in 
muscular strength may be due to the high-intensity strength training and low testosterone 
concentration due to the ageing process, and the herbal supplement may have an anabolic 
effect. Apart from muscular strength improvement through supplementation of E. 
longifolia, studies have shown that the plant extract effectively improves the 
psychological mood state and sexual function wellbeing in animal studies. Although a 
small number of human studies have been conducted, it is still too early to conclude its 
efficacy in improving mood state and sexual function in various age groups.  
 
 In conclusion, studies have been conducted to elucidate the mechanism of E. 
longifolia via the changes in reproductive hormones to determine the effect of the plant 
on muscular strength, mood and sexual function. Numerous cytotoxicity tests have been 
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performed on numerous cell lines, but more extensive studies in human and skeletal 






CHAPTER 3: THE CYTOTOXICITY OF E. longifolia ON C2C12 MURINE 




Various parts of the plant demonstrate anti-cancer, anti-ulcer, anti-tumour, anti-
pyretic, anti-schistosomal and anti-malarial properties (Ismail et al., 1999; Harun et al., 
2015). Numerous bioactive compounds, such as quassinoid, alkaloids, triterpenes, and 
steroidal compounds, have been isolated. However, not all of the bioactive compounds 
have been screened for their cytotoxic effects. Quassinoids and alkaloids exhibit a 
cytotoxic effect on certain cells lines: for example, epidermoid carcinoma (KB) and 
murine lymphocytic leukaemia (P-388) cell lines (Morita et al., 1990; Kardono et al., 
1991; Morita et al., 1993; Kuo et al., 2004; Chan et al., 2004).  
 
Many studies have been conducted to isolate the bioactive compound of E. longifolia, 
which has then been used to determine the cytotoxicity effect on various cell lines, and a 
preliminary in vitro cell culture study was performed to examine any potential 
cytotoxicity of E. longifolia on SMCs, which exhibits the characteristics of normal 
myoblastic cells. In the present study, C2C12 cells from the thigh muscle of 2-month-old 
normal mice were used to examine the response of SMCs to exposure to E. longifolia 
during differentiation. C2C12 cells are derived from murine SMCs, and there is a well-
established model to study muscle regeneration and differentiation. An extract is 
considered cytotoxic if it interferes with the attachment of SMCs, significantly changing 
the morphology, affecting the rate of cell growth, and causing the cells to die (Horvath, 
1980). A cytotoxicity study is the first step in examining the toxicity of E. longifolia, and 
this is the first time it is being tested on SMCs.    
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3.2 Literature Review 
  
 Several studies have shown the androgen-like or testosterone-enhancing effects 
of E.longifolia. E. longifolia has been found to increase the copulatory activity, leavator 
ani muscle activity, the initiation of sexual performance, and spermatogenesis in animal 
studies (Ang et al., 2000; Ang & Cheang, 2001; Ang & Lee, 2002; Zanoli et al., 2009; 
Tambi & Imran, 2010; Wahab et al., 2010; Erasmus et al., 2012). In human studies, 
individuals with LOH, is a condition in older men that has low testosterone levels have 
shown improvements when treated with E. longifolia (Tambi et al., 2012). These animal 
and human studies collectively show that E. longifolia has the potential to be an 
alternative to testosterone therapy. However, E. longifolia also exhibits cytotoxicity 
effects on cancer cell lines (Thu et al., 2017).  
 
3.2.1 Cytotoxicity Effect of E. longifolia on Cell Lines 
 
 Table 2.2 in Chapter 2 summarise the findings of studies related to the cytotoxicity 
effect of E. longifolia on various cell lines at a different dosage of bioactive compounds 
isolated from it. The studies demonstrate cytotoxicity and anti-proliferative effects mainly 
from E. longifolia methanol and chloroform extracts with doses ranging from 2.5 to 100 
μg/ml of E. longifolia on A-549 lung cancer cell line, MCF-7 breast cancer cell line, 
HT1080 fibrosarcoma cancer cell line, HeLa cervical cancer cell line, CaoV-3 human 
ovarian cancer cell line, HepG2 human liver cancer cell line, HM3KO melanoma cells, 
LNCap human prostate cancer cells, and murine lymphocytic leukaemia (P-388) (Table 
3.1). (Kardono et al., 1991; Kuo et al., 2003, 2004; Chuen & Pihie, 2004; Nurhanan et 
al., 2005; Mahfudh & Pihie, 2008; Zakaria et al., 2009; Wong et al., 2012; Al-Salahi et 
al., 2014; Hajjouli et al., 2014; Park et al., 2014; Tong et al., 2015). Their findings 
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indicate the termination of cell growth or cell death post-E. longifolia administration in 
cancer cell lines.  
 
 While many demonstrate cytotoxicity in cancer cells, little is known about E. 
longifolia water extract’s effect on normal cell lines. Although limited, one study has 
shown no cytotoxic effect when E. longifolia is administered to bovine kidney cells 
(MDBK) (Nurhanan et al., 2005). Also, concentrations ranging from 5 - 2500 μg/ml of E. 
longifolia were administered to osteoblast MC3T3-E1 cell line, but only the concentration 
of 1 - 25 μg/ml E.longifolia showed a significant increase in the proliferation in MC3T3-
E1 (Thu et al., 2017). Both studies suggest that E. longifolia extract is not toxic or harmful 
to normal cells and can prevent osteoporosis by increasing proliferation rate in a selective, 
time and dose-dependent manner. However, no cytotoxicity test has been conducted on 
SMCs, and it is still unknown whether it can produce the same results found in Nurhanan 
et al. (2015) and Thu et al. (2017).   
  
3.2.2 Cytotoxicity Assay 
  
 Various tests to measure the bioactive compounds’ cytotoxicity effect, e.g. MTT, SRB, 
and MTS assay. The MTT assay is used to measure cellular activity to determines cell 
viability. Among all the cytotoxicity tests, the MTT assay is the most commonly used 
method to test the cell culture’s cell growth rate and toxicity. Although the MTT assay is 
accurate compared to other detection methods, there are problems in the application. For 
example, the test results are not the same when using different doses of extract: at high 
concentrations, the particles accumulate in the bottom of the culture wells and hinder the 
measurement of optical density; it is also a cumbersome procedure (Allen et al., 1994; Li 
et al., 2015).   
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The Lactate dehydrogenase (LDH) assay has been developed as a standard test and is 
used regularly in human medicine as a diagnostic test for myocardial injury and neoplasia 
(Allen et al., 1994). The levels of LDH activity in samples of cell lysate are measured 
using an LDH assay kit. The enzyme is released into the culture medium only if the 
plasma membrane is damaged, and the release of LDH from cells has been used 
extensively as an accurate marker for cell death.  
In the present study, the LDH assay is used as a cytotoxicity detection method. It has 
high reliability and is suitable for the screening and characterising of plant extracts as 
phytotherapeutic compounds (Specian et al., 2016). Furthermore, according to the LDH 
assay’s basis shown in Figure 3.1, LDH levels can be detected accurately to determine 
whether there is any cell death happening due to the plant extract.  Since plant extract 
users have increased tremendously over the years for various purposes, such as improving 
strength and muscle mass, it is vital to examine E.longifolia crude extract on SMC to 
identify potential cytotoxicity at an early stage. Hence, the present study is aimed at 













                    
 




















reading at 490 nm 
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3.3 Methods 
3.3.1 General Cell Culture for Skeletal Muscle 
 
Cell culture was conducted under the cell culture hood by Kojair Biowizard Silverline 
class II hood (Kojair. Vippula, Finland), and all cells cultured were incubated in the 
HERA cell 150i Incubator (ThermoScientificInc. Cheshire, UK) at 5% CO2 and 37 ºC. 
Commercially available C2C12 cells population were purchased from ATCC and cultured 
on T75 cm2 (Nunc. Roskilde, Denmark) culture flasks. Experiments were also conducted 
on cell monolayers seeded on sterile six-well plates (Nunc. Roskilde, Denmark). All 
culture flasks and the six-well plates were coated with 2 ml/l porcine gelatin solution 
(~90-110 g Bloom; Sigma-Aldrich Company Ltd. Dorset, UK) to enable cell adhesion.  
Waste media, supernatant, phosphate-buffered saline (PBS) wash, and any other liquid 
were discarded using an extraction pump (Charles Austen Pump Ltd, Surrey, UK). As for 
the solution’s preparation, dH2O from a MilliQ water purification system (Merck KGaA. 
Darmstadt, Germany) was used.  
 
Skeletal muscle cell culture was performed prior to the experimental study. All T75 
flask was gelatinised with 8 ml of gelatin (0.2% gelatin solution) using the 10 ml pipette 
in a sterile condition, and was T75 was left under the flow hoods for 10 minutes at room 
temperature. Following that, T75 was relocated to the incubator at 37ºC for 10 minutes. 
At the same time, the growth media were warmed up in the small oven at 37 ºC. Whilst 
the culture flasks are warming in the incubator, one vial of cells was taken out from the 
liquid nitrogen storage. The vial is then placed in the water bath and leave the cells in the 
vial to thaw for approximately two to three minutes in the water bath. When the vial of 
cells is thawed, the oven’s growth was place under the hood. Next, the T75 was removed 
from the incubator, and the excess gelatin was aspirated off, and 14 ml of growth media 
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was added to the T75 using a 25 ml pipette. Pipette 1 ml from the vial on top of the media 
into the T75 flask. The T75 flask was gently moved from side to side six times in each 
direction to ensure the cells are evenly distributed and are not clumped together. 
Following that, the T75 flask was clean with a paper towel with 70 % ethanol before 
placing the flask into the incubator at 37 ºC (5 % CO2). The T75 was incubated for 72 
hours to allow the cells to attach and proliferate to confluence. A similar procedure was 
performed on the six-well plates. 
 
3.3.2 Reagents, Media, and Cell Culture Preparation 
 
Reagents consisted of Dulbecco’s Modified Eagles Medium (DMEM), purchased 
from Sigma-Aldrich (Sigma-Aldrich Co. Dorset, UK). Heat-inactivated horse serum 2% 
(HS), 10 % heat-inactivated foetal bovine serum (FBS), 10% heat-inactivated newborn 
calf serum (NBCS) and 1% penicillin-streptomycin (PS) were purchased from Gibco 
(Life Technologies. California, US). Phosphate buffered saline (PBS) for cell monolayer 
washes was purchased in tablet form from Sigma-Aldrich and reconstituted to give a 
working concentration of 0.01 M phosphate buffer, 0.0027 M KCl, and 0.137 M NaCl, 
pH 7.4 in dH2O.  
 
Primary culture myoblast growth media (GM) for murine C2C12 cells consisted of 
DMEM, 10% FBS (50 ml), 10% NBCS (50 ml), 1% penicillin-streptomycin (50 units 
penicillin / 50 μg streptomycin) and 2 mM L-Glutamine (5 ml). Differentiation media 
(DM) preparation for C2C12 growth consisted of DMEM, 2% heat-inactivated horse 
serum (10 ml) and 1% penicillin-streptomycin (5 ml) and 2 mM L-Glutamine (5 ml). Both 
penicillin-streptomycin and L-Glutamine were filtered through a 0.445 μl filter before 
adding into DMEM.  
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Before using the cell culture hood and all equipment placed under the hood were 
sprayed with 70% ethanol for sterilisation.  Next, the T75 flask was gelatinised with 
approximately 5 to 8 ml of 0.2 % gelatine solution using a large pipettor and 10 ml pipettes 
in sterile conditions. Gelatine is a translucent and colourless substance extracted from an 
animal, which acts as an extracellular matrix (ECM) protein so that C2C12 attaches to the 
base of the flask via integrin binding. Gelatinised flask was left under the hood for 10 
minutes at room temperature and subsequently transferred into the incubator 37 ºC for 
another 10 minutes.  
 
According to Pronsato et al. (2013), skeletal muscle cells, C2C12 with passage numbers 
less than 20 and passage numbers more than 60, are considered low and high passage 
numbers. High passage numbers exhibit alteration in cell morphology by demonstrating 
reduced proliferation or differentiation. Thus a low (passage 13) and mid (passage 26) 
passage number were chosen for the present study. Both passage numbers can grow 
confluent better than other passage numbers below passage 30 in the present laboratory.  
 
Vials of C2C12 cells from passages 13 and 26 were thawed for 2 to 3 minutes.   Next, 
1 ml of C2C12 cells was seeded onto the gelatinised T75 at 1 x 10
6 cells/ml in a growth 
medium pre-heated to 37 oC. The cells were then distributed evenly by moving the T75 
flask side to side gently six times in each direction. Immediately the T75 was cleaned 
with 70 % ethanol just before placing it in the incubator at 37 ºC (5% CO2). The cells 
were incubated for 72 hours to allow the cells to attach and proliferate to confluence. The 
cells were checked for any contamination, and growth media was changed at 24 and 48 
hours during the incubation period.  
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3.3.3  Eurycoma longifolia Stock Solution Preparation 
 
Eurycoma longifolia was sponsored for this study (ERP Two One Technologies & 
Innovations Sdn Bhd). The quality of E. longifolia was based on the level of 
eurycomanone, which is the main compound found in E. longifolia (Norhidayah et al., 
2015). The Malaysian Standard (2011) stated that the level should be from 0.8-1.5 w/v 
(%). The E. longifolia used in the present study complied with the standard since 
eurycomanone content was 1.21 w/v (%) (Appendix B).  
 
The stock solution of E. longifolia was prepared prior to addition to the media. To 
prepare a 200 mg/ml stock solution, mix 1000mg of E. longifolia with 5 ml of GM. 
Following that, the stock was filtered with a 0.2 μl filter. Since no previous studies have 
been conducted on C2C12, various doses were tested at 2.0, 1.0, 0.5, 0.25, 0.125 mg/ml of 
E. longifolia, and differentiation media (DM) as a control. A dilution of 1:100 of the E. 
longifolia stock (200 mg/ml) produced 2.0 mg/ml starting volume. A 0.1 ml of E. 
longifolia from the stock volume was added to 9.9 ml of DM to make 10.0 ml of 2.0 
mg/ml E. longifolia. Double dilution was performed to prepare the 1.0, 0.5, 0.25, 0.125 
mg/ml of E. longifolia.  Differentiation media was made and act as a control treatment 
(CON). The five doses of E. longifolia and CON were seeded onto a 6-well plate seeded 
with C2C12. 
 
3.3.4 Microscopy  
All cell imaging and photography were performed on a Leica DMI 6000B inverted 
research microscope (Leica Biosystems GmbH. Nussloch, Germany). Images were 
captured with a 10X objective and 0.5 magnification c-mount lens fitted to a camera. 
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3.3.5 Dose-response and Cytotoxicity Lactate Dehydrogenase Assay 
 
After 72 hours of incubation, C2C12 cells were examined under the microscope. Once 
80% confluence was attained, cells were trypsinised.  Existing growth media (GM) in the 
T75 flask was aspirated and subsequently rinsed twice with PBS. Next, 1 ml of trypsin 
was injected into the T75 flask slowly, and the dish was tapped to make sure the trypsin 
solution covered the entire flask. The flask was then incubated at 37 ºC for 5 minutes. 
After 5 minutes, the cells were examined under the microscope to ensure non-adherence 
to the flask. Following that, 4 ml of fresh GM was added into the T75 to neutralise the 
trypsin. It was then mixed by collecting up and down approximately 5 to 10 times in a 10 
ml pipette tube and transferred into a 50 ml tube.   
 
Neubauer haemocytometer was used for cell counting.  The cells were prepared as a 
1:1 suspension in 0.4% trypan blue stain and loaded into the haemocytometer. A 50 μl of 
cell suspension was collected and mixed with 50 μl of Trypan blue stain (1:1 ratio). The 
mixture was then pipetted onto the haemocytometer and was placed under the 
microscope. Cells were counted under the microscope at 10X magnification. Only viable 
cells were counted (small, round, and visible). The cells were then seeded at 100,000 
cells/ml on gelatinised six-well plates (Nunc, Roskilde, Denmark). The cells were 
allowed to proliferate to 80% confluence for 72 hours of incubation using similar cell 





3.3.6 Phase 1: E. longifolia treatment on C2C12 passage 13 (P13) and passage 26 
(P26). 
 
Once 80% confluence, C2C12 cells were treated with 2.0, 1.0, 0.5, 0.25, 0.125 mg/ml 
of E. longifolia and CON. The treated C2C12 cells were then incubated. The image under 
the microscope was photographed at 0, 24, and 48 hours. Cells treated with the various 
doses of E. longifolia and CON were observed to determine any detachment of cells from 
the flask. 
 
Figure 3.2 Example of cell death through imaging 
 
3.3.7 Phase 2: Lactate Dehydrogenase (LDH) Cytotoxicity  
 
A similar procedure explained in section 3.3.4 was conducted in phase 2. Once C2C12 
passage 13 (P13) and passage 26 (P26) achieved 80% confluent, the GM was aspirated 
from the 6-well plate and washed with PBS. Before E. longifolia treatment, fresh DM 
was then added to the 6-well plate to allow the C2C12 P13 and P26 cells to fused and 
differentiate. The 6-well plate was incubated for 72 hours. The C2C12 P13 and P26 cells 
were examined under the microscope to make sure the cells had fused and differentiated. 
Immediately, the fused cells were washed with PBS and then treated with 1.0 and 0.5 
mg/ml of E. longifolia and CON. Images were photographed using the microscope, and 
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supernatants were collected at 96, 120, and 144 hours from differentiated cells, and the 
cytotoxicity LDH test was conducted.  
 
 Cytotoxicity LDH assay was used to quantitate cytotoxicity based on the measurement 
of LDH activity released from C2C12 cells, which have gone through population doubling 
and administration of E. longifolia extract. Thus, the cytotoxicity detection kit was used 
to determine cell death after being dosed with E. longifolia at two different doses (1.0 and 
0.5 mg/ml of E. longifolia) and CON.  
 
 At each time point (96, 120 and 144 hours), 200 µl of supernatant was harvested from 
each well and stored at -20 °C until further analysis.  The supernatant was thawed, and 
100 μl supernatant was transferred into the sterile 96-well tissue culture plate.  A total of 
50 µl was utilised for the LDH (Roche, Germany) test and was prepared before the 
cytotoxicity test according to the manufacturer's protocol. According to the 
manufacturer's instruction, the reaction mix was transferred onto the 96-well plate using 
a multichannel pipette and was then immediately transferred into a cabinet to avoid bright 
light. It was kept at room temperature for 20 minutes. An increase in the number of dead 
or plasma membrane-damaged cells was indicative of an increase in the total LDH 
enzymatic activity in the cell culture supernatant. This increase in LDH activity directly 
correlates with the amount of formazan product formed. The red formazan product is 
water-soluble and has a broad absorbance maximum of around 500 nm. According to the 
manufacturer's protocol, the value of spectral absorption of the resulting formazan at 490 
nm is directly proportional to the number of damaged cells. Thus the samples were 
analysed via spectrophotometry at 490 nm absorbance using an ELISA plate reader 
(Clariostar, BMG Labtech, Offenburg, Germany) to quantified LDH activity. Cell 
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viability was then determined by dividing the treatment mean value divide with the mean 
control treatment and multiply with 100%. 
 
 
Note: Photographs at each time points (96, 120 and 144 hours 
Samples were analysed using spectrophotometry at 490nm absorbance and ELISA plate reader 
(Clariostar, BMG Labtech, Offenburg, Germany) was used to quantified LDH activity 
Figure 3.3 Skeletal muscle cell culture process prior to LDH assay analysis 
 
3.3.8 Statistical Analysis  
 
All statistical analyses were performed using Statistical Package for the Social 
Sciences (SPSS) (v.20, IBM Corporation. New York, US). For the comparison of group 
means, a t-test was used, and where a comparison of multiple time points of means was 
required, a repeated measure analysis ANCOVA was used. Normal distribution of data 
sets was first checked for any violation of the assumption of normality using the Shapiro-
Wilk test. Data violated the assumption of Mauchly's test of sphericity, Greenhouse-
Geiser, or Huyn-Feldt correction factors were used. Significance was assumed when α 






3.4.1 Dose-response on Murine Skeletal Muscle Cell   
 
Dosages used for the phase 1 study were 2.0, 1.0, 0.5, 0.25, and 0.125 mg/ml of               
E. longifolia, while differentiation media (DM) was used as the control treatment (CON). 
Figure 3.4 shows the image of C2C12 P13 photographed at 0, 24, and 48 hours. Figure 3.4 
(A) showed the image of C2C12 P13 before the treatment of E. longifolia and CON. 
Figures 3.4 (B - K) showed the images of C2C12 P13 dosed with 2.0, 1.0, 0.5, 0.25 and 
0.125 mg/ml of E. longifolia following incubation for 24 hours and 48 hours, respectively. 
During the incubation period, no cell death was observed, and the cell remains adherent 
to the flask for C2C12 P13 dosed with 1.0 mg/ml (Figure 3.4 D and E) and 0.5 mg/ml 
(Figure 3.4 F and G) of E. longifolia. However, in phase 1, cell death was only monitored 
through imaging and cell death was observed in a low dose of 0.25, 0.125 mg/ml, and a 
high dose of 2.0 mg/ml of E. longifolia (Figure 3.4 B, C, H, I, J, K). 
 
Murine skeletal muscle C2C12 P26 cells were also photographed at 0, 24, and 48 hours, 
as shown in Figure 3.5. Figure 3.5 (A) shows the pre-treatment of E. longifolia and CON. 
C2C12 P26 cells treated with 2.0, 1.0 0.5, 0.25, and 0.125 mg/ml of E. longifolia and 
incubated for 24 and 48 hours are shown in Figure 3.5 B - K respectively, and imaging 
shows no cell death was observed after the treatment duration, and cells are still adherent 
to the plate for cell treated with 1.0 and 0.5 mg/ml of E. longifolia. However, general 
observation through imaging shows cell death was observed in C2C12 P26 cells at 48 hours 




3.4.2 Cytotoxicity lactate dehydrogenase effect of E. longifolia on murine skeletal 
muscle C2C12 
 
Through imaging, general observation shows that cells treated with E. longifolia (0.5 
mg/ml and 1.0 mg/ml) are still adherent to the flask and did not observed any cell 
detached. However, images showed larger myotube (Figure 3.6 D, E) growth when 
compared to P13 dosed with 1.0 mg/ml (Figure 3.6 B, C) of E. longifolia. Also, skeletal 
muscle C2C12 P26 cells dosed with 0.5 mg/ml also showed larger myotube at 144 hours 
(Figure 3.7 E) when compared to P26 dosed with 1.0 mg/ml of E. longifolia at 120 and 
144 hours (Figure 3.7 B, C) and CON at 96 hours (Figure 3.7 A). Similar to P13, C2C12  
P13 and P26 treated with E. longifolia remained adherent to the flask and did not observe 
any cell death.  
 
Meanwhile, Figure 3.8 shows the cytotoxicity activity at 96, 120, and 144 hours post 
E. longifolia administration on P13 and P26 C2C12. There was no significant main 
interaction between group and time for LDH activity (F1.066, 12.791 = 0.060, p = 0.825). 
However, there is significant main effect of time (F1.066, 12.791 = 17.419, p = 0.001) (Figure 
3.8 A, B, C).  
 
ANCOVA repeated measurement showed significant increase in LDH activity in P13 
C2C12 treated with CON from 96 hours [Mean(M) = 0.138, 95% CI = 0.116, 0.160] to 
120 hours (M = 0.438, 95% CI = 0.224, 0.653) and 144 hours (M = 0.612, 95% CI = 
0.188, 1.035).  A significant increase in LDH activity in P13 C2C12 treated with 0.5 mg/ml 
E. longifolia from 96 hours (M = 0.138, 95% CI = 0.116, 0.160) to 120 hours (M = 0.425, 
95% CI = 0.237, 0.614) and 144 hours (M = 0.526, 95% CI = 0.230, 0.822). 
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(A)      (B)                    (C)    (D)          (E) 
          
             0 hr Prior dosing              24 hr 2 mg/ml       48 hr 2 mg/ml (cell death)       24 hr 1.0 mg/ml              48 hr 1.0 mg/ml 
        (F)    (G)             (H)        (I)            (J)             (K)    
      
       24 hr 0.5 mg/ml             48 hr 0.5 mg/ml          24 hr 0.25 mg/ml             48 hr 0.25 mg/ml 24 hr 0.125 mg/ml         48 hr 0.125 mg/ml  
           (cell death)                                                             (cell death) 
 
 Figure 3.4: E. longifolia treatment at different dosage on passage 13 C2C12 murine skeletal muscle cell 
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(A)      (B)          (C)    (D)                                 (E) 
         
             0 hr Prior dosing            24 hr 2.0 mg/ml                48 hr 2.0 mg/ml             24 hr 1.0 mg/ml              48 hr 1.0 mg/ml  
      (F)            (G)    (H)       (I)         (J)            (K) 
      
24 hr 0.5 mg/ml    48 hr 0.5 mg/ml         24 hr 0.25 mg/ml         48 hr 0.25 mg/ml          24 hr 0.125 mg/ml  48 hr 0.125 mg/ml  
Figure 3.5: Pre-treatment and post E. longifolia treatment on passage 26 C2C12 murine skeletal muscle cell 
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(A)      (B)             (C) 
     
P13 DM 96 hr Prior dosing     P13 1.0 mg/ml 120 hr     P13 1.0 mg/ml 144 hr  
             (D)      (E) 
   
            P13 0.5 mg/ml 120hr           P13 0.5 mg/ml 144hr  
Figure 3.6: Pre treatment and post E. longifolia treatment at two different dosages 
(0.5 and 1.0 mg/ml of E. longifolia) dosed after cells are fused on passage 13 C2C12 










(A)      (B)      (C) 
       
  P26 DM 96 hr Prior dosing        P26 1.0 mg/ml 120 hr     P26 1.0 mg/ml 144 hr  
     
     (D)                   (E)  
     
         P26 0.5 mg/ml 120 hr            P26 0.5 mg/ml 144 hr 
Figure 3.7: Pre-treatment and post E. longifolia treatment at two different dosages 
(0.5 and 1.0 mg/ml of E. longifolia) dosed after cells are fused on passage 26 C2C12 







Similarly, significant increase in C2C12 treated with 1.0 mg/ml E. longifolia from 96 
hours (M = 0.138, 95% CI = 0.116, 0.160) to 120 hours (M = 0.345, 95% CI = 0.215, 
0.476) and 144 hours (M = 0.448, 95% CI = 0.260, 0.635). While P13 treated with CON 
shows 3.27 fold increase from 96 hours to 120 hours, P13 treated with 0.5 mg/ml and 1.0 
mg/ml demonstrate only 3.2 and 2.58 fold increase respectively in LDH activity from 96 
hours to 120 hours. Finding also found that P13 treated with CON has a higher cell 
viability of 327 ± 189 % compare to P13 treated with 0.5 mg/ml (320 ± 169 %) and 1.0 
mg/ml (258 ± 120 %) of E. longifolia from 96 hours to 120 hours. Also, LDH activity 
from 96 to 144 hours also shows P13 treated with CON has higher fold increase (4.61) in 
LDH activity compared to 3.92 and 3.35 fold increase in P13 treated with 0.5 mg/ml and 
1.0 mg/ml, respectively. Similarly, CON has a non significant higher cell viability of 461 
± 362 % compared to P13 treated with 0.5 mg/ml (392 ± 257 %) and 1.0 mg/ml (335 ± 
169 %) of E. longifolia from 96 hours to 144 hours.  A lower LDH activity in P13 dosed 
with E. longifolia (CON > 0.5 mg/ml > 1.0 mg/ml) was observed.  
 
Similar findings were mostly observed in P26 cells treated with DM and E. longifolia 
extract. ANCOVA repeated measurement showed no significant increase in LDH activity 
in P26 treated with DM from 96 hours (M = 0.124, 95% CI = 0.115, 0.133) to 120 hours 
(M = 0.384, 95% CI = 0.100, 0.668) but an increase from 96 hours to 144 hours (M = 
0.544, 95% CI = 0.123, 0.965) was observed.   
 
A significant increase in LDH activity in P26 C2C12 treated with 0.5 mg/ml E. 
longifolia from 96 hours (M = 0.124, 95% CI = 0.115, 0.133) to 120 hours (M = 0.330, 
95% CI = 0.177, 0.484) and 144 hours (M = 0.413, 95% CI = 0.182, 0.644). Similarly, 
significant increase in C2C12 treated with 1.0 mg/ml E. longifolia from 96 hours (M = 
0.124, 95% CI = 0.115, 0.133) to 120 hours (M = 0.327, 95% CI = 0.138, 0.517) and 144 
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hours (M = 0.486, 95% CI = 0.176, 0.795). Similarly, P26 treated with CON shows a 3.02 
fold increase in LDH activity from 96 hours to 120 hours, and P26 treated with 0.5 mg/ml 
and 1.0 mg/ml demonstrate a lower increase in LDH activity of 2.61 and 2.59 fold 
increase respectively from 96 hours to 120 hours. P26 treated with CON has a non-
significant higher cell viability of 302 ± 231 % compare to P13 treated with 0.5 mg/ml 
(261 ± 122 %) and 1.0 mg/ml (259 ± 150 %) of E. longifolia from 96 hours to 120 hours. 
Also, LDH activity from 96 to 144 hours shows P26 treated with CON has a higher fold 
increase (4.28) in LDH activity compared to 3.27 and 3.84 fold increase in P26 treated 
with 0.5 mg/ml and 1.0 mg/ml, respectively. Cell treated with CON demonstrated higher 
cytotoxicity compared to the two E. longifolia doses. The lower dose (0.5 mg/ml) of E. 
longifolia demonstrated lower cytotoxicity compared to the higher E. longifolia dose (1.0 
mg/ml after 48 hours of treatment in P26 C2C12. In addition, CON has a higher cell 
viability of 428 ± 345 % compared to P26 treated with 0.5 mg/ml (327 ± 188 %) and 1.0 
mg/ml (384 ± 250 %) of E. longifolia from 96 hours to 144 hours.   
 
A repeated study (Figure 3.9) with similar cell culture procedure and LDH assay test 
were conducted to validate the previous findings. A paired-samples t-test was conducted 
to compare three different treatments treated in P13 and P26 C2C12. Whilst a significant 
difference in the scores for P26 treated with CON (M = 0.344, SD = 0.043) and P26 
treated with 0.5mg/ml E. longifolia (M = 0.291, SD = 0.032) conditions; t(5) = 5.072, p 
= 0.004,  there are no significant difference in P26 treated with CON with P26 treated 
with 1.0 mg/ml E. longifolia (M = 0.320, SD = 0.042);  t(5) = 2.219, p = 0.077. Also, 
there is a significant difference between P26 treated with 0.5 mg/ml and 1.0 mg/ml of 
E.longifolia (t5 = -3.817, p = 0.012). These results suggest that C2C12 cell treated with 0.5 






Figure 3.8: Effect of E. longifolia (0.5 and 1.0 mg/ml) and DM (control) treated on 
C2C12 (P13 and P26) on the lactate dehydrogenase (LDH) activity over time 
φ, *Denotes indicate there is a significant change over time; φ Denotes indicate a significant increase from 











































































































































































Figure 3.9: Lactate dehydrogenase activity differences within and between P13 and 
P26 treated with three different treatment doses at 144 hours. 
* † Denotes indicate significant differences within P13 and P26 C2C12 cells; *Denote indicate a significant 
lower LDH activity between DM and 0.5 mg/ml; †Denotes indicate significant differences between 0.5 
mg/ml and 1.0 mg/ml 
 
 
However, P13 C2C12 treated with the three treatment did not show any significant 
differences. No significant differences in the scores for P13 treated with CON (M = 0.350, 
SD = 0.120) and P13 treated with 0.5mg/ml E. longifolia (M = 0.321, SD = 0.135) 
conditions; t (5) = 1.903, p = 0.115. Also, no significant difference in P13 treated with 
CON with P13 treated with 1.0 mg/ml E. longifolia (M = 0.316, SD = 0.050); t (5) = 
0.577, p = 0.589. Lastly, no significant difference between P13 treated with 0.5 mg/ml 
and 1.0 mg/ml of E. longifolia [(t (5) = 0.080, p = 0.939]. Although no significant 
differences were observed, E. longifolia treated cells demonstrated lower LDH activity 
















































Whilst findings show some differences within the two cells, there are no differences 
between P13 and P26 when the cells are treated with CON, and the two E. longifolia 
doses.  There was no significant difference in the LDH activity between P13 and P26 
treated with CON [t (10) = 0.105, p = 0.918], 0.5 mg/ml E. longifolia [t (10) = 0.531, p = 




 The present study aims to examine E. longifolia water extract’s cytotoxicity on murine 
SMC C2C12 cell line for the first time. Various concentrations of E. longifolia were used 
to determine the appropriate dosage, and the chosen dosage (0.5 mg and 1.0 mg/ml) was 
then used to examine the cytotoxicity effect on C2C12 murine SMCs. The cells treated 
with 0.5 mg/ml and 1.0 mg/ml demonstrated lower cytotoxicity level compared to cells 
treated with DM as a control treatment. Also, an increase in cell viability in C2C12 P13 
and P26 treated with E. longifolia, indicating potential cell growth.  
 General observation through imaging found that E. longifolia concentrations of 2.0, 
0.25, and 0.125 mg/ml administered to C2C12 resulted in cell detaching from the flask, but 
this was not the case for 0.5 mg/ml and 1.0 mg/ml concentrations. Hence this 
concentration was used to examine the cytotoxicity effect. Differentiated C2C12 (P13 and 
P26) cell lines were dosed with 0.5 and 1.0 mg/ml and incubated for 120 and 144 hours. 
During this incubation period, general observation showed the myotube increased in size 
compared to cells treated with DM. Since this is the first study of its kind, the reason for 
the increase in myotube size is still not apparent.  
 Whilst LDH activity was used to examine cytotoxicity and cell viability upon E. 
longifolia treatment, the pathway causing cell death (apoptosis or necrosis) due to 
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cytotoxicity was not determined in the current study. Lactate dehydrogenase (LDH) is a 
cytosolic enzyme available in numerous different cells types, e.g. SMCs. As soon as the 
plasma membrane is damaged, LDH is released into the cell culture media. Cell 
membrane damage leads to the release of cytoplasmic enzymes, and the measurement of 
LDH release was used to estimate cell membrane integrity and to quantify cell 
cytotoxicity (Mosmann, 1983; Korzeniewski & Callewaert, 1983; Roehn et al., 1991; 
Legrand et al., 1992; Arechabala et al., 1999; Choi et al., 2009). Once cells are impaired 
by stress, injury, chemicals or intercellular signals, LDH is rapidly released from the cell 
membrane. The amount of released LDH into the surrounding extracellular space after 
the cell membrane integrity is compromised can be used as a cell death marker (Kumar 
et al., 2018). 
 The LDH cytotoxicity test demonstrated a non-significant increase in LDH level over 
time in P13 and P26 dosed with 0.5 mg/ml and 1.0 mg/ml of E. longifolia.   Interestingly 
the LDH activity level was lower than the CON, indicating a possible reduction in 
cytotoxicity or cell death rate. While there is no study conducted on C2C12 prior to the 
current study, Thu et al. (2017) found E. longifolia is less toxic than the control treatment, 
and the extract increased proliferation. The fold increase of cytotoxicity level in E. 
longifolia treated cells was lower when compared to the cells treated with CON.  While 
lower cytotoxicity was observed in C2C12 cell, the previous study has shown that higher 
concentrations and longer durations of E. longifolia treatment with cancer cells inhibit 
cell growth and cell death occurs (Hajjouli et al., 2014; Tong et al., 2015). In addition, 
cell viability also demonstrated that C2C12 treated with E. longifolia has no significant 
difference with CON, indicating the murine cells survived after being treated with E. 
longifolia. Also, 1.0 mg/ml of E. longifolia has shown higher cell viability compared to 
0.5mg/ml for P26. It is suggested that the high concentration of superoxide dismutase 
(SOD) found in E. longifolia (Tambi & Imran, 2010) accelerate the bone formation and 
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reduce the rate of resorption (Effendy et al., 2012). Hence, the high concentration of SOD 
may potentially reduce harmful oxygen molecules in cells to prevent damage to tissues 
and subsequently increase the proliferation, decreased apoptosis and growth (Hollander 
et al., 1999; Che et al., 2016), which demonstrate why C2C12 treated with E. longifolia 
has lower cytotoxic activity compared to the control treatment and reported higher cell 
viability in C2C12 especially in P26. Thus indicating that there is a dose response towards 
older murine cell culture. Hence, the present study concurs with previous studies that E. 
longifolia treatment of healthy cells is non-toxic towards healthy cells (Hajjouli et al., 
2014; Thu et al., 2017). 
 Another possible reason behind these findings could be due to the availability of E. 
longifolia’s bioactive compound, which comprised of 1% eurycomanone, 22% protein, 
30% polysaccharides, and 35% glycosaponin (Lin et al., 2001; Tambi & Kadir, 2005; 
Athimulam et al., 2006). The protein component (a type of protein not mentioned in any 
published article) in E. longifolia may contribute to the growth in hypertrophy. A review 
of muscle protein synthesis in response to nutrition by Atherton and Smith (2012) found 
that the anabolic effects of a meal were attributable to essential amino acids (Smith et al., 
1992). Atherthon and Smith (2012) further suggest that the anabolic response is transient, 
and if the adaptive increase in muscle protein breakdown is neglected, hypertrophy can 
be achieved by just eating protein.  However, more studies to examine the effect of the E. 
longifolia component, especially the protein, in increasing hypertrophy are needed.   
 The administration of E. longifolia to SMCs demonstrate a different response when 
compared to cancer cells, where inhibition in growth and cell death is not observed. One 
possible reason that E. longifolia provokes lower LDH activity than the control treatment 
may be due to the other compounds belonging to the alkaloid class and not just 
eurycomanone. Alkaloids and triterpene act as antioxidants and have been reported to 
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reduce bone loss and maintain the bone formation rate (Effendy et al., 2012). Although 
not proven in the present study, triterpenes in E. longifolia may increase murine skeletal 
muscle. Kunkel et al. (2011) and Kunkel et al. (2012) found that ursolic acid, a natural 
triterpene found in various herbs, can induce skeletal muscle hypertrophy by increasing 
the protein kinase Akt in murine skeletal muscle and cultured C2C12 skeletal myotube. 
Hence a further study looking into this compound in inducing SMC hypertrophy is 
warranted. 
 The current study on the cytotoxicity effect of E. longifolia on C2C12 has demonstrated 
low toxicity level and increased cell viability in both P13 and P26. Whilst finding 
demonstrate E. longifolia is not toxic to C2C12 cell line and even increased cell viability, 
the possible factors contributed to the study outcome such as the concentration of SOD 
(Tambi & Imran, 2010), protein contents (Lin et al., 2001; Tambi & Kadir, 2005; 
Athimulam et al., 2006), triterpene (Kunkel et al., 2012) was not examined. Also, whether 
E. longifolia prevent cell growth or promote growth, investigating the signalling pathway 
of apoptosis and necrosis is warranted. While the C2C12 cell line derived from murine 
SMCs is a useful cellular model for investigating muscle regeneration and differentiation 
(Schöneich et al., 2014), the data presented here served as a preliminary study 
investigating for the first time its effect on C2C12 cell line and may not precisely mirror 
human.  
 In this preliminary study, E. longifolia treatment on C2C12 resulted in lower toxicity 
and increased cell viability indicating an increase in growth. However, more studies, such 
as an evaluation of the cell death pathway, myogenic potential (myogenic differentiation 
(MyoD) and myogenin) of E. longifolia, the pharmacological effect of superoxide 
dismutase in E. longifolia, and the protein content in E. longifolia are warranted to 




 Eurycoma longifolia was examined for the first time for its dose-response and 
cytotoxicity effect on the murine C2C12. The present study has shown that there was a 
dose-dependent effect toward C2C12 murine SMCs. A dose of 0.5 and 1.0 mg/ml of E. 
longifolia did not induce cell death, but there was an increase in cell viability, indicating 
possible myotube growth. Interestingly cytotoxicity levels increased in the control 
treatment over time, but C2C12 cells treated with E. longifolia showed lower toxicity. 
Also, E. longifolia showed a favoured response in reducing toxicity in ageing cells. 
Thus, E. longifolia could be beneficial in slowing down age-related muscle loss. 
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CHAPTER 4: EFFECT OF SHORT AND LONG-TERM CONSUMPTION OF E. 





In recent years, E. longifolia has gained popularity due to its ability to increase the 
production of reproductive hormones such as testosterone, which is important in the 
development of secondary male characteristics such as voice deepening, increase in penis 
size, and growth of facial and body hair. Although studies have examined the 
effectiveness of E. longifolia in enhancing testosterone levels, clinical trials are scarce, 
and the findings based on the limited studies are inconclusive: some show an increase 
(Tambi et al., 2012; Talbott et al., 2013; Henkel et al., 2013; Udani et al., 2014) and 
others a decrease (Ismail et al., 2012; Chen et al., 2014). Also, the underlying mechanisms 
on how E. longifolia regulates testosterone levels in humans have not been examined. 
 
The regulation of testosterone production is controlled by the hypothalamic gonadal 
(HPG) axis to ensure normal blood concentrations are maintained (Palaparthi, 2017). 
Testosterone is the primary regulator of gonadotrophin-releasing hormone (GnRH) 
secretion, which stimulates LH and FSH production from the anterior pituitary, which in 
turn stimulates the production of testosterone and sperm by the Leydig cells and Sertoli 
cells (Bhatnagar et al., 1992). A study examining the effect of E. longifolia 
supplementation in rats has shown similar testosterone regulation in humans, with an 
increase in testosterone level, LH and FSH. (Low et al., 2013b). Indeed, based on the 
findings of Low et al. (2013), it is proposed that the E. longifolia treatment down-
regulates the negative feedback, stimulating the pituitary gland to release LH and FSH, 
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which subsequently increases testosterone production (Tambi et al., 2012; Low et al., 
2013b).  
 
Most related studies have been carried out on older participants, particularly those 
diagnosed with late-onset of hypogonadism (LOH). The optimal duration of treatment is 
debatable, where short-term supplementation (2 - 5 weeks) (Qureshi et al., 2014) shows 
an increase in testosterone, while longer-term (> 5 weeks) (Quinn et al., 2010) does not 
show an increase. Moreover, E. longifolia supplementation for 4 to 12 weeks (long-term) 
does not demonstrate any testosterone boosting effect. Tachyphylaxis and drug tolerance 
have been used to describe the phenomena causing reduced drug effectiveness. 
Tachyphylaxis is known to develop quickly when drugs are used repeatedly over a short 
period, with no response occurring when the dosage is increased. However, the effect can 
be restored by stopping the administration for a short time (Binder, 2012). On the other 
hand, tolerance is known as the prolonged administration of a drug at a set dose, 
producing either a reduced effect or no further change in response (Branch, 1993). The 
drugs’ effect can be improved by increasing the dosage given over a short time interval, 
but efficacy is not restored if the treatment is halted temporarily (Binder, 2012). Based 
on this, it is speculated that the effect of E. longifolia may have achieved tolerance due to 
dosage (Ismail et al., 2012; Chen et al., 2014; George et al., 2018; Chen et al., 2019). 
  
Apart from older adults, there are a substantial number of reports showing that the 
younger population are affected by psychological stress (Vo et al., 2008; Sifferlin, 2013; 
Pascoe et al., 2019); however, to date, there is no study investigating the effect of E 
longifolia on this population.  The transition from childhood to adulthood involves the 
attainment of sexual maturity and the attainment of a variety of psychological and social 
factors (Sisk and Zehr, 2005; Lürzel et al., 2010). Many have perceived that testosterone 
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treatment improves or alleviates psychological outcomes such as mood, stress and 
wellbeing in men with low testosterone levels and have even suggested that testosterone 
levels are reduced in response to stress (Choi et al., 2012).  Many stressors, such as 
psychological stress and physical stress, decrease LH by inhibiting its release by the 
anterior pituitary, leading to decreased testosterone production (Rivest & Rivier, 1995; 
Chichinadze & Chichinadze, 2008).    
 
It is uncertain at present whether short and long-term administration with a higher dose 
of E. longifolia supplementation will have any impact on reproductive hormones in the 
younger population due to its testosterone boosting effect.  Hence, an investigation is 
needed to determine the changes in testosterone, free testosterone, luteinizing hormone 
(LH), follicle-stimulating hormone (FSH), oestrogen and sexual hormone-binding 
globulin (SHBG) concentration levels to understand the mode of action of E. longifolia. 
In order to demonstrate a more significant improvement, appropriate dosage and duration 
are needed to prevent any possible tolerance. In this study, the dosage, duration (short and 
long-term) of supplementation, age and health of participants were taken into 
consideration to enable a thorough investigation into the efficacy of E. longifolia on the 
changes in reproductive hormones. 
 
Therefore, this study aims to examine the effect of E. longifolia on male reproductive 
hormone regulation in healthy young adults and assess the toxicity effect of E. longifolia 
on liver function after two and eight weeks of supplementation. 
 
82 
4.2 Literature Review 
4.2.1 The effects of Eurycoma longifolia on testosterone production 
 
To date, nine studies have investigated the effect of E. longifolia on testosterone levels 
in humans and animals (Tables 4.1 and 4.2). In humans, most studies show an increase in 
testosterone levels following E. longifolia supplementation. Data from many of them 
were extracted from participants diagnosed with a history of LOH (Tambi et al., 2012; 
Talbott et al., 2013; Henkel et al., 2013; Udani et al., 2014), with ages ranging from 30 
to 72 years. However, there are three studies in which testosterone levels did not change 
when supplemented with E. longifolia (Ismail et al., 2012; Chen et al., 2014; George et 
al., 2018). The lack of change could be attributed to the participants’ characteristics, 
including health status and physical activity level.  It is also worth noting that greater 
changes in testosterone levels were seen when initial levels were low (LOH and 
moderately stressed individuals) compared to a healthy individual with normal 
testosterone levels.  E. longifolia supplementation appeared to restore the testosterone 
concentration to the optimal level among LOH and moderately stressed participants 
(Talbott et al., 2013). However, as time passed, E. longifolia demonstrated a diminishing 
effect in increasing testosterone levels. Hence, studies examining a higher dose of E. 
longifolia supplement on healthy young men level at different duration to determine its 
efficacy in increasing testosterone production in a population that has normal testosterone 







Table 4.1: Studies conducted to examine the effect of E. longifolia on testosterone 




Outcome Participants References 
200 mg 
(4 weeks) 
Increased T but 
maintained at normal 
values 
LOH patients           (30 - 
64 years) 




No significant changes in 
T, IGF-1, SHBG, and 
DHEASO4 
Healthy males          (30 - 
55 years) 




Increase T Sub-fertile and moderately 
psychological stressed 
male                         (45 - 
65 years) 




Increase T and FT Physically active male and 
female              (57 - 72 
years) 
Henkel et al. 
(2014) 
300 mg EL and 
PM 
(12 weeks) 
Increased T Healthy males          (40 - 
65 years) 
Udani et al. 
(2014) 
400 mg       (6 
weeks) 
No difference in the T 
and EP ratio 
Recreational athletes (29.0 
± 5.5 years) 
Chen et al. 
(2014) 
50 mg EL and 
MV (24 weeks) 
No changes in T, 
increased in FT 
Moderately stressed male                         
(25 - 65 years) 
George et al. 
(2018) 
200 mg EL 
8 weeks 
No significant changes in 
T/E ratio 
Young male 
(19 – 25 years) 
Chen et al. 
(2019) 
Note: Late-onset of hypogonadism (LOH); E. longifolia (EL); Polygonum minus (PM); Testosterone (T); 
Epitestosterone (EP); Free testosterone (FT) Insulin-like growth factor-1 (IGF-1); Sexual hormone-binding 
globulin (SHBG); Dehydroepiandrosterone sulfate (DHEASO4) 
 
 
4.2.2 Factors Affecting the Regulation of Testosterone Due to Eurycoma 
longifolia Consumption. 
 
According to the findings shown in Table 4.1, several inter-related factors, such as 
dose and duration of supplementation and participants’ age and health status, may affect 
the regulation of testosterone due to E. longifolia consumption. Supplementation of 200 
and 400 mg of E. longifolia in older participants with LOH or moderately stressed 
participants demonstrated a significant increase in testosterone level (Tambi et al., 2012; 
Talbott et al., 2013; Henkel et al., 2013); however, this was not observed by Chen et al. 
(2019) which they supplemented E. longifolia on young healthy adults with no history of 
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low testosterone level. While LOH is a syndrome associated with advancing age and 
characterised by symptoms and a deficiency in serum testosterone levels (Huhtaniemi, 
2014; Wang et al., 2009), evidence suggests that there is also a reduction in testosterone 
levels in response to stress (Afrisham et al., 2016). Studies have also shown that low 
testosterone levels were reported in individuals facing psychological stress, physical 
stress, actual stress, anxiety and irritability (Schulz et al., 1996; Sternbach,1998; Choi et 
al., 2012). Rivest and Rivier (1995) indicated that stressors, such as psychological stress, 
decrease LH and, consequently, testosterone level by inhibiting the secretion of LH from 
the pituitary gland. Thus the potential mechanism of E. longifolia in increasing 
testosterone levels may be its ability to stimulate the secretion of LH to produce more 
testosterone in the HPG axis and, subsequently, increase the level of testosterone in this 
group of individuals. However, the level of LH during stress remains conflicting and not 
clearly described. Thus examining the gonadotropin-releasing hormone responsible for 
the release of LH and FSH from the anterior pituitary may be vital in understanding 
whether E. longifolia stimulated LH and FSH in the HPG axis.  
   
After the age of 30, there could be a 1% decline in testosterone level per year due to 
ageing (Belanger et al., 1994; Litman et al., 2006). Participants from previous studies 
(Table 4.1) were mainly between the ages of 30 to 72 years and diagnosed with LOH 
symptoms and stress that may contribute to a lower testosterone level. At present, the 
dose administered in humans ranges from 100 mg to 400 mg and is based on limited 
studies: a low dose might be considered below 300 mg, while above 300 mg might be 
considered a high dose. Studies by Ismail et al. (2012) and Chen et al. (2019) show that 
the administration of a low dose of E. longifolia shows no increase in testosterone level 
in a healthy male with normal testosterone levels (19 to 55 years). These indicate that this 
dose of E. longifolia has no effect on physically active young and older healthy 
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participants with testosterone levels within the normal concentration range. Hence a 
higher dose may be warranted to demonstrate a significant effect.  
 
Studies using a combination of 300 mg of E. longifolia with Polygonum minus and 50 
mg of E. longifolia with multivitamins for 12 weeks and 24 weeks respectively showed 
an increase in testosterone and free testosterone (Ismail et al., 2012; Udani et al., 2014). 
Polygonum minus is a herbal plant that contains antioxidants, flavonoids and phenolic 
compounds (Qader et al., 2012). Apart from quassinoids, which are often said to be the 
compound that induces testosterone elevation, flavonoids in Polygonum minus may also 
contribute to the increase in testosterone (Zohre et al., 2015). Hence, with the combination 
of E. longifolia and Polygonum minus, there is an increase in the amount of bioactive 
compound especially in quassinoids and flavonoid responsible for the increase in 
testosterone and may not solely from E. longifolia. In addition, a dosage above 300 mg 
of E. longifolia has demonstrated an increase in testosterone levels among healthy 
participants (Henkel et al., 2014). A recent study by Chen et al. (2019) has shown that 
200 mg of E. longifolia, supplemented daily for eight weeks, did not increase testosterone 
levels, and it is suggested that the dose is insufficient to elicit any effects in young 
individuals. Studies are needed to investigate the effects of flavonoids in increasing 
testosterone levels and at a different dosage. 
 
The duration of supplementation may be another potential factor that may determine 
the effectiveness of E. longifolia. In general, two to five weeks of dietary supplementation 
is considered short-term (Qureshi et al., 2014), while over five weeks might be considered 
long-term (Quinn et al., 2010). Apart from E. longifolia, a multitude of herbal 
supplements have the potential to increase testosterone after a period of supplementation: 
for example, astragalus membranaceus (Jiang et al., 2006; Kim et al., 
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2012), fenugreek (Bushey et al., 2009; Steels et al., 2011), barrenwort (Zhang et al., 
2011), ginseng (Fahim et al., 1982), passiflora incarnate (Dhawan & Sharma, 2002 & 
2003), mucuna pruriens (Shukla et al., 2009; Shukla et al., 2010; Muthu & 
Krishnamoorthy, 2013), ginkgo biloba (Markowitz et al., 2005; Ahmed et al., 
2009), Tribulus Terrestris (Neychev & Mitev, 2005; Rogerson et al., 2007; Wankhede et 
al., 2014; Maheshwari et al., 2017) and ashwagandha (Sengupta et al., 2018; Lopresti et 
al., 2019). These herbal supplements have been supplemented between 2 to 12 weeks in 
both animals and humans. Supplementation for longer than four weeks in humans did not 
show any increase in testosterone levels.  The shortest duration of E. 
longifolia supplementation is four weeks and the longest 12 weeks. Previous studies 
shown in Table 4.1 have demonstrated that short-term supplementation might increase 
testosterone levels (Tambi et al., 2012; Talbott et al., 2013; Henkel et al., 2014), but long-
term supplementation has demonstrated otherwise (Ismail et al., 2012; Chen et al., 2014; 
George et al., 2018). Supplementation of E longifolia lasting between 6 and 12 weeks did 
not demonstrate any increase in testosterone levels. However, the testosterone level 
remains in the healthy range (Ismail et al., 2012; Chen et al., 2014; George et al., 2018).   
 
Tolerance is often said to happen when the effect of a specific drug dose decreases 
over some time, and to further improve on the efficacy, an increase in the dosage is 
required (Branch, 1993; Siegel, 2005; Campbell & Cohall, 2017). However, 
tachyphylaxis is another term used to demonstrate the effect of repeatedly used drugs over 
a short period with no response occurring when the dosage is increased (Binder, 2012).  
Repeated exposure to E. longifolia longer than six weeks may cause gradual diminishing 
effects of the herbal extract, and it is speculated that E. longifolia has achieved tolerance 
and not tachyphylaxis since few studies have demonstrated an increase in testosterone 
level with a high dose of E. longifolia (Ismail et al., 2012; Chen et al., 2014; George et 
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al., 2018; Chen et al., 2019). However, E. longifolia has not been used to investigate the 
aspect of tolerance and tachyphylaxis thoroughly. The effect of E. longifolia on 
testosterone regulation needs to be examined further through continuous monitoring of 
different dosages and duration of supplementation.  
 
4.2.3 The Postulated Mechanism of Action on E. longifolia Supplementation. 
 
The hypothalamus and pituitary gland regulate the circulating concentration of 
testosterone and testosterone production. Upon detecting low circulating testosterone 
levels, the gonadotrophin-releasing hormone (GnRH) is secreted by the hypothalamus to 
the anterior pituitary, where it stimulates the production of LH and FSH. Following that, 
LH and FSH then stimulate the Leydig cells and Sertoli cells in the testes to produce 
testosterone and stimulate spermatogenesis. An elevated testosterone concentration in 
men causes negative feedback inhibition of the HPG axis by decreasing GnRH, LH and 
FSH from the hypothalamus and pituitary gland. Also, testosterone is converted into 
oestrogen by the enzyme aromatase, thus increasing the circulating concentration of 
oestrogen, which subsequently down-regulates the HPG axis, resulting in a further 
reduction in GnRH, LH and FSH production. As a result, testosterone concentration is 
decreased and maintained in its optimal range (Ullah et al., 2014; Majzoub & Saganegh, 
2016) (Figure 4.1).  
 
At present, the mechanisms involved in raising testosterone levels have been shown in 
animal studies conducted by Low et al. (2013a & 2013b). Both studies have demonstrated 
that 2 hours and 48 hours of E. longifolia supplementation increases testosterone 
production, LH and FSH secretion but reduces oestrogen levels in rats. Initially, the 
mechanism behind the effects of E. longifolia on testosterone was postulated by Low et 
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al. (2013a) (Table 4.2), where steroidogenesis and spermatogenesis were explored by 
incubating the extract with rat Leydig cells. Testosterone production increased when 
treated with 0.1, 1.0, and 10.0 μM (p < 0.05) of the plant extract, with a concomitant 
reduction in oestrogen. The authors speculated that these observations could be due to 
aromatase inhibition, thus preventing the conversion of testosterone to oestrogen. In a 
subsequent study by Low et al. (2013b) (Table 4.2), 25 mg/kg of E. longifolia reported 
an increase in plasma testosterone, LH and FSH levels, while oestrogen levels were 
significantly suppressed. These findings provide a preliminary understanding of the 
effects of E. longifolia, which may, potentially, down-regulate the oestrogen-mediated 
feedback effect on LH and FSH secretion in the HPG axis.  
 
Low et al. (2013a; 2013b) concluded that E. longifolia affects hormonal regulation, 
namely testosterone, free testosterone, oestrogen, LH, FSH, and SHBG, activating the 
HPG axes. Although these preliminary findings demonstrate the possible mechanism 
of E. longifolia on the HPG axis, both studies were conducted in cell cultures and rat 
models (Table 4.2). Rats are often used in biomedical and comparative medicine research 
due to their many similarities to human in terms of anatomy and physiology (Bryda, 
2013). However, it is to early to speculate that what works in rats will in humans. To date, 
the mechanism behind the reputed effect of E. longifolia in terms of testosterone 
regulation in humans has not been examined and, thus, remains unknown. Hence, 
additional studies are needed to fully understand the underlying mechanism of E. 
longifolia supplementation in increasing testosterone production.  
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Figure 4.1 The testosterone negative feedback loop. The hypothalamus secretes GnRH and stimulates the anterior pituitary to secrete LH and 
FSH. Leydig cells and Sertoli cells in testes then produce testosterone. Increased testosterone production causes negative feedback, and the 
hypothalamus stops GnRH production. A concomitant reduction in   LH and FSH secretion results in reduced testosterone production.  




Table 4.2: Studies conducted to examine the effect of E. longifolia on testosterone 
production in animals 
 




at 0.1, 1.0 and 
10μM (2 hours 
incubation) 





T to oestrogen 
Low et al. 
(2013a) 
25 mg/kg body 
weight 
(bioactive 





increased T  




Low et al. 
(2013b) 
Note: E. longifolia (EL); Luteinizing hormone (LH); Follicle-stimulating hormone 
(FSH); Testosterone (T) 
 
Animal and human studies have revealed the potential of E. longifolia in increasing 
testosterone levels following the administration of E. longifolia extract. Evidence 
suggests that the increase in testosterone happens largely in older participants with LOH 
and those who are moderately stressed. Current health status, E. longifolia dose, and age 
appear to play a role in determining the effects of E. longifolia in increasing testosterone 
levels. Based on previous studies, long-term supplementation did not demonstrate a 
significant increase in testosterone level, and it is suggested that higher dosages may be 







4.3 General methods 
4.3.1 Participants 
 
A total of 16 males for short-term supplementation and 21 males for long-term 
supplementation were recruited for study Chapters 4, 5 and 6. They were between 18 to 
30 years old, and a summary of participants’ characteristics are listed in Table 4.3.   The 
participants recruited were sedentary male adults, who did not participate in any high-
performance sport.   Due to the scarcity of study examining E. longifolia toward young 
adult males, the sample size was determined based on previous studies that recruited 
young adult males ranging from 13 to 30 participants (Talbott et al., 2006; Chen et al., 
2014). The study was approved by the Liverpool John Moores University Ethics 
Committee (14/SPS/013), and all participants provided their informed consent. Study 
Chapter 4 was conducted concurrently with Chapter 5, which examined the psychology 
mood state and sexual function and Chapter 6, which examined the muscular strength, 
anaerobic power and body composition. All participants were free from any 
musculoskeletal injury and did not exhibit any health problems such as diabetes mellitus, 
heart disease, kidney disease, liver disease, and sleep apnoea. In addition, those who 
smoked or used other recreational or prescribed drugs were excluded. Also, the study 
participants do not participate in any physical activity or compete in any high-level 
competition throughout the supplementation period. Elite athletes were also excluded due 
to the active phytochemicals content of the supplement. Competitive athletes who were 
subject to anti-doping regulations and drug tests were excluded from the study to mitigate 















Table 4.3 Demographic data for participants enlisted in the short-term and 
prolonged supplementation phases 
  Short-term  Long-term 
 EL(n = 8) PLA(n = 8) p  EL(n=11) PLA(n=10) p 
  
M ± SD 
/Med 
(IqR) 
M ± SD 
/Med 
(IqR)  
M ± SD 
/Med 
(IqR) 
M ± SD 
/Med 
(IqR)  
       
Age (years) 25.3 ± 5.0 23.5 ± 4.5 0.470† 22.6 ± 4.1 22.8 ± 3.4 0.905† 
       
Body 
Weight (kg) 74.5 ± 8.7 72.9 ± 8.6 0.709† 78.7 ± 8.3 76.9 ± 5.7 0.579† 
       
Height (cm) 172.5 ± 7.5 176.21 ± 5.6 0.282† 180.0 ± 9.3 180.0 ± 7.5 0.960† 
       
Body Fat 
(%)††† 18.95 (5.2) 13.55 (2.6) 0.052†† 14.78 ± 4.7 14.22 ± 3.6 0.764† 
       
Lean Body 
Mass 
(kg)††† 60.30 (6.4) 57.9 (11.5) 0.834†† 66.92 ± 6.5 66.08 ± 5.6 0.757† 
Notes: Mean (M); Standard Deviation (SD); E. longifolia (EL); Placebo (PLA) 
†denotes p value based on parametric test (independent t-test) 
††denotes p value based on non-parametric test (Mann-Whitney test) 
†††denotes that body fat % and Lean Body Mass are reported in Median (Med), Interquartile range(IqR) 
 
 
4.3.2 Experimental Design 
The study was a randomized double-blind, placebo-controlled, body weight matched-
paired design to investigate the effect of E. longifolia on hormonal changes among adult 
males. The study consisted of two phases; the short-term consumption phase (2 weeks) 
and the long-term consumption phase (8 weeks). Participants in both phases were 
assigned to the placebo (PLA) and E. longifolia treatment group (EL) using a matched-
paired design according to their body weight. The participants are grouped into pairs, 
based on their body weight. Then, within each pair, the participants are randomly assigned 
to E. longifolia or Placebo treatment. The participants and the researcher in the studies 
did not know who is received the placebo or EL treatment. The E. longifolia and placebo 
were assigned by the researcher’s supervisor. This procedure was conducted to prevent 
any bias in the research outcomes. 
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4.3.2.1 Short-term supplementation phase 
 
Participants were assigned to either a PLA (n = 8) or EL (n = 8) group. A total of six 
laboratory visits were scheduled: Visit 1 - Baseline anthropometric assessment and blood 
collection (Day 1); Visits 2 to 4 - Blood collections (Days 2, 3, 5); Visit 5 - Interim 
anthropometric assessment and blood collection (Day 7); and Visit 6 - Post-
supplementation anthropometric assessment and blood collection (Day 14). All blood 
collection was collected in the morning from 8 a.m to 9 a.m. 
 
4.3.2.2 Long-term supplementation phase 
 
Participants recruited to the prolonged supplementation phase were assigned to either 
a PLA (n = 10) or EL (n = 11) group. A total of three laboratory visits were scheduled: 
Visit 1 - Baseline anthropometric assessment and blood collection (Week 0); Visit 2 - 
Interim anthropometric assessment and blood collection (Week 4); and Visit 3 - Post-
supplementation anthropometric assessment and blood collection (Week 8).  
 
4.3.3 Experimental Protocol  
 
Pre-baseline sessions consisted of a health screen that incorporated measurement of 
resting heart rate and blood pressure and the implementation of a health-based physical 
activity readiness questionnaire (PAR-Q) to ensure that each participant fulfils the study 
criteria. Thorough instruction on supplementation and prior testing criteria was given to 
ensure valid and reliable data collection. 
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Each subsequent laboratory visits for the short (Days 1, 2, 3, 5, 7, 14) and prolonged 
supplementation phase (Week 0, 4, 8) involved health-related assessments of each 
participant, including anthropometric profiling (weight, height, body fat percentage, fat-
free mass); cardiovascular measures (resting heart rate and blood pressure and blood lipid 
profiles); hormonal profiles (testosterone, free testosterone, oestrogen, LH, FSH, and 
SHBG); and dietary and physical activity assessment (24-hour recall). The dietary and 
physical activity recording was needed to identify whether participants were consuming 
any other performance-enhancing supplements and involved in any high-intensity 
exercise and to enable replication of diet and physical activity before subsequent visits. 
Participants administered 600 mg of E. longifolia or placebo daily throughout the short 
(2 weeks) and prolonged (8 weeks) phase. Prior to each visit, all participants were asked 
to complete an overnight fast and refrain from alcohol and caffeine consumption, 
strenuous activity, and sexual activity eight hours before testing commenced. 
Participants’ adherence to the protocol was assessed using the dietary recall diary, where 
the time they took the supplement and how they felt at different times during the day were 
recorded. Additionally, reminders were sent out via text messages to ensure compliance. 
  
4.3.3.1 Anthropometric assessment 
 
Height and body weight were determined using a stadiometer and weighing scales 
(SECA, Hamburg). Body compositions were determined using Bioelectrical Impedance 
Analysis (BIA; Bodystat 1500, Douglas, Isle of Man, UK). Body fat percentage, lean 
body mass, total weight, and body water was recorded. Prior to the testing, participants 
were asked to remove their shoes and socks, accessories such as watches or bracelet on 
the right side to reduce the possibility of impeding the electrodes’ correct placement. 
Participants were assessed in a supine position. Before the commencement of the test, 
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participants were asked to rest for 5 minutes. The legs and arms were spread out, so they 
couldn’t make contact with other part of their body. Alcohol wipes were used to clean the 
area of the skin where the electrodes are to be attached. The self-adhesive disposable 
electrodes were attached to the right hand and right foot before the leads were connected. 
 
4.3.3.2 Blood pressure assessment 
 
Prior to any performance test, resting heart rate and blood pressure were tested using 
an automated sphygmomanometer (Critikon, Tampa, Florida, USA). Participants were 
asked to rest in a supine position for 10 minutes before the blood pressure measurement.  
 
4.3.3.3 Dietary supplementation 
 
A dose of 600 mg per day of E. longifolia or 600 mg placebo (maltodextrin) in a 
double-blind manner was administered. The participants were required to consume 
supplements each day between 8 a.m to 9 a.m and asked not to change their dietary or 
physical activity patterns significantly throughout this period. Participants completed the 
24-hour diet recall and physical activity questionnaire on the first visit and were asked to 
replicate the same diet and physical activity before the second visit. However, dietary and 
physical activity was not accessed. Participants’ adherence to the protocol was assessed 
using the dietary recall diary, where the time they took the supplement and how they felt 
at different times during the day were recorded. Additionally, reminders were sent out via 
text messages to ensure compliance. For the short supplementation phase, participants 
were given two weeks supply of E. longifolia or placebo in a capsule that contained 600 
mg/day of EL (efficacy reported in Tambi, 2005). Participants for the prolonged phase 
were given two month's supply of E. longifolia or placebo in capsule form.  The quality 
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of EL was based on the level of eurycomanone, which is the main compound found in EL 
(Norhidayah et al., 2015). The Malaysian Standard (2011) stated that the level should be 
from 0.8-1.5 w/v (%). The E. longifolia used in the present study complied with the 
standard since eurycomanone content was 1.21 w/v (%). A capsule of 600 mg of E. 
longifolia consists of 7.26 mg of eurycomanone based on the 1.21% w/v. 
 
 
4.3.3.4 Blood collection and analysis 
 
The collection of venous blood (15 ml) was done by a qualified phlebotomist from an 
antecubital vein using serum separation tubes (BD Vacutainer, New Jersey, USA) in the 
morning between 8 a.m to 9 a.m. After one hour, at room temperature (20°C), blood was 
centrifuged at 4000 rpm (Sigma 3-16KL, Germany), and serum was separated and 
transferred to micro-tubes and stored at -80 °C until analysis.  
a) Liver damage tests (AST and ALT) were assessed using enzymatic assays and 
automated benchtop spectrophotometry (RX Daytona) supplied by Randox 
Laboratories Limited (Crumlin, Co. Antrim, UK). ALT is an enzyme within the 
aminotransferase group and also the most sensitive liver enzymes. The normal 
concentration levels of ALT in the blood are low. However, when the liver is 
damaged, the level of ALT increases. Aspartate aminotransferase is measured 
together with ALT to examine liver damage. Aspartate aminotransferase is an 
enzyme found in the body, and an elevated level in the blood is directly correlated 
to the severity of the tissue damage. 
b) Hormone profiles (testosterone, free testosterone, sexual hormone-binding 
globulin (SHBG), oestrogen, luteinizing hormone (LH), and follicle-stimulating 
hormone (FSH) were assessed by enzyme-listed immunosorbent assay (ELISA; 
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IBL International, Hamburg, Germany) coupled to a spectrophotometer at 490 nm 
absorbance for detection (Clariostar, BMG Labtech, Offenburg, Germany). The 
ELISA Kit is a solid phase enzyme-linked immunosorbent assay based on the 
principle of competitive binding. Prior to the analysis, all reagents, samples, 
control and standards were prepared according to the manufacture procedures. 
Next, the samples, standards and control were added to the 96-well plate pre-coated 
with antibodies. HRP-Conjugate was added to the 96-well plate, and the plate was 
covered with aluminium foil. The wells were allowed to incubate at 37º for 1 hour. 
Following incubation and washing, 100 μL TMB substrate solution was added into 
all wells and incubate for another 15 minutes at room temperature in the dark. 
Lastly, add 100 μL stop solution into all wells and shake the microplate gently. 
Measure the absorbance of the sample at 490 nm.  
  
4.3.4 Statistical analysis  
 
All statistical analysis for study Chapter 4, 5 and 6 were conducted using the Statistical 
Package for the Social Sciences (SPSS) for Windows version 22.0 (SPSS Inc., Chicago, 
USA). Baseline data were analysed using the parametric (independent t-test) and non-
parametric test (Mann Whitney test). All data in text and tables are presented as means ± 
SD (parametric) and median (interquartile range) with p values < 0.05 indicating 
statistical significance. Assumptions of normality, homogeneity of variances, compound 
symmetry and homogeneity of regression were checked and fulfilled using the Shapiro-
Wilk test before the repeated measurement analysis of covariance (ANCOVA) was 
performed to determine the effect of the E. longifolia supplementation over the entire 
period of studies (2 weeks and 8 weeks). Analysis of covariance for repeated measures 
(ANCOVA) was performed to determine the group’s treatment effects and between-
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group differences. In consideration of participants having individual differences at 
baseline and this differences might have an impact on the outcome of the treatment, the 
repeated measures ANCOVA was used to correct the baseline variables and were 





The demographic characteristics of participants for short and long term studies in EL 
and PLA groups are presented in Table 4.1.  There was no significant difference (p > 
0.05) in all parameters between the two groups. Similarly, no significant difference (p > 
0.05) between the EL and PLA were identified in the prolonged supplementation phase.  
 
4.4.1 Liver function test  
 
Baseline results indicated no significant difference in the AST between EL (20.3 ± 
11.95 U/L) and PLA (20.8 ± 12.96 U/L); t (14) = -0.070, p = 0.945 and ALT level between 
EL (16.9 ± 4.1 U/L) and PLA (31.3 ± 48.8 U/L); t(14) = -0.830, p = 0.420 in the two 
weeks supplementation phase. Figure 4.2 shows findings of liver function after two weeks 
of E. longifolia supplementation. No significant main effect of time F1.274, 16.565 = 2.666, 
p = 0.115) and also no significant main interaction between group and time for AST 
(F1.274, 16.565 = 0.933, p = 0.372). ANCOVA repeated measurement with the baseline 
measure as covariate showed no significant changes within EL and PLA after two weeks 
of supplementation.  Findings shows no significant difference between Day 1 (20.3 ± 
11.95 U/L) and Day 14 (20.94 ± 9.1) [Mean difference (MD) = -0.625 U/L, 95% CI = -
7.120, 5.870, p = 1.000] in EL. Placebo also showed no significant difference between 
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day 1 (20.8 ± 12.96 U/L) and day 14 (33.5 ± 35.2 U/L) (MD = -12.75 U/L, 95% CI = -
75.046, 49.546, p = 1.000). AST level in EL is highest at Day 3 but reduces in the 
following days and PLA has the highest AST level at Day 14.  Also, no significant 
difference between EL and PLA at all time point. Upon completion of the study at day 
14, no significant difference in AST level was observe between EL (M = 20.94 ± 9.1 U/L) 
and PLA (33.5 ± 35.2 U/L), t (14) = - 0.978, p = 0.345.  
 
In Figure 4.2(B), there is a significant main effect of time (F1.816, 23.609 = 6.616, p = 
0.006). However, there was no significant main interaction between group and time for 
ALT (F1.816, 23.609 = 1.066, p = 0.354). ANCOVA repeated measurement showed no 
significant changes within EL and PLA after two weeks of supplementation.  Findings 
shows no significant difference between Day 1 (16.9 ± 4.1 U/L) and Day 14 (17.4 ± 4.7) 
[Mean difference (MD) = -0.563 U/L, 95% CI = -6.77, 5.65, p = 1.000] in EL. PLA also 
showed no significant difference between day 1 (31.3 ± 48.8 U/L) and day 14 (28.3 ± 
25.0 U/L) (MD = 3.00 U/L, 95% CI = -27.71, 33.71, p = 1.000). However, in PLA, there 
are significant drop in ALT level from Day 1 to Day 5 (MD = 6.88 U/L, 95% CI = 2.22, 
11.53, p = 0.007) and also from Day 1 to Day 7 (MD = 8.125, 95% CI = 3.63, 12.62, p = 
0.002). ALT level in EL is highest at Day 3 and reduces in the following days. PLA has 
the lowest ALT level at Day 7 before the level increases back on Day 14.  Similary, 
independent sample t-test shows no significant difference between EL and PLA at all time 
point. At day 14, no significant difference in ALT level between EL (M = 17.4 ± 4.7 U/L) 
and PLA (28.3 ± 25.0 U/L), t (14) = - 1.205, p = 0.248.   
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Figure 4.3 Effect of two weeks E. longifolia supplementation on liver function  
Note: Aspartate Aminotransferase (AST); Alanine Aminotransferase(ALT) 
Repeated measures ANCOVA between-group analysis with regard to time was applied. Numerical 
covariates (baseline – D0) were controlled by using repeated measurement ANCOVA. Assumption of 
normality, homogeneity of variances, compound symmetry, and homogeneity of regression were checked 
and were fulfilled. 
* denotes indicate significant differences within E.longifolia (EL) group and Placebo (PLA) group 
compared to baseline with ANCOVA repeated measurement applied. 





Following the two weeks supplementation period, the eight week E. longifolia 
supplementation was performed. Baseline results indicated no significant difference in 
the AST between EL (18.64 ± 6.4 U/L) and PLA (22.05 ± 7.1 U/L); t (19) = -1.158, p = 
0.261 and ALT level between EL (19.32 ± 9.3 U/L) and PLA (21.65 ± 5.6 U/L); t (19) = 
-0.688, p = 0.500 in the eight weeks supplementation phase.  
 
Figure 4.4 shows findings of liver function after eight weeks of E. longifolia 
supplementation. No significant main effect of time (F2, 36 = 0.756, p = 0.100) and no 
significant main interaction between group and time for AST (F2, 36 = 0.788 p = 0.463) 
(Figure 4.4A). ANCOVA repeated measurement showed no significant changes within 
EL and PLA after eight weeks of supplementation.  Findings shows no significant 
difference between baseline (18.64 ± 6.4 U/L) and post-test (20.30 ± 7.7 U/L) (MD = -
1.664 U/L, 95% CI = -8.115, 4.788, p = 1.000] in EL. Placebo also showed no significant 




















































2.81 U/L, 95% CI = -0.830, 6.450, p = 0.145). AST level in EL increase at interim but 
reduces at post test and placebo demonstrate a decreasing trend from baseline to post test.   
 
As for ALT level, there was no significant main effect of time (F2,36 = 1.325, p = 0.221) 
(Figure 4.4B) and no significant main interaction between group and time for ALT (F2,36 
= 1.314, p = 0.281). However, ANCOVA repeated measurement showed no significant 
changes within EL and PLA after eight weeks of supplementation.  Findings shows no 
significant difference between baseline (19.32 ± 9.3U/L) and post-test (23.23 ± 10.0 U/L) 
(MD = -3.91 U/L, 95% CI = -12.352, 4.533, p = 0.622) in EL. PLA also showed no 
significant difference between baseline (21.65 ± 5.6 U/L) and post-test (19.95 ± 8.9 U/L) 
(MD = 1.70 U/L, 95% CI = -6.770, 10.170, p = 1.000).  
 
   
Figure 4.4 Effect of eight weeks E. longifolia supplementation on liver function  
Note: Aspartate Aminotransferase (AST); Alanine Aminotransferase(ALT) 
Repeated measures ANCOVA between-group analysis with regard to time was applied. Numerical 
covariates (baseline – D0) were controlled by using repeated measurement ANCOVA. Assumption of 
normality, homogeneity of variances, compound symmetry, and homogeneity of regression were checked 
and were fulfilled. 
 
 
Similar to AST level, ALT level in EL also increases at interim but reduces at post test 
and PLA also demonstrates a decreasing trend from baseline to post test.  Independent 
sample t-test show no significant difference in ALT level between EL and PLA (MD = 











































4.4.2 Effects of E. longifolia supplementation on reproductive hormones 
 
Table 4.4 shows no significant difference between EL and PLA for all reproductive 
hormones on Day 1. The findings were measured using the independent sample t-test for 
testosterone, oestradiol, FSH and SHBG. Free testosterone and LH were analysed using 
the Mann-Whitney U test and reported in the median and Interquartile range. 
 
Similar to the short-term phase, the long-term phase also examined a similar hormonal 
profile, including testosterone, free testosterone, oestradiol, LH, FSH, and SHBG after 8 
weeks E. longifolia supplementation. The baseline result (Table 4.5) showed no 
significant difference between EL and PLA for all parameters.  
 
Table 4.4: Baseline measurement on the effect of two weeks E. longifolia 
supplementation on selected reproductive hormones 
 
  EUR (n = 8) PLA (n = 8) t (14) / U p  
  
M ± SD/ 
Med (IqR) 
M ± SD/ 
Med (IqR)     
Testosterone(ng/ml) 8.71 ± 2.0 8.63 ± 1.5 -0.037 0.971† 
Free Testosterone(pg/ml)††† 7.66 (3.7) 6.30 (6.8) 26.00 0.529†† 
Oestradiol(pg/ml) 44.1 ± 18.1 63.65 ± 21.0 -1.994 0.066† 
LH(mIU/ml)††† 8.18 (5.4) 8.13 (3.9) 31.00 0.916†† 
FSH(mIU/ml) 4.75 ± 1.3 5.40 ± 1.9 -0.794 0.44† 
SHBG(nmol/L) 47.77 ± 11.0 36.07 ± 27.7 1.112 0.285† 
          
Notes: Mean (M); Standard deviation (SD); Median (Med); Interquartile range (IqR); luteinizing hormone 
(LH); follicle-stimulating hormone (FSH); sexual hormone-binding globulin (SHBG) 
†denotes p value based on parametric test (independent t-test). 
††denotes p value based on non-parametric test (Mann-Whitney U test). 







Table 4.5: Baseline measurement on sex-related hormonal profile prior to 8 weeks 
supplementation. 
 
  EUR (n = 11) PLA(n = 10) t (19) / U p  
  
M ± SD/Med 
(IqR) 
M ± SD/Med 
(IqR)     
Testosterone(ng/ml) 6.85 ± 2.4 7.25 ± 1.7 0.436 0.668† 
Free Testosterone(pg/ml) 6.77 ± 1.9 7.61 ± 2.2 -0.939 0.359† 
Oestradiol(pg/ml)††† 31.74 (17.6) 32.49 (65) 52.00 0.863†† 
LH(mIU/ml)††† 4.12 (2.1) 2.67 (2.6) 31.00 0.099†† 
FSH(mIU/ml)††† 4.73 (5.2) 2.89 (4.1) 52.00 0.863†† 
SHBG(nmol/l)††† 15.86 (3.5) 16.85 (4.2) 48.00 0.654†† 
          
Note: Mean(M); Median (Med); standard deviation (SD), Interquartile range (IqR); luteinizing hormone 
(LH), follicle-stimulating hormone (FSH); sexual hormone-binding globulin (SHBG) 
† Denotes p value based on parametric test (independent t-test) 
†† Denotes p value based on non-parametric test (Mann-Whitney U test) 







4.4.2.1 Effects of two weeks and eight weeks of E. longifolia supplementation on 
selected reproductive hormones  
 
Two weeks of E. longifolia supplementation 
 
Significant main effect of time (F2.40, 31.17 = 5.416, p = 0.007 was observed and there is 
no significant main interaction between group and time for testosterone level (F2.40, 31.17 = 
4.221, p = 0.118). EL shows significant increase (11.1%) in testosterone level from day 
1 (8.71 ± 2.0 ng/ml) to day 14 (9.68 ± 0.7 ng/ml), (MD = -0.97 ng/ml, 95% CI = -1.908, 
-0.029, p = 0.043) and PLA did not demonstrate any significant increase but a decrease 
(-8.4%) in testosterone level from day 1 (8.63 ± 1.5 ng/ml) to day 14 (7.90 ± 1.5 ng/ml) 
(MD = 0.73 ng/ml, 95% CI = -1.977, 3.432, p = 1.000). Significant higher testosterone 




No significant main effect of time (F1.07, 13.95 = 0.204, p = 0.676) and no significant 
main interaction between group and time (F1.07, 13.95 = 0.631, p = 0.451) was observed in 
free testosterone level. No significant differences within and between EL and PLA after 
two weeks of supplementation (Figure 4.5B).  
 
Following testosterone and free testosterone level, no significant main effect of time 
(F5, 65 = 2.446, p = 0.443) was observed in oestradiol level. Oestradiol level showed no 
significant main interaction between group and time (F5, 65 = 0.474, p = 0.794). No 
significant changes within EL and PLA throughout the supplementation period. Only at 
day 3, PLA (66.23 ± 12.5 pg/ml) has significant higher oestradiol level compared to EL 
(45.94 ± 22.7 pg/ml), t (14) = -2.216, p = 0.004 (Figure 4.5C).  
 
Next, data shows no significant main effect of time (F1.99, 25.90 = 2.014, p = 0.154) and 
no significant main interaction between group and time (F1.99, 25.90 = 1.389, p = 0.267) for 
LH level. As for FSH level, there is a significant main effect of time (F5, 65 = 2.583, p = 
0.034) but no significant main interaction between group and time (F5, 65 = 0.617, p = 
0.687) was observed.  Both LH and FSH level shows no significant differences within 
and between EL and PLA after two weeks of supplementation (Figure 4.5D and 4.5E).  
 
Lastly, no significant main effect of time (F5, 65 = 1.918, p = 0.103) but there is a 
significant main interaction between group and time (F5, 65 = 4.268, p = 0.002) in SHBG 
level. Within group analysis shows no significant changes within EL and PLA. There is 
a significant higher SHBG level in EL (53.06 ± 15.4 nmol/l) compared to PLA (30.55 ± 
17.7 nmol/l) at day 7, t (14) = 2.718, p = 0.017 (Figure 4.5F).  
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Figure 4.5 Effect of 2 weeks of E. longifolia supplementation on testosterone (A), free testosterone (B), oestradiol (C), LH (D), FSH (E) and 
SHBG (F) 
Note: Repeated measurement ANCOVA between-group analysis with regard to time was applied. Numerical covariates (baseline – D0) were controlled by using repeated 
measurement ANCOVA. Assumption of normality, homogeneity of variances, compound symmetry, and homogeneity of regression were checked and were fulfilled. 
* denotes indicate that there is a significant increase compare to day 1; †denotes indicate significant differences between E. Longifolia group and Placebo group.                    













































































































































































Table 4.6 shows the mean differences and the percentage of changes after two weeks 
of E. longifolia and placebo supplementation on all hormones. All hormones increase in 
EL except for the LH level. On the other hand, PLA shows decreased in testosterone, 
oestradiol, and LH and a minimal increase in free testosterone, FSH, and SHBG.  
 
 
Table 4.6: Effect (Week 0 vs. Week 2) of E. longifolia and placebo supplementation 
on hormone after 14 days of supplementation. 
 
Variable 
                       EL(n = 8) PLA(n = 8) 
MD 
[95% CI] p % 
MD 
[95% CI] p % 
Testosterone (ng/ml) 0.97 
[-1.91,-0.03] 









1.00 24.7 0.12 
[-5.06, 4.81] 
1.00 1.6 
       
Estradiol (pg/ml) 7.46 
[-55.60, 40.69] 





LH (mIU/ml) -0.54 
[-2.31, 3.40] 
1.00 -7.81 -1.69 
[-1.95, 5.33] 
1.00 -22.0 
       
FSH (mIU/ml) 0.35 
[-2.11, 1.4] 
1.00 7.6 0.37 
[-3.90, 3.16] 
1.00 6.8 
       
SHBG (nmol/L) 0.60 
[-16.38, 15.17] 
1.00 1.3 5.94 
[-25.76, 13.88] 
1.00 16.5 
Note: Day 0 (D0); Day 14 (D14); MD=Mean difference; CI=Confidence interval; LH=luteinising 
hormone; FSH=follicle-stimulating hormone; SHBG=sexual hormone binding globulin; 
Numerical covariate (baseline) was controlled by using ANCOVA repeated measurement. 
*Level of significance was set at 0.05 (two-tailed); % increased or decreased (-) 
 
Eight weeks of E. Longifolia supplementation 
 
No significant main effect of time (F2, 36 = 5.287, p = 0.110) and no significant main 
interaction between group and time for testosterone level (F2, 36 = 0.233, p = 0.794). EL 
and PLA show no significant changes in testosterone level within and between groups 
from baseline to post test (Figure 4.6A).  
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There is a significant main effect of time (F2, 36 = 4.142, p = 0.024) was observed in 
free testosterone level. Findings shows no significant main interaction between group and 
time (F2, 36 = 1.398, p = 0.260) in free testosterone level. However, EL shows significant 
decrease in free testosterone level from baseline (6.77 ± 1.9 pg/ml) to interim (5.67 ± 0.8 
pg/ml), (MD = 1.09 pg/ml, 95% CI = 0.38, 1.81, p = 0.005) before a slight increase at 
post test (MD = -0.51 pg/ml, 95% CI = -2.52, 1.50, p = 1.000). PLA did not demonstrate 
any significant changes from baseline to post test. Between group analysis shows PLA 
(7.47 ± 2.8 pg/ml) had significant higher free testosterone at interim compared to EL (5.67 
± 0.8 pg/ml), t (19) = -2.151, p = 0.045 (Figure 4.6B).  
 
Next, a significant main effect of time (F2, 36 = 7.603, p = 0.002) was found in oestradiol 
level there but no significant main interaction between group and time (F2, 36 = 0.235, p = 
0.791). The pairwise comparison shows no significant changes within and between EL 
and PLA throughout the three time point Figure 4.6(C).  
 
No significant main effect of time (F2, 36 = 2.747, p = 0.078) for LH level. The data 
also shows no significant main interaction between group and time (F2, 36 = 0.825, p = 
0.446). As for FSH level, no significant main effect of time (F1.46, 26.31 = 0.649, p = 0.484) 
and no significant main interaction between group and time (F1.46, 26.31 = 0.575, p = 0.687) 
was observed.  Similar to the hormone level found in the short term, both LH and FSH 
level also shows no significant differences within and between EL and PLA after eight 
weeks of supplementation (Figures 4.6D and 4.6E).  
 
Lastly, no significant main effect of time (F2, 36 = 2.345, p = 0.11) in SHBG level but 
there is a significant main interaction between group and time (F2, 36 = 5.388, p = 0.009). 
Within group analysis shows significant increase from baseline (17.33 ± 5.3 nmol/l) to 
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post test (22.96 ± 13.8 nmol/l) in EL (MD = -5.64 nmol/l, 95% CI = -10.46, - 0.818, p = 
0.022 but no significant changes in PLA. Also, analysis also shows no significant 
difference between EL and PLA at each time point (Figure 4.6F).  
 
Table 4.7 shows the mean differences and the percentage of changes after eight weeks 
of E. longifolia and placebo supplementation on all hormones. In EL, all hormones reduce 
except for FSH and SHBG. PLA, on the other hand, changes after eight weeks is minimal. 
 
 
Table 4.7: Effect (Baseline vs. Post) of E. longifolia and placebo supplementation on 
endocrine hormone after 8-weeks of supplementation. 
Note: MD=Mean difference; CI=Confidence interval; LH=luteinising hormone; FSH=follicle-stimulating 
hormone; SHBG=sexual hormone-binding globulin; EL= Eurycoma longifolia. Numerical covariate 
(baseline) was controlled by using ANCOVA repeated measurement. 
*Level of significance was set at 0.05 (two-tailed); % increased or decreased (-) 
 
Variable 
EL (n = 11)   PLA (n = 10)   
Mean difference  
(95% CI) p  % 
Mean difference  
(95% CI) p  % 
       
Testosterone -0.142 [-1.99, 2.27] 1.00 -2.00 0.054 [-1.67, 1.56] 1.00 0.80 
       
Free Testosterone -0.582 [-1.35, 2.51] 1.00 -8.60 0.169 [-3.01, 2.68] 1.00 2.20 
       
Oestradiol -10.105 [-7.16, 27.37] 0.36 -26.52 -0.037 [-18.62, 18.70] 1.00 -0.09 
       
LH -1.003 [-0.78, 2.78] 0.40 -24.63 0.063 [-1.77, 1.65] 1.00 2.06 
       
FSH 0.546 [-2.37, 1.28] 1.00 12.56 -0.332 [-2.51, 3.18] 1.00 -7.84 
       
SHBG 5.64 [-10.45, -0.82] 0.022* 32.49 -1.655 [-1.15, 4.46] 0.34 -9.19 
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Figure 4.6 Effect of eight weeks of E. longifolia supplementation on testosterone (A), free testosterone (B), oestradiol (C), LH (D), FSH (E) and 
SHBG (F) 
Note: Repeated measurement ANCOVA between-group analysis with regard to time was applied. Numerical covariates (baseline – D0) were controlled by using repeated 
measurement ANCOVA. Assumption of normality, homogeneity of variances, compound symmetry, and homogeneity of regression were checked and were fulfilled. 
* denotes indicate that there are significant changes within groups; †denotes indicate significant differences between E. Longifolia group and Placebo group.  *,†denotes level of 
















































































































































This chapter aims to determine the efficacy of E. longifolia on reproductive hormones. 
Data have demonstrated that the administration of E. longifolia for two weeks produces 
significantly higher total testosterone (11.1%) and a non-significant increase in free 
testosterone (24.7%) levels compared to PLA. PLA recorded a decrease in testosterone 
(8.4%; p > 0.05) and an increase of 1.6% (p > 0.05) in free testosterone level from D0 to 
D14. However, a decrease in testosterone (-2.0%) and free testosterone levels (-8.6%) in 
EL and a minimal increase in PLA; testosterone (0.8%) and free testosterone (2.2%) after 
eight weeks of supplementation. The findings for the long-term supplementation shows 
no significant changes. Although supplementation of 2 weeks of E. longifolia increased 
the total testosterone levels among young participants, supplementation of 8 weeks of E. 
longifolia demonstrates otherwise. Findings also show that E. longifolia may not affect 
the LH and oestrogen in the HPG axis.  
 
The current study findings demonstrated similarity with previous studies which 
reported that short-term supplementation of E. longifolia increased total testosterone 
(Tambi et al., 2012; Talbott et al., 2013; Henkel et al., 2013) and long-term 
supplementation studies (Ismail et al., 2012; Chen et al., 2014; Chen et al., 2019) showed 
no changes. A low dose (200 to 400 mg) of E. longifolia did not elicit any significant 
increase in testosterone levels among young, healthy males with normal testosterone 
levels (Chen et al., 2014; Chen et al., 2019). However, present findings demonstrated that 
two weeks of a higher dose of 600 mg of E. longifolia supplementation increased 
testosterone levels significantly compared to placebo.  
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It is postulated that the increase in total testosterone is said to be due to a bioactive 
peptide of 4.3 kDa (Tambi et al., 2012; Talbott et al., 2013; George et al., 2018) and 
eurycomanone, identified and isolated in E. longifolia, which restores and increases 
testosterone (Low et al., 2013a and 2013b). While data demonstrated an increase in 
testosterone and free testosterone in just two weeks of E. longifolia supplementation, the 
increase may also be affected by other confounding variables such as participants 
performing resistance training, food and supplements. Although participants are 
monitored through dietary and physical activity recording, there is also a possibility that 
participant may not comply with the study criteria, which may contribute to the outcome 
of the study.  
 
An increase in free testosterone (p > 0.05) was observed after two weeks of 
supplementation. However, individual data were examined and found that two 
participants’ data reported a higher increase from day 1 to day 14 than the other six 
participants. In addition to the variability of the individual’s data, a larger decrease in 
PLA testosterone level migh have contributed to the significant difference between the 
two groups (Figure 4.5A). In addition, no significant difference between the lean body 
mass in both short-term and long-term study. However, the EL group had a higher lean 
body mass compared to PLA in the short term.  Generally, men with high total 
testosterone levels had more lean body mass (Mouser et al., 2016). Hence, EL play a 
possible role in producing higher testosterone in the short term study and might promote 
an increase in lean body mass.   
 
Data relating to the use of E. longifolia for two weeks from the human clinical trial are 
still scarce. Thus, further investigation is needed to validate whether E. longifolia (600 
mg) on healthy young adults is able to increases testosterone in a short period (2 weeks). 
113 
However, in the long-term study, no changes were observed throughout the study period, 
indicating that E. longifolia supplementation alone may not inhibit any increase in 
testosterone level in healthy young adults. Hence, the present study shows that the current 
dose of 600 mg may not be sufficient if the duration is extended for more than two weeks. 
 
In relation to the effect of E. longifolia on the HPG axis, the present study reported a 
non-significant decrease in the LH level in EL after two weeks and eight weeks of 
supplementation. The HPG axis regulates testosterone production, and when testosterone 
levels are low, GnRH is secreted by the hypothalamus, which results in LH production 
from the anterior pituitary. The LH then stimulates the Leydig cells in the testes to 
produce testosterone. In contrast, when testosterone levels are high, the negative feedback 
will inhibit the HPG axis by decreasing GnRH and LH production and, subsequently, 
reduce testosterone production. Total testosterone and free testosterone regulate the 
negative feedback loop, and one of its roles is to suppress the secretion of LH (Veldhuis et 
al., 1984; Mulligan et al., 1997; Veldhuis, 1999; Friedl, 2005; Stankovićet al., 2013). 
Even though there is an increase in testosterone level in the short-term supplementation, 
findings suggest that E. longifolia did not stimulate LH production, which subsequently 
increases testosterone levels.  
 
The current study shows that the oestradiol concentration increased from day 1 to day 
14 in EL. Also, a decrease was observed after supplementation for eight weeks in EL.  
However, the outcome did show any significant changes in the oestradiol levels. Hence 
there is no indication that E. longifolia inhibits aromatase from preventing testosterone 
conversion to oestradiol to increase the testosterone level. It would seem that the higher 
testosterone in the short-term study has prompted a higher conversion to oestrogen and, 
thus, increased the circulating concentration of oestrogen, which, subsequently, down-
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regulates the HPG axis, resulting in further decreased production of LH ( Ullah et al., 
2014; Majzoub & Saganegh, 2016). However, the total testosterone level still increased 
at day 14, suggesting that E. longifolia does not directly affect the HPG axis activity in 
increasing LH secretion.  According to Figure 4.5C, oestrogen level does not significantly 
differ between EL and PLA, and the increase in oestrogen in EL may be due to inter-
individual variance. Therefore, the data are not in agreement with the study conducted by 
Low et al. (2013a and 2013b), which reported that E. longifolia enhanced testosterone 
production in rats by inhibiting the aromatase conversion of testosterone to oestrogen. 
Hence, further investigation is required to elucidate this mechanism suggested by Low et 
al. (2013a and 2013b) before a conclusion can be made since the present study did not 
measure the aromatase enzyme. 
 
Two weeks of  E.longifolia supplementation have shown a low concentration level in 
SHBG in EL (1.3%) compared to PLA (16.5%), demonstrating higher circulating total 
testosterone (11.1%) and free testosterone (24.7%) levels unbound to SHBG in EL 
compared to the total circulating testosterone (-8.4%) and free testosterone (1.6%) in 
PLA. In the long term supplementation, a significant increase in SHBG in EL 
demonstrates decreased testosterone and free testosterone. Testosterone is bound with 
SHBG, and only a small fraction of about 2 to 5% circulates as free testosterone in the 
body. As circulating SHBG increases with age, the total testosterone concentration level 
will decrease gradually. An increase in SHBG and a decrease in testosterone result in a 
greater decline in free testosterone (Rosner et al., 2007; Wu et al., 2008; Hammond et al., 
2012; Antonio et al., 2016). The precise mechanism by which E. longifolia restores 
normal testosterone levels are still not well explained, but it has been suggested by Tambi 
(2003) that E. longifolia influences the release rate of free testosterone from SHBG. 
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However, the current study’s findings did not demonstrate E. longifolia influencing the 
testosterone and free testosterone from SHBG.  
 
 While the current study did not show E. longifolia affect the HPG axis, an earlier study 
on endurance cyclists showed that the cortisol levels were 32% lower and testosterone 
levels were 16% higher in the E. longifolia-supplemented cyclist compared to placebo 
(Talbott et al., 2006). Another study also reported a reduction in cortisol levels and 
increased testosterone levels (Talbott et al., 2013). Cortisol produced from the HPA axis 
may have inhibited testosterone by reducing HPG activity and blocking androgen 
receptors (Sherman et al., 2016; Viau, 2002; Chen et al., 1997). Thus, the increase in 
testosterone in EL may be due to E. longifolia affecting the HPA axis, resulting in a 
possible reduction in the stress hormone cortisol and causes an increased in testosterone 
(George et al., 2018; Sherman et al., 2016).  
 
 Findings from the long-term study have indicated that 600 mg of E. longifolia did not 
elicit the same effect found in the short-term study due to the human body trying to 
maintain homeostasis in individuals with a normal circulating level.  Repeated exposure 
to E. longifolia for eight weeks did not demonstrate any diminishing effect of the E. 
longifolia extract. Thus, the current study is not able to determine whether there is any 
dose-dependent effect on the tolerance level because the dosage used in the current study 
may not be sufficient in affecting changes in the hormones. A higher dose may be needed 
to produce or enhance the effect of E. longifolia in the production of testosterone in 
young, healthy male individuals. However, a high dose may not be needed for older 
individuals since previous studies (Table 4.1) have shown a low dosage (200 to 400 mg) 
of E. longifolia supplemented for 4 to 12 weeks can increase the testosterone level. Hence, 
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age, health and dosage appear to play a significant role in determining the efficacy of E. 
longifolia.   
 
 Although there is a significant increase in the testosterone level in the short-term 
supplementation, there is a possible confounding factor affecting the outcome or the 
study. It is said that the ELISA kit may need to be validated analytically, physiologically 
or biologically (Gholib et al., 2020) to enable more reliable measurement of testosterone, 
free testosterone, LH, FSH, oestrogen and SHBG. However, the current study did not 
validate the reliability of the kit. Nevertheless, current studies’ findings provide valuable 
information regarding E. longifolia and its mechanism in affecting testosterone levels via 
the HPG axis. However, the current study also acknowledges that the high inter-
individual variation may obscure the outcome of the findings due to the measurement’s 
reliability.  
 
 The E. longifolia used in the current study has a eurycomanone content of 1.21 w/v, 
equivalent of 7.26 mg of eurycomanone in a capsule of 600 mg E. longifolia. The 
euryomanone content used complied with the standard recommendation (0.8 – 1.5 
w/v %). The amount of active ingredient available in the dosage supplemented to the 
participants may not be sufficient. Also, previous studies have not reported the 
appropriate amount of active ingredient available in the dosage they used in their 
supplementation studies. Hence, a study investigating different doses of the active 
ingredient may be warranted.  
  
 The current study has demonstrated that the supplementation of 600 mg of  
E.longifolia, which is considered the highest dose supplemented in humans at the 
moment, did not induce toxicity to the liver among the studies’ participants, based on the 
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measurement of AST and ALT. Although lower AST and ALT levels were recorded in 
short-term treatment and higher AST and ALT in long-term treatment than PLA, the AST 
(8 - 48 U/L) and ALT (7 - 55 U/L) levels were still at the normal concentration levels. 
Thus, this supports the study by Tambi (2005), who demonstrated that 600 mg of E. 
longifolia is not toxic to healthy males’ liver function. This suggests that supplementation 
of 600 mg of E. longifolia is safe for prolonged supplementation in humans.     
 
4.6  Conclusion 
 
The present study has investigated, for the first time, the potential relationship between 
E. longifolia and the hormonal changes in humans, specifically young, healthy males. 
Although there are differences in total testosterone and free testosterone levels between 
short and long-term studies, our findings are in agreement with several previous studies, 
which have demonstrated an increase in testosterone levels. The findings show a 
beneficial effect in short-term supplementation by increasing testosterone and free 
testosterone but not in the long-term supplementation of E. longifolia in young 
individuals. However, possible confounding factors such as exercising during the 
supplementation period and a larger decrease in testosterone in PLA may affect the 
study’s outcome. The findings also demonstrate that E. longifolia did not affect the HPG 
axis.  Hence the claim that E. Longifolia acts as a testosterone booster might not be 
accurate in a population with normal circulating testosterone levels, even with a high dose 
and extended supplementation period.  
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CHAPTER 5: THE EFFECTS OF Eurycoma longifolia ON MOOD AND SEXUAL 




Herbal medicines have been used to treat various health challenges (WHO, 2004), such 
as those concerned with psychological mood and sexual function (Litwin et al., 1998; 
Shabsigh et al., 1998; Laumann et al., 1999; Althof, 2002). It is known that a significant 
development in hormonal changes among adolescents in the endocrine system may be 
due to the activation of the HPG axis, which enhances the secretion of sex hormones to 
induce adaptations in physical (i.e., sexual health) and psychological characteristics (i.e., 
mood) (Naughton et al., 2000). 
 
Most testosterone therapies are prescribed to middle-aged and older men with age-
related declines in testosterone (US Food and Drug Administration, 2014). While the 
effects of exogenous testosterone on physical functions are well documented (Anderson 
& Wu, 1996; Bhasin et al., 1996; Bhasin et al., 2001), much remains to be learned about 
its effects on mood and sexual function. The results concerning the use of testosterone 
therapy in men and data from previous studies examining the effects of testosterone 
supplementation in men with low testosterone level on mood and sexual health are limited 
and conflicting, with some suggesting improvements (Steidle et al., 2003; Wang et al., 
2004; Cavallini et al., 2004; Daniell et al., 2006;  Wang et al., 2011), while some suggest 
otherwise (Seidman et al., 2001; Shores et al., 2009; Pope et al., 2010). Thus, alternative 
and complementary medicines, such as herbal supplements, are considered replacements 
to conventional therapeutics to improve mood and sexual function. 
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 Eurycoma longifolia has a wide range of therapeutic properties as general health 
remedies, which include enhancement in physical and mental energy levels and aspects 
of overall quality of life, such as mental health, physical functioning, role limitations due 
to physical health, role limitations due to emotional health, energy/fatigue ratio (vitality), 
emotional wellbeing, social functioning, pain and general health (Ali & Saad, 1993; Bhat 
& Karim, 2010). Most importantly, E. longifolia can increase testosterone production in 
humans (Tambi et al., 2012; Henkel et al., 2014), which may have a beneficial effect in 
improving mood, physical status (i.e., strength, body composition), and sexual function 
(Miller, 2009; Grossmann, 2011).  
     
 Although limited, studies involving the consumption of E. longifolia have 
demonstrated exciting findings that show a higher testosterone level is associated with an 
improved psychological mood state (Talbott et al., 2013; George et al., 2018). Also, in 
recent years, E. longifolia has been shown to improve sexual function (Goreja, 2004; Bhat 
& Karim, 2010; Talbott et al., 2013; Wizneh & Asmawi, 2014) through the elevation of 
reproductive hormones, in particular, testosterone (Talbott et al., 2006; Tambi et al., 
2012; Henkel et al., 2013; Udani et al., 2014). Earlier studies have identified that 
eurypeptides, a group of bioactive peptide fractions (4300-dalton glycopeptide with 36 
amino acids) found in E. longifolia, are able to increase muscle size and strength (Hamzah 
and Yusof, 2003; Sarine et al., 2009),  improve overall sexual wellbeing (Ismail et al., 
2012; Udani et al., 2014), accelerate recovery from exercise (Talbott et al., 2006), reduce 
stress and improve mood (Talbott et al., 2013), and reduce symptoms of fatigue (Tambi, 
2003; Tambi, 2005; Tambi, 2007) by elevating testosterone (Ang et al., 2001; Asiah et 
al., 2007; Zanoli et al., 2009; Tambi et al., 2012). Recent studies then reported how 
eurycomanone, a quassinoid isolated from E. longifolia, demonstrated an ability to 
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increase the production of testosterone in isolated rat testicular Leydig cells (Low et al., 
2013a, 2013b) 
 
 Daily stress and aspects of lifestyle, such as diet, exercise and sleep patterns, among 
the youth may hasten the lowering of testosterone levels, affecting their psychological 
mood state and sexual function. Therefore, maintaining a youthful testosterone level 
should enable the human body to maintain or improve its psychological mood and general 
wellbeing, including sexual function (Miller, 2009; Grossmann, 2011). Though there are 
a couple of studies that have reported on an older age population (George et al., 2013; 
Talbott et al., 2013), there are no studies that have reported on the effects of E. 
longifolia on psychological and sexual function among a younger cohort of people who 
are going through ageing, daily stress, and changes in lifestyle, which are subsequently 
affecting their mood and sexual function.    
      
The present study aims to address the following:  
(i) to investigate the short and long-term effects of E. longifolia supplementation on 
psychological mood state among collegiate males; and 
(ii) to investigate the short and long-term effects of E. longifolia supplementation on 
sexual function among collegiate males. 
  
5.2 Literature Review   
5.2.1 Testosterone Levels on Psychological Wellbeing and Sexual Function 
 
Testosterone levels decrease gradually by 40% between the ages of 40 to 70 years 
(Davidson et al., 1983; Seidman, 2007; Bhasin et al., 2010). Hypogonadism is described 
as involving one or more symptoms, including low libido, erectile dysfunction and 
121 
osteoporosis. It is also defined as involving two or more symptoms, such as sleep 
disturbance, depressed mood, lethargy or low physical performance, or a total 
testosterone level below 300 ng/dL (Araujo et al., 2007; Johnson et al., 2013). Studies 
have shown that testosterone replacement therapy significantly improves sexual function 
(sexual desire, enjoyment without a partner, enjoyment with a partner, percentage of full 
erection, self-assessment of satisfaction with erection), positive mood scores (alert, full 
of energy, friendly, feeling well/good) and combats negative mood scores (angry, 
irritable, sad or blue, tired and nervous (Bhasin et al., 2010; Bhasin & Basaria, 2011). 
However, studies also suggest no correlation between lower testosterone and depressive 
disorders, and further study is warranted (Araujo et al., 1998; Barrett-Connor et al.,1999; 
Booth et al., 1999; Johnson et al., 2013). The potential adverse effects associated with 
exogenous testosterone administration are still limited and unknown (Grech et al., 2014; 
Ryan and Nathan., 2017).  
 
5.2.2 Effect of E. longifolia consumption on psychological mood 
 
Complementary and alternative medicine (CAM) has become popular among adults to 
alleviate stress and avoid the possible adverse effects of pharmaceutical drugs (George et 
al., 2018). However, few studies have sought the perspective of young adults on how 
CAM is used, a population said to be facing high levels of stress and poor mental health 
(Patel et al., 2007; Blanco et al., 2008; Storrie et al., 2010; Sifferlin, 2013; Eisenberg et 
al., 2013). Perceived stress and poor mental health are prevalent among young adults in 
the range of 16 to 24 years old (Storrie et al., 2010; Eisenberg et al., 2013), and often this 
condition is related to anti-social behaviour and poor social relations (Johnson, 1991; 
Sandi & Haller, 2015). This stress condition, if left untreated, will significantly increase 
the risk of developing an array of symptoms, such as anxiety, depression, and fatigue 
122 
(Lazarus, 1999; George et al., 2018). Pharmaceutical drugs are commonly used to treat 
stress and anxiety disorder. While there is a concern that someone taking anti-depressant 
drugs may become addicted and dependent on them (Fernandes et al., 2018), data are still 
limited.  
 
At present, only two studies have examined the effect of E. longifolia on psychological 
mood state in humans using the POMS questionnaire (Table 5.1). Both studies recruited 
similar age groups (46 to 65 years), and the participants were moderately stressed. Talbott 
et al. (2013) revealed that 200 mg/day of E. longifolia showed improvement in the tension 
(-11%), anger (-12%), and confusion (-15%) domains. On the other hand, George et al. 
(2018) found the combination of E. longifolia (50 mg) and multivitamins showed 
improvement in the vigour domain (14.1%) and decreased negative mood. The authors 
suggest that a positive mood state, which indicates positive mental health or desirable 
emotional health status among the older population, is achievable by 
administrating         E. longifolia.  It is postulated that the improvement may be due to the 
eurypeptides in E. longifolia which improve energy status and sex drive by raising 
testosterone in rodent’s studies.  
 
Also, eurypeptides are said to influence free testosterone release of from SHBG 
(Chaing et al., 1994; Tambi, 2003).  The stress hormone cortisol increases under stressed 
states and, as a result, the opposite effect is that the testosterone levels decrease 
(Sherman et al., 2016). While Talbott et al. (2013) reported a rise in testosterone levels 
and a reduction in cortisol levels, George et al. (2018) only managed to report an increase 
in testosterone without measuring the cortisol level.  Cortisol, a primary stress hormone, 
is produced via the HPA axis. However, no studies examined how E. longifolia affect the 
glucocorticoid biosynthesis pathway in producing cortisol.    Thus, the precise mechanism 
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of restoring testosterone levels via HPG and reducing the cortisol levels via HPA is still 
unknown and, at the very least, requires further study. 
 
A positive mood state (i.e., an increase in vigour and a reduction in tension, anger, 
depression and fatigue) can be achieved when testosterone levels are restored to their 
normal range (Anderson et al., 1999; Wang et al., 2000; O'Connor et al., 2001). 
Testosterone has long been associated with mood, and often it is reported in case reports 
involving exogenous testosterone administration (Talih et al., 2007; Johnson et al., 2013). 
Talbott et al. (2013) and George et al. (2018) have suggested that the positive mood state 
improvement is likely due to the association with the restoration of normal sexual function 
through the consumption of E. longifolia. However, only a small number of studies have 
provided information on the ability of E. longifolia  to improve mood by restoring or 
maintaining healthy testosterone levels (Ang & Cheang, 1999; Talbott et al., 2013; 
Johnson et al., 2013).
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Table 5.1: Studies on the effect of E. longifolia on psychological mood state. 
Study Test Dosage Outcome Reference 
The anxiolytic activity of E. 
longifolia Jack roots  
Adult mice Twice daily for 5 
days. 
Open-field test, elevated plus-
maze, and anti-fighting tests. 
 
E.longifolia fractions: 
Chloroform (0.3 g/kg) 
Methanol (0.3 g/kg) 
Water (0.3 g/kg) 
Butanol (0.3 g/kg) 
Control (3 ml/kg) 
Diazepam (1 mg/kg) 
E. longifolia attenuated anxiety 
parameters in open-field and plus-maze 
test and inhibited footshock-induced 
fighting.  
Ang and Cheang 
(1999) 
Effect of E. longifolia on stress 
hormones and psychological mood 
state  
POMS in 63 moderately stress 
men and women. Supplemented 
for 4 weeks 
200 mg / day  Significant improvement for tension, 
anger, and confusion   
Cortisol and testosterone significantly 
improve, reduced cortisol exposure and 
increased testosterone  
Talbott et al. 
(2013) 
Efficacy and safety of E. longifolia 
(Physta) water extract plus 
multivitamins on quality of life, 
mood, and stress 
POMS in 93 moderately stress 
subjects.  
E. longifolia plus multivitamins 
12 weeks 
50 mg /day Increased trend in POMS vigour domain 
Significant improvement on POMS 
vigour for age 46-65 men 
George et al. 
(2018) 
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5.2.3 The effect of E. longifolia supplementation on sexual function 
 
Eurycoma longifolia root is a popular traditional supplement to enhance sexuality and 
fertility (Ang and Sim, 1998; Tambi and Imran, 2010). The water extract contains various 
bioactive compounds with pro-fertility and aphrodisiac properties, as seen in animal and 
human studies (Sambandan et al., 2006; Asiah et al., 2007; Tambi and Imran, 2010). 
 
E. longifolia improves erectile dysfunction in hypogonadal men by enhancing 
testosterone levels (Hussein et al., 2007; Bhat & Kharim, 2010; Hassali et al., 2009). 
Hence demonstrating the aphrodisiac effects of E. longifolia in improving libido and 
countering erectile dysfunction (Ang and Thai, 2001; Ang and Lee, 2002). Bioactive 
compounds, such as phenolic compounds, polypeptides, diterpenoids, alkaloids and 
quassinoids, found in E. longifolia have been reported to be the factors behind the 
aphrodisiac effect (Ang and Thai, 2001; Ang and Lee, 2002).   Various fractions of E. 
longifolia have been used to investigate the effect on sexual function in rats (Ang and 
Lee, 2003; and Ang et al., 2003) and have highlighted that eurypeptides exhibited 
aphrodisiac effects by increasing testosterone levels (Ang and Lee, 2003; and Ang et al., 
2003). While studies examining eurypeptide influencing testosterone increase are scarce, 
recent studies have shown eurycomanone, a quassinoid in E. longifolia, also exhibiting 
the ability to increase testosterone levels in rats by affecting the HPG axis (Low et al., 
2013a & 2013b).  
 
The impact of E. longifolia in handling male sexual dysfunction has primarily been 
studied using in vivo animal models (Ang and Thai, 2001; Ang and Lee, 2002; Ang et al., 
2003; Ang et al., 2004) and some human models (Tambi, 2009; Tambi et al., 2012; Ismail 
et al., 2012; Talbott et al., 2013; Henkel et al., 2014; George and Henkel, 2014; Udani et 
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al., 2014) (Table 5.2). In a study conducted by Udani et al. (2014), a 12 week randomised, 
double-blind, placebo-controlled, and parallel-group study demonstrated that the 
combination of 300 mg of E. longifolia and Polygonum minus (an antioxidant) improves 
sexual intercourse performance, the concentration of male sex hormone, sex libido and 
overall sexual wellbeing in men between 40 to 65 years old.  
 
Also, two earlier studies, by Ismail et al. (2012) and Tambi et al. (2012), have shown 
similar findings. The effect of 300 mg of E. longifolia daily in healthy men between 30 
to 55 years old have shown improvements in sexual libido, sexual activities and sexual 
satisfaction, and positive effects on seminal parameters, which include the volume and 
concentration of sperm and the proportion of sperm having normal motility (Ismail et al., 
2012). A lower dose of 200 mg per day in hypogonadic men between 30 to 64 years old 
found an improvement in sexual performance, including erectile function, sexual 
intercourse performance, and penile hardness (Tambi et al., 2012). All three studies 
demonstrated an improvement in testosterone levels. 
 
Several other studies have been performed to investigate the effect of E. longifolia on 
male sexual libido. Talbott et al. (2013) performed a clinical placebo-controlled trial in 
63 subjects by supplementing 200 mg of E. longifolia for four weeks and found significant 
improvement in testosterone levels, with concurrent improvement in sexual activities. 
Another study by Henkel et al. (2014) examining the effects of 400mg of E. longifolia on 
age-related sexual impotence among 13 physically active males aged between 57 to 72 
years for five weeks found an improved sexual function with an improvement in the total 
and free testosterone concentrations.  Similarly, the significance of E. longifolia in 
improving male sexual libido and testosterone levels have been shown in a study 
conducted by George and Henkel (2014). They reported the supplementation of E. 
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longifolia had successfully restored serum testosterone levels compared to the 
conventional testosterone replacement therapy and demonstrated that E. longifolia could 
improve male sex libido in elderly patients with 40 to 50 % lower testosterone levels 
compared to young patients. The increase in testosterone levels, reported in the above 
published clinical studies, may contribute to improving sexual performance in male 
adults, especially in adults between 30 to 65 years old who have lower baseline 
testosterone levels. 
 
Considering the adaptogenic nature of E. longifolia, the plant could be more effective 
in adult participants with lower baseline levels of testosterone and not in those with 
optimum health and wellbeing (Tambi et al., 2012; Udani et al., 2014). While there are 
reports of high numbers of sexual problems and rates of sexual dysfunction in adulthood, 
few recent survey studies have found that there is such a high prevalence of problems in 
sexual functioning among adolescents and young adults (Akre, Berchtold, Gmel & Suris, 
2015; Mitchell et al., 2016; O'Sullivan et al., 2016). Based on the clinical evidence from 
previous studies demonstrating the benefits of E. longifolia in men age 30 to 64 years in 
improving sexual function, it would be misleading to make any definitive claims that the 
effects of E. longifolia concerning sexual function will be the same on young, healthy 
participants below the age of 30 years, with normal circulating testosterone levels. At the 







Table 5.2: Studies demonstrating promising potential in improving male sexual function 
Test Subjects  Dosing regimen and 
duration 
Findings Reference 
Sexual Intercourse Attempt diary, 
Erection Hardness Scale, Sexual 
Health Inventory of Men, and Aging 
Male Symptom 
30 healthy male 
aged 40 - 65 years 
 
300 mg daily  
6 months 
Significant improvements in all test Udani et al. 
(2014) 
The Ageing Males’ Symptoms 
(AMS) and the serum testosterone 
concentration  
76  patient with 
LOH aged 30 - 64 
years 
200 mg daily 
1 month 
Improved AMS score, serum testosterone concentration. 
Improvement in sexual performance 
Tambi et al. 
(2012) 
International Index of Erectile 
Function (IIEF) and Sexual Health 
Questionnaires (SHQ); Seminal 
Fluid Analysis (SFA) 
109  healthy men 
aged 30 - 55 years 
300 mg daily  
3 months 
Improved in the domain Physical Functioning, Erectile 
Function domain, sexual libido  
Ismail et al. 
(2012) 
Electrical copulation cage  
 
Sexually sluggish 
old adult male rats 
 
0.5 g/kg E. longifolia 
 
Decreased the hesitation time of noncopulator male rats 
Transient increase in the percentage of the male rats 
responding to the right choice  
Ang and Ngai 
(2001) 
Monitoring orientation activities  
towards the receptive females  
Adult middle-aged  
9 months old and 
retired breeders 
200, 400 and 800 




Increased orientation activities towards the receptive 
females (anogenital sniffing, licking and mounting), 
increased genital grooming towards themselves  
Ang et al. 
(2000) 
Electrical copulation cage during the 
dark phase of the light-dark cycle 
and in subdued light. 
Adult male rats, 9 
months old and 
retired 
Breeders 
0.5 g/kg of E. 
longifolia 
 
control group : 3 ml/kg 
of normal saline daily 
for 12 weeks 
Enhanced sexual qualities by decreasing their hesitation 
time to controls.  
 




5.3.1 Participants  
  
The participant information and participant’s anthropometric is presented in Chapter 3, 
Table 4.3. The study was approved by the Liverpool John Moores University Ethics 
Committee (14/SPS/013), and all participants provided their informed consent before 
embarking on the study.  
 
5.3.1.1 Experimental Design  
 
The study was a double-blind, placebo-controlled matched-paired design and was 
conducted concurrently with the study of the reproductive hormone presented in Chapter 
4. The duration of the short and long term phase was 2 weeks and 8 weeks, respectively. 
Participants for the short term phase were asked to complete the Brunel of Mood Scale 
(BRUMS) questionnaire every day and the Brief Male Sexual Function Inventory (BSFI) 
questionnaire on days 0, 7, and 14. As for the long-term phase, participants were asked 
to complete the BRUMS questionnaire three times each week for 8 weeks and the BSFI 
at baseline (Day 0), interim (week 4), and post supplementation (week 8).  
 
5.3.2 Experimental Protocol  
5.3.2.1 Mood state measurement 
  
 The participant's mood was assessed using the BRUMS (Terry et al., 2003). The 
BRUMS questionnaire consists of six subscales including anger, confusion, depression, 
tension, fatigue and vigour assessed using 24 self-report items with a five-point Likert 
scale (0 = not at all, 1 = a little, 2 = moderately, 3 = quite a lot, 4 = extremely). Each 
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subscale consists of four items. Tension consists of items such as "worried" and 
"anxious", anger includes "furious" and "bad-tempered", fatigue include "worn out" and 
"exhausted", vigour includes "lively and "energetic", confusion include "mixed-up" and 
"uncertain" and lastly depression includes item such as "miserable" and "downhearted". 
Mood states are presented as standard scores illustrated in Table 5.3. To identify the 
standard score for each domain, the items were added accordingly. Items 1, 13, 14, and 
18 for tension score, items 5, 6, 12 and 16 for depression score, items 7, 11, 19 and 22 for 
anger score, items 2, 15, 20 and 23 for vigour score and items 3, 9, 17 and 24 for confusion 
score. BRUMS was developed by Terry et al. (1999) and has undergone rigorous validity 
testing (Terry et al., 2003). BRUMS reported a high internal consistency, with Cronbach 
coefficient alphas ranging from 0.74 to 0.90 for each of the subscales (Terry et al., 1999). 
The test-retest reliability demonstrates a coefficient ranging from 0.26 to 0.53 over a one-
week period, which is suitable for measuring transient feeling states. 
 
The raw score obtained was converted into the standard score (Table 5.3). The standard 
score on the BRUMS was converted into a standard T-score format (Mean = 50.0 and SD 
=10.0) corresponding to the raw score for each subscale (Karageorghis, 2017). The 
standard score has a range of 1 to 100 and can be interpreted as a percentage score. The 
standard score is identified by reading across from the raw score (i.e., a raw score of 4 
has a standard score of 57 for tension, a raw score of 7 for depression has a standard score 
of 67). High vigour score (standard score more than 50) and low tension, depression, 





Table 5.3: BRUMS standard score for adults. 
Raw Score  Tension  Depression Anger Vigour Fatigue Confusion 
0 42 43 44 34 38 42 
1 46 47 48 36 40 45 
2 49 50 51 39 42 48 
3 53 54 54 42 45 51 
4 57 57 58 45 47 55 
5 61 60 61 47 49 58 
6 65 64 64 50 51 61 
7 69 67 67 53 54 64 
8 72 71 71 55 56 68 
9 76 74 74 58 58 71 
10 80 77 77 61 61 74 
11 84 81 81 64 63 77 
12 88 84 84 66 65 81 
13 92 88 87 69 67 84 
14 96 91 90 72 70 87 
15 99 94 94 75 72 91 
16 103 98 97 77 74 94 
Source: Karageorghis (2017) 
 
5.3.2.2 Sexual function measurement 
 
Sexual function was assessed using the Brief Male Sexual Function Inventory (BSFI; 
O’Leary et al., 1995). The questionnaire includes 11 questions divided into five domains: 
sexual drive (two items), erection (three items), ejaculation (two items), problem 
assessment (three items) and overall satisfaction (one item), of which the responses to 
each are based on a Likert scale from 0 to 4. The first ten-item covers the functional 
aspects of male sexuality, and the last item in overall satisfaction is not considered a 
functional question (MyKletun et al., 2005). Participants were required to answer 
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questions related to the five domains, such as "During the past 30 days, on how many 
days have you felt sexual drive?', "Over the past 30 days, how often have you had partial 
or full sexual erections when you were sexually stimulated in any way?", "In the past 30 
days, how much difficulty have you had ejaculating when you have been sexually 
stimulated?", "In the past 30 days, to what extent have you considered a lack of sexual 
drive to be a problem?", "Overall, during the past 30 days, how satisfied have you been 
with your sex life?". The findings are presented according to the average score added for 
each item in respective domains. BSFI reported an internal consistency, with Cronbach 
coefficient alphas ranging from 0.62 to 0.95 for each domain. Test-retest reliability for a 
1-week interval showed an intra-class correlation coefficient of 0.70 to 0.90. 
 
5.3.3 Statistical Analysis   
 
All statistical analysis was conducted using the Statistical Package for the Social 
Sciences (SPSS) for Windows version 22.0 (SPSS Inc., Chicago, USA). Within-between 
group differences to examine the time-treatment interaction within-group differences to 
examine time effect and between-group differences to examine treatment effect was 
analysed using the repeated measurement ANCOVA. Assumption of normality, 
homogeneity of variances, compound symmetry, and homogeneity of regression was 
checked and fulfilled using the Shapiro-Wilk test. Baseline data were also analysed using 
the parametric (independent t-test). All data in text, figures, and tables were presented as 






5.4.1 Effect of E. longifolia on mood state based on the Brunel Mood Scale 
(BRUMS) assessment. 
 
Prior to the E. longifolia and placebo intervention for the short and long-term 
supplementation period, baseline measurements were recorded (Table 5.4). Baseline 
measurements showed that the participants in both short and long-term supplementations 
matched the inclusion criteria and did not exhibit any mood state and sexual function 
abnormality. There were no differences at baseline between EL and PLA in both the short 
and long-term supplementation studies for the BRUMS domains, i.e., tension, anxiety, 
depression, vigour, fatigue, and confusion. Statistically, there is no significant (p > 0.05) 
difference between the EL and PLA on mood state profile throughout both short and long 
term supplementation periods, respectively.  
 
Figure 5.1A and B shows the mood state profile of both short and long term 
supplementation periods at baseline. A positive mood state demonstrates high vigour 
activity above the average standard score of 50.0 and low or below the average standard 
score of 50.0 in the negative mood domains such as anger, confusion, depression, fatigue, 
and tension (Morgan, 1980). The baseline findings showed that all the mood domains 
well above the average standard score (Figure 5.1A and 1B). In the short-term 
supplementation study shown in Figure 5.1A, vigour recorded a higher score compared 
to depression, anger, fatigue, and confusion but lower than the tension score.  A similar 
trend is also found in the long term supplementation period (Figure 5.1B), and all domains 




Table 5.4: Baseline measurement on mood states in short and long term E. longifolia 
or placebo supplementation  
  Short term Long term 
 
EL 
(n = 8) 
PLA 
(n = 8) p 
EL 
(n = 11) 
PLA 
(n = 10) p 
  M ± SD M ± SD  M ± SD M ± SD  
Tension 67.13 ± 11.61 65.13 ± 7.95 0.694 64.46 ± 6.50 70.20 ± 9.92 0.130 
       
Anger 61.13 ± 5.64 59.88 ± 3.18 0.594 61.36 ± 5.50 62.00 ± 4.90 0.783 
       
Depression 61.75 ± 7.11 60.00 ± 6.16 0.607 59.18 ± 4.49 63.40 ± 6.65 0.102 
       
Vigour 63.63 ± 7.01 61.25  ± 6.69 0.500 62.00 ± 8.31 60.40 ± 9.11 0.678 
       
Fatigue 58.63 ± 9.47 58.13 ± 7.16 0.907 56.64 ± 7.84 58.10 ± 6.61 0.651 
       
Confusion 60.50 ± 6.55 58.75 ± 3.50 0.516 58.46 ± 6.59 59.10 ± 5.47 0.811 





Figure 5.1: Baseline measurement of mood state profiling for (A) short term and (B) 










- Long term - Long term 
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5.4.1.1 Short term E. longifolia supplementation 
 
Throughout the short term supplementation study, ANCOVA repeated measurement 
was used to analyse the findings. No significant main effect of time for tension (F2, 26 = 
5.941, p = 0.088) was observed throughout the short-term period. There is no significant 
main interaction between group and time for tension score (F2, 26 = 0.299, p = 0.744). 
Pairwise comparison within EL from baseline (67.13 ± 11.61%) to post (61.75 ± 9.48%) 
(MD = 5.38%, 95% CI = - 4.438, 15.188, p = 0.365) supplementation and PLA from 
baseline (65.13 ± 7.95%) to post tests (63.75 ± 9.30%) (MD = 1.38%, 95% CI = - 9.90, 
12.652, p = 1.000) shows no significant changes in tension. No significant differences 
between EL and PLA in tension score at post test, t (14) = - 0.426, p = 0.677 (Figure 
5.2A).  
 
In the anger domain, there was a significant main effect of time (F1.293, 16.813 = 8.961, p 
= 0.005) observed in the anger domain. There is no significant interaction between group 
and time (F1.293, 16.813 = 1.442, p = 0.255). After two weeks of E. longifolia 
supplementation, a significant decrease in anger score in EL from baseline (61.13 ± 
5.64%) to post test (58.00 ± 0.00%) (MD = -3.13%, 95% CI = 3.125, 3.125, p < 0.001) 
compared with PLA (MD = 0.50%, 95% CI = -3.99, 2.99, p = 1.000). Independent t-test 
shows no significant changes in anger score between EL and PLA at post-test, t (14) = - 
1.199, p = 0.251) (Figure 5.2B). 
 
In the depression domain, no significant main effect of time (F2, 26 = 8.697, p = 0.100) 
and no significant interaction between group and time (F2, 26 = 0.355, p = 0.705) was 
reported. Pairwise comparison shows no significant changes within EL from baseline 
(61.75 ± 7.11%) to post-test (59.13 ± 4.91%) (MD = 2.63%, 95% CI = - 2.812, 8.062, p 
136 
= 0.491) and also in PLA from baseline (60.00 ± 6.16%) to post-test (60.38 ± 4.96%) 
(MD = -0.38%, 95% CI = - 3.822, 3.072, p = 1.000). Also no significant differences 
between EL and PLA observed throughout the two-week supplementation, t (14) = -
0.136, p = 0.620 (Figure 5.2C). 
 
No significant main effect of time (F2, 26 = 1.377, p = 0.270) and no significant main 
interaction between group and time (F2, 26 = 0.829, p = 0.448) for the vigour domain. 
Pairwise comparison within group did not report any significant changes in EL from 
baseline (63.63 ± 7.00%) to post-test (64.00 ± 9.10%) (MD = - 0.37%, 95% CI = - 9.721, 
8.971, p = 1.000) and also in PLA from baseline (61.25 ± 6.69%) to post-test (59.88 ± 
10.64%) (MD = 1.38%, 95% CI = - 11.980, 14.730, p = 1.000). No significant difference 
between EL and PLA was observed at post test, t (14) = 0.833, p = 0.419 (Figure 5.2D). 
 
In the fatigue domain, there was a significant main effect of time (F1.405, 18.265 = 6.288, 
p = 0.014) but no significant main interaction between group and time (F1.405, 18.265 = 
0.172, p = 0.766). Pairwise comparison shows a significant decrease in fatigue score in 
EL from baseline (58.63 ± 9.47%) to post test (52.13 ± 5.08%) (MD = 6.50%, 95% CI = 
0.385, 12.615, p = 0.039) and also in PLA from baseline (58.13 ± 7.16%) to post test 
(51.50 ± 4.50%) (MD = 6.63%, 95% CI = 1.537, 11.713, p = 0.016) (Table 5.5). There 
was no significant difference between EL and PLA at post-test, t (14) = 0.260, p = 0.798 
(Figure 5.2E).   
 
In the confusion domain, a significant main effect of time (F2, 26 = 2.398, p = 0.011) 
and no significant main interaction between group and time (F2, 26 = 1.524, p = 0.237) 
was observed. Pairwise comparison showed a significant decrease in confusion score in 
EL from baseline (60.50 ± 6.55%) to post test (55.75 ± 2.12%) (MD = 4.75%, 95% CI = 
137 
2.722, 6.778, p = 0.001) but no significant changes in PLA from baseline (58.75 ± 3.50%) 
to post test (58.50 ± 5.95%) (MD = 0.25%, 95% CI = -4.587, 5.087, p = 1.000) was 
observed (Table 5.5).  There is no significant difference between EL and PLA at post-
test, t (14) = - 1.231, p = 0.239 (Figure 5.2F). 
 
Table 5.5: Treatment effect of Eurycoma longifolia and placebo after two week 
supplementation and the percentage changes from baseline to post-test. 
Variable 
EL (n = 8)   PLA (n = 8)   
MD (95% CI) p % MD (95% CI) p % 
Tension -5.375[-4.438, 15.19] 0.365 -8.01 -1.375[-9.90, 12.65] 1.000 -2.12 
       
Anger -3.125[3.125, 3.125] 0.000* -5.12 0.500 [-3.99, 2.99] 1.000 0.84 
       
Depression -2.625 [-2.81, 8.06] 0.491 -4.24 0.375 [-3.82, 3.07] 1.000 0.63 
       
Vigour 0.375 [-9.72, 8.97] 1.000 0.58 -1.375 [-11.98, 14.73] 1.000 -2.24 
       
Fatigue -6.50 [0.39, 12.62] 0.039* -11.09 -6.63 [1.54, 11.71] 0.016* -11.41 
       
Confusion -4.750 [2.72, 6.778] 0.001* -7.85 -0.250 [-4.59, 5.09] 1.000 -0.43 
Note: Day 0 (Baseline); Day 14 (Post); MD = Mean difference; CI = Confidence interval; EL = E. longifolia 
group; PLA = Placebo. 
Numerical covariate (baseline) was controlled by using ANCOVA repeated measurement. 
*Level of significance was set at 0.05 (two-tailed); % increased or decreased (-) 
 
 
5.4.1.2 Long-term E. longifolia supplementation 
 
There was a significant main effect of time (F2, 36 = 1.041, p = 0.044) and no significant 
main interaction between group and time for tension (F2, 36 = 0.584, p = 0.563) was 
observed. After 8 weeks of E. longifolia supplementation, pairwise comparison showed 
a significant decrease in tension score in EL from baseline (64.46 ± 6.50%) to post test 
(59.18 ± 3.74%) (MD = -5.27%, 95% CI = 1.901, 8.645, p = 0.004) compare with PLA 
from baseline (70.20 ± 9.92%) to post-test (69.40 ± 16.58%) (MD = 0.80%, 95% CI = -
13.024, 14.624, p = 1.000) (Table 5.6). Between group analysis shows no significant 
difference between EL and PLA at post test, t (19) = -1.994, p = 0.061 (Figure 5.3A). 
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Figure 5.2: Effect of E. longifolia on tension (A), anger (B), depression (C), vigour (D), fatigue (E), and confusion (F) based on BRUMS 
assessment in the short-term phase to examine the time effect within-group and between-group (2 weeks) 
*indicates significant differences within group with ANCOVA repeated measurement applied (Baseline vs. Post). 


























































































































































































There was significant main effect of time (F1.233, 22.188 = 6.399, p = 0.014) and there 
was no significant interaction between group and time (F1.233, 22.188 = 0.352, p = 0.604) for 
anger domain. Pairwise comparison show a significant decrease in anger in EL from 
baseline (61.36 ± 5.50%) to post test (58.82 ± 1.94%) (MD = -2.55%, 95% CI = 0.782, 
4.309, p = 0.007) but PLA did not show significant changes from baseline (62.00 ± 
4.90%) to post-test (60.50 ± 4.22%) (MD = 1.50%, 95% CI = -2.50, 5.503, p = 0.874 
(Table 5.6). Independent t-test shows no significant differences in anger score between 
EL and PLA at post-test, t (19) = -1.192, p = 0.248 (Figure 5.3B). 
 
 No significant main effect of time (F1.389, 25.003 = 1.402, p = 0.259) and no significant 
interaction between group and time (F1.389, 25.003 = 0.218, p = 0.723) was reported in the 
depression domain. Pairwise comparison shows no significant changes in depression 
score in EL from baseline (59.18 ± 4.49%) to post test (58.55 ± 4.23%) (MD = 0.64%, 
95% CI = - 3.268, 4.541, p = 1.000) and also in PLA from baseline (63.40 ± 6.65%) to 
post-test (62.40 ± 8.73%) (MD = 1.00%, 95% CI = - 5.68, 7.68, p = 1.000) (Table 5.6). 
There is no significant difference between EL and PLA was observed post eight week 
supplementation, t (19) = - 1.307, p = 0.207 (Figure 5.3C). 
 
In vigour no significant main effect of time (F2, 36 = 2.634, p = 0.086) and no significant 
main interaction between group and time (F2,36 = 0.178, p = 0.838). Pairwise comparison 
shows no significant changes in depression score in EL from baseline (62.00 ± 8.31%) to 
post test (61.64 ± 9.77%) (MD = 0.36%, 95% CI = -8.341, 9.068, p = 1.000) and also in 
PLA from baseline (60.40 ± 9.11%) to post-test (63.90 ± 11.03%) (MD = -3.50%, 95% 
CI = - 13.93, 6.93, p = 1.000) (Table 5.6). There are no significant differences between 
EL and PLA at post-test, t (19) = - 0.499, p = 0.624. (Figure 5.3D). 
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In the fatigue domain, no significant main effect of time (F2, 36 = 4.429, p = 0.119) but 
no significant main interaction between group and time (F2, 36 = 0.674, p = 0.516). 
However, in the pairwise comparison shows no significant changes in fatigue score in EL 
from baseline (56.64 ± 7.84%) to post test (54.27 ± 6.41%) (MD = 2.36%, 95% CI = -
3.014, 7.742, p = 0.688) and also in PLA from baseline (58.10 ± 6.61%) to post-test (54.60 
± 8.823%) (MD = 3.50%, 95% CI = -4.474, 11.474, p = 0.667) (Table 5.6). Also there is 
no significant differences between EL and PLA after 8 weeks of supplementation, t (19) 
= -0.098, p = 0.923 (Figure 5.3E).  
 
In the confusion domain, no significant main effect of time (F2, 36 = 0.611, p = 0.548) 
and no significant main interaction between group and time (F2, 36 = 1.743, p = 0.189) 
was observed. Pairwise comparison showed no significant changes in EL from baseline 
(58.46 ± 6.59%) to post test (56.36 ± 2.46%) (MD = 2.09%, 95% CI = -0.19, 4.37, p = 
0.075) but a significant increase in PLA from baseline (59.10 ± 5.47%) to post test (63.00 
± 11.81%) (MD = -3.90%, 95% CI = -7.64, -0.16, p = 0.041 (Table 5.6). There are no 
significant differences observed between EL and PLA at post-test, t (19) = -1.825, p = 








Table 5.6: Treatment effect of E. longifolia and placebo after 8-week 
supplementation and the percentage changes from baseline to post-test. 
 
Variable 
EL (n = 11)  PLA (n = 10)  
Mean difference 
(95% CI) p % 
Mean difference 
(95% CI) p % 
       
Tension 5.273 [1.90, 8.65] 0.004* -8.19 0.800 [-13.02, 14.62] 1.000 1.14 
       
Anger 2.545 [0.78, 4.31] 0.007* -4.14 1.500 [-2.50, 5.50] 0.874 -2.42 
       
Depression 0.636 [-3.27, 4.54] 1.000 -1.07 1.000[-5.68, 7.68] 1.000 -1.58 
       
Vigour 0.364 [-8.34, 9.07] 1.000 -0.58 -3.50 [-13.93, 6.93] 1.000 5.80 
       
Fatigue 2.364 [-3.01, 7.74] 0.688 -4.18 3.500 [-4.47, 11.47] 0.667 -6.02 
       
Confusion 2.091 [-0.19, 4.37] 0.075 -3.59 -3.900 [-7.64, -0.163] 0.041* 6.60 
        
Note: CI=Confidence interval; EL = E. longifolia; PLA = placebo 
Numerical covariate (baseline) was controlled by using ANCOVA repeated measurement. 
*Level of significance was set at 0.05 (two-tailed); % increased or decreased (-) 
 
 
5.4.2 Effect of E. longifolia on sexual function based on The Brief Sexual 
Function Inventory (BSFI) assessment 
 
Baseline measurements were recorded prior to the supplementation of E. longifolia 
and placebo (Table 5.7). Baseline measurements showed that the participants in both short 
and long-term supplementations matched the inclusion criteria and did not exhibit sexual 
function abnormality. There were no differences at baseline between EL and PLA in both 
the short and long-term supplementation studies for the BSFI domains, i.e., sexual desire, 




   
Figure 5.3: Effect of E. longifolia on tension (A), anger (B), depression (C), vigour (D), fatigue (E) and confusion (F) based on BRUMS assessment 
in the long term phase to examine the time effect within-group and between-group (8 weeks) 
*denotes indicate significant differences within group with ANCOVA repeated measurement applied (Baseline vs. Post). 

























































































































































































Table 5.7: Baseline measurement on sexual function prior to E. longifolia and 
placebo supplementation 
  Short Long 
 
EL          
(n = 8) 
PLA          
(n = 8) p 
EL          
(n = 11) 
PLA           
(n = 10) p 
  M ± SD M ± SD  M ± SD M ± SD  
       
Sexual desire 3.19 ± 0.70 2.38 ± 0.92 0.067 2.40 ± 0.80 2.35 ± 0.78 0.866 
       
Erection 3.71 ± 0.38 3.34 ± 0.69 0.200 2.82 ± 1.14 3.04 ± 0.87 0.624 
       
Ejaculation 3.75 ± 0.38 4.00 ± 0.00 0.104 3.32 ± 1.27 3.85 ± 0.24 0.201 
       
Problem 
assessment 4.00 ± 0.00 3.71 ± 0.38 0.069 3.52 ± 0.41 3.54 ± 0.67 0.929 
       
Overall 
satisfaction 3.00 ± 0.76 2.63 ± 0.52 0.266 2.46 ± 1.13 2.40 ± 0.70 0.897 
† Denotes p value based on parametric test (independent t-test) 
Note: E. longifolia (EL); placebo (PLA), mean (M); standard deviation (SD) 
 
5.4.2.1 Short-term supplementation phase 
 
There was no significant main effect of time (F2, 26 = 1.653, p = 0.211) and no 
significant main interaction between group and time for sexual desire domain (F2, 26 = 
5.663, p = 0.089) was observed. Pairwise comparison showed no significant changes in 
sexual desire score in EL from baseline (3.19 ± 0.70) to post test (3.00 ± 0.71) (MD = 
0.188, 95% CI = -0.13, 0.51, p = 0.307) and also in PLA from baseline (2.38 ± 0.92) to 
post-test (2.50 ± 0.93) (MD = -0.13, 95% CI = -0.56, 0.31, p = 1.000) (Table 5.8). 
Between group analysis also showed no significant difference between EL and PLA at 
post test, t (14) = 1.214, p = 0.245 (Figure 5.5A). 
 
In the erection domain, no significant main effect of time (F1.361, 17.693 = 1.244, p = 
0.296) and no significant interaction between group and time (F1.361, 17.693 = 3.915, p = 
0.053). Pairwise comparison showed no significant changes in erection score in EL from 
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baseline (3.71 ± 0.38) to post test (3.71 ± 0.29) (MD = 0.00, 95% CI = -0.143, 0.143, p = 
1.000) and also in PLA from baseline (3.34 ± 0.69) to post-test (3.50 ± 0.72) (MD = -
0.163, 95% CI = -0.48, 0.16, p = 0.439) (Table 5.8). No significant changes in erection 
domain score between EL and PLA at post-test, t (14) = 0.779, p = 0.449 (Figure 5.5B). 
 
 A significant main effect of time (F2, 26 = 8.449, p = 0.001) was reported in the 
ejaculation domain but no significant interaction between group and time (F2,26 = 0.478, 
p = 0.626). In the pairwise comparison, there was a significant increase in EL from 
baseline (3.75 ± 0.38) to post-test (3.94 ± 0.18) [MD = -0.19, 95% CI = -0.32, -0.06, p = 
0.011) (Table 5.8) but no significant was found in PLA from baseline (4.00 ± 0.00) to 
post-test (3.94 ± 0.18) [MD = 0.06, 95% CI = -0.13, 0.26, p = 1.000). No significant 
differences between EL and PLA after two weeks supplementation, t (14) = 0.000, p = 
1.000 (Figure 5.5C). 
 
The problem assessment domain showed a significant main effect of time (F2, 26 = 
41.016, p < 0.001) but no significant main interaction between group and time (F2,26 = 
0.206, p = 0.815). Pairwise comparison showed no significant changes in EL from 
baseline (4.00 ± 0.00) to post test (3.96 ± 0.11) [MD = 0.04, 95% CI = -0.08, 0.16, p = 
1.000) but PLA showed a significant increase from baseline (3.71 ± 0.38) to post-test 
(3.89 ± 0.16) [MD = -0.18, 95% CI = -0.29, -0.07, p = 0.006) (Table 5.8).  No significant 
differences between EL and PLA, t (14) = 1.128, p = 0.278. (Figure 5.5D). 
 
In overall satisfaction domain, no significant main effect of time (F2, 26 = 1.337, p = 
0.280) and no significant main interaction between group and time (F2, 26 = 2.706, p = 
0.086) was observed (Table 5.8). Pairwise comparison showed no significant changes in 
overall satisfaction score in EL from baseline (3.00 ± 0.76) to post test (3.38 ± 0.74) (MD 
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= -0.38, 95% CI = -0.98, 0.23, p = 0.263) and also in PLA from baseline (2.63 ± 0.52) to 
post-test (2.75 ± 0.71) (MD = -0.13, 95% CI = -0.55, 0.30, p = 1.000) (Table 5.8). No 
significant differences between EL and PLA after 2 weeks of supplementation, t (14) = 
1.722, p = 0.107 (Figure 5.5E).  
 
Table 5.8: Effect (Baseline vs Post-test) of E. longifolia and placebo supplementation 
on sexual function after 14 days of supplementation. 
Variable 
EL (n = 8)  PLA (n = 8)  
Mean difference 
(95% CI) p % 
Mean difference 
(95% CI) p % 
Sexual desire 0.19 [-0.13, 0.51] 0.307 -5.96 0.13 [-0.56, 0.31] 1.000 5.46 
       
Erection 0.00 [-0.14, 0.14] 1.000 0.00 0.16 [-0.48, 0.16] 0.439 4.80 
 
Ejaculation 0.23 [-0.32, -0.06] 0.011* 6.13 0.11 [-0.13, 0.26] 1.000 
-
2.75 
        
Problem assessment 0.04 [-0.08, 0.16] 1.000 -1.00 0.18 [-0.29, -0.07] 0.006* 4.90 
       
Overall satisfaction 0.38 [-0.98, 0.23] 0.263 12.67 0.13 [-0.55, 0.30] 1.000 4.94 
              
Note: CI = Confidence interval; EL = E. longifolia; PLA = placebo 
Numerical covariate (baseline) was controlled by using ANCOVA repeated measurement. 





Figure 5.4: Effect of E. longifolia on sexual desire (A), erection (B), ejaculation (C), problem assessment (D), and overall satisfaction(E) 
domains based on BSFI assessment between EL and PLA group to examine the time effect within-group and between-group (2 weeks) 
*indicates significant changes in overtime within-group (Baseline vs Post-test)with ANCOVA repeated measurement applied. 











































































































































5.4.2.2 Long-term supplementation period 
 
There was no significant main effect of time (F2, 36 = 0.677, p = 0.503) and no 
significant main interaction between group and time for the sexual desire domain (F2, 36 = 
0.377, p = 0.688) observed. Although not significant, pairwise comparison showed an 
increase in sexual desire domain score within EL from baseline (2.40 ± 0.80) to post-test 
(2.96 ± 0.85) [MD = -0.55, 95% CI = -1.12, 0.03, p = 0.063) and no significant change in  
PLA from baseline (2.35 ± 0.78) to post-test (2.70 ± 0.89) [MD = -0.35, 95% CI = -1.171, 
0.471, p = 0.703) (Table 5.9) as well. Between group analysis also showed no significant 
difference between EL and PLA at post-test, t (19) = 0.671, p = 0.510 (Figure 5.6A). 
 
In erection domain, there was a significant main effect of time (F2, 36 = 25.274, p < 
0.001) but no significant interaction between group and time (F2, 36 = 0.683, p = 0.512). 
Pairwise comparison showed a significant increase from baseline (2.82 ± 1.14) to interim 
(3.42 ± 0.69) [MD = -0.60, 95% CI = -1.08, -0.12, p = 0.016) and to post-test (3.55 ± 
0.50) [MD = -0.763, 95% CI = -0.91, -0.54, p < 0.001) but no significant change found 
in PLA from baseline (3.04 ± 0.87) to post test (3.40 ± 0.80) [MD =-0.36, 95% CI = -
1.02, 0.30, p = 0.407) (Table 5.9). However, no significant differences in erection score 
between EL and PLA at post-test, t (19) = 0.506, p = 0.619 (Figure 5.6B). 
 
 There was significant main effect of time (F2, 36 = 192.495, p < 0.001) in the 
ejaculation domain but no significant interaction between group and time (F2,36 = 0.628, 
p = 0.540). In the pairwise comparison a significant increase from baseline scores (3.32 
± 1.27) to interim (3.82 ± 0.25) [MD = -0.50, 95% CI = -0.72, -0.28, p < 0.001) and to 
post-test (3.82 ± 0.34) [MD = -0.50, 95% CI = -0.73, -0.27, p < 0.001) was observed, but 
no significant change found in PLA from baseline (3.85 ± 0.24) to post-test (3.95 ± 0.16) 
148 
[MD =-0.100, 95% CI = -0.24, 0.04, p = 0.180) (Table 5.9). However, no significant 
changes between EL and PLA after eight weeks supplementation, t (19) = -1.127, p = 
0.274 (Figure 5.6C). 
 
The problem assessment domain showed no significant main effect of time was 
observed (F1.277, 22.994 = 0.314, p = 0.114) but no significant main interaction between 
group and time (F1.277, 22.994 = 0.155, p = 0.758). Pairwise comparison showed no 
significant changes in EL from baseline scores (3.52 ± 0.41) to post-test (3.66 ± 0.49) 
[MD = -0.145, 95% CI = -0.573, 0.282, p = 1.000) and also in PLA from baseline (3.54 
± 0.67) to post test (3.60 ± 0.77) [MD =-0.06, 95% CI = -0.69, 0.57, p = 1.000) (Table 
5.9). Also, there was no significant difference between EL and PLA at post-test, t (19) = 
0.227, p = 0.823. (Figure 5.6D). 
 
There was a significant main effect of time (F2, 36 = 15.328, p < 0.001) but no 
significant main interaction between group and time (F2, 36 = 1.479, p = 0.241) observed 
in overall satisfaction domain. In the pairwise comparison there was a significant increase 
from baseline scores (2.46 ± 1.13) to post-test (3.27 ± 0.79) [MD = -0.82, 95% CI = -
1.44, -0.19, p = 0.012) in EL and significant changes was also found in PLA from baseline 
(2.40 ± 0.70) to post test (3.00 ± 0.67) [MD =-0.60, 95% CI = -1.19, -0.01, p = 0.047) 
(Table 5.9). There were no significant differences between EL and PLA after 8 weeks of 






Table 5.9: Effect (Baseline vs. Post-test) of E. longifolia and placebo supplementation 
on sexual function after 8-weeks of supplementation. 
 
Variable 
EL (n = 11)  PLA (n = 10)  
Mean difference 
(95% CI) p % 
Mean difference 
(95% CI) p % 
       
Sexual desire 0.55 [-1.12, 0.03] 0.063 22.92 0.35 [-1.17, 0.47] 0.703 14.89 
       
Erection 0.73 [-0.91, -0.54] 0.000* 25.89 0.36 [-1.01, 0.29] 0.407 11.84 
       
Ejaculation 0.50 [-0.73, -0.27] 0.000* 15.06 0.10 [-0.24, 0.04] 0.18 2.60 
       
Problem assessment 0.15 [-0.57, 0.28] 1.000 4.26 0.06 [-0.69, 0.57] 1.000 1.70 
       
Overall satisfaction 0.82 [-1.44, -0.19] 0.012* 33.33 0.60 [-1.19, -0.007] 0.047* 25.00 
              
Note: CI = Confidence interval; EL = Eurycoma longifolia group; PLA = placebo 
Numerical covariate (baseline) was controlled by using ANCOVA repeated measurement. 
*Level of significance was set at 0.05 (two-tailed); % increased or decreased (-) 
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Figure 5.5: Effect of 8 week E. longifolia on sexual drive (A), erection (B), ejaculation (C), problem assessment (D) and overall satisfaction 
(E) domains based on BSFI assessment between EL and PLA group to examine the time effect within-group and between-group (8 weeks) 
* indicates significant changes in overtime within-group (Baseline vs Interim, Baseline vs Post-test)with ANCOVA repeated measurement applied. 

















































































































































The present short and long-term supplementation of E. longifolia has demonstrated 
improved psychological mood state and sexual function among young male adults. 
Significant improvement in anger, fatigue, and confusion has been observed after short-
term E. longifolia supplementation. Although not significant, improvement in tension, 
depression, and vigour has also been demonstrated. On the other hand, long-term 
supplementation has shown improvement in all negative mood domains (tension, anger, 
depression, fatigue, confusion), with significant improvement observed in tension and 
anger domains only. However, a minimal decrease in vigour domain post-long-term 
supplementation has been observed. In contrast, long-term supplementation of E. 
longifolia has also shown improvement in sexual function, with three domains 
demonstrating significant improvement compared to short-term supplementation, with 
only one significant improvement.  
 
The increase (short term) and no change (long-term) in the secretion of sex hormones 
(i.e., testosterone) may provide some form of adaptation in physical and psychological 
characteristics. While testosterone concentration could benefit the psychological mood 
state and sexual function, current findings found that E. longifolia did not improve all the 
domains but only selected mood and sexual function domains in both mood state and 
sexual function. Findings demonstrate some benefits in sexual function assessment and 
mood state, which concur with previous studies demonstrating the aphrodisiac and 
adaptogen effects of E. longifolia. However, other confounding factors such as stress, 
anxiety, depression, poor sleep, interaction with people, poor nutrition, to name a few, 
may have contributed to the findings. Hence, a further investigation involving the 
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monitoring of possible confounding factors affecting mood state and sexual function is 
needed.  
 
5.5.1 Psychological Mood State 
 
A positive mood state profile indicates positive mental health (Morgan, 1980) and 
should demonstrate more vigour (positive domain) and less anger, tension, depression, 
fatigue and confusion (negative domains), which was demonstrated in Morgan (1980). 
Unfortunately, the participants supplemented with E. longifolia after two weeks and eight 
weeks of supplementation in the present study did not demonstrate an optimal peak in 
vigour above 50% of the standard score and recorded a low negative mood state (below 
50% of the standard score). Hence, the present short and long-term supplementation 
period study did not demonstrate a positive mood state profile among young men. 
Although the present findings did not show a positive mood state profile, there were still 
changes within the negative mood domains and positive mood domains. Indeed, findings 
are in agreement with previous studies that E. longifolia does improve certain 
psychological mood state parameters (Talbott et al., 2013; George et al., 2018) but does 
not improve the mood state profile.  
 
 The measurement for all mood state domains was reported to be above the average 
standard score of 50 before supplementation. Hence, E. longifolia supplementation may 
not be able to improve a positive mood state profile. However, the current short-term and 
long-term supplementation period found that daily supplementation with E. longifolia 
(600 mg/day) improves all individual negative mood state domains (tension, depression, 
anger, fatigue and confusion). The anger, fatigue and confusion domains in the short-
term, and the tension and anger domains in the long-term supplementation period, showed 
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significant improvement. These findings are in agreement with several supplementation 
trials performed with humans, suggesting E. longifolia may be an effective extract to 
reduce the negative effects of chronic stress (Talbott et al., 2006; Talbott et al., 2013, 
George et al., 2018). While Talbott et al. (2013) reported improvement in tension, anger, 
and confusion, the present short and long-term supplementation period not only reported 
improvement in the same three domains, it also saw an improvement in reducing 
depression and fatigue. Another study by George et al. (2018) highlighted a significant 
improvement in vigour and improvement in the negative mood domains. However, 
findings showed no significant difference between PLA, indicating that the EL group’s 
improvement may not be entirely due to E. longifolia.  
  
  Although it is perceived by many that testosterone administration improves mood in 
men with low testosterone levels, the association between testosterone and psychological 
mood state outcomes remains poorly understood. Observational studies have shown a 
weak association of low testosterone with depressed mood, fatigue and reduced vigour 
(Barrett-Connor et al., 1999; Araujo et al., 2007). Also, few studies have found 
differences between findings, such as no significant differences in mood between 
testosterone and placebo, inconsistent effects of testosterone, or improvements in 
depression (Seidman et al., 2001; Steidle et al., 2003; Cavallini et al., 2004; Shores et al., 
2009; Pope et al., 2010). However, open-label, uncontrolled studies have found 
supplementation of testosterone in men with low testosterone levels improves mood and 
wellbeing (Wang et al., 2004; Daniell et al., 2006; Wang et al., 2011).  
 
The present study examining the psychological mood state was performed 
concurrently with reproductive hormones. The participants demonstrated an increase in 
testosterone in the short-term supplementation period, while testosterone remained in a 
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normal concentration range without observing any changes during long-term 
supplementation. It has been suggested that the ability of E. longifolia to increase 
testosterone levels in humans (Tambi, 2007) may contribute to the improvement in mood 
state, especially in the vigour domain, among older participants facing a gradual decline 
in testosterone levels (Talbott et al., 2013; George et al., 2016; George et al., 2018). 
However, this is not the case in participants aged between 18 to 45 years with normal 
circulating testosterone levels, as was demonstrated in a study conducted by George et al. 
(2018) and repeated in the current study. Hence, the testosterone and free testosterone 
finding demonstrate any association with the improvement of the psychological mood 
domains. 
 
Also, the vigour domain did not see any changes after two and eight weeks of E. 
longifolia supplementation.  A possible factor affecting the study’s outcome may be due 
to participants’ testosterone remain unchanged presented in Chapter 4 and participants 
are not actively involved in physical activities. Furthermore, the current study did not 
have any resistance training intervention. Resistance training has been shown to improve 
testosterone level and overall psychological profile (Zanuso et al., 2012). Studies 
examining a group of cyclist and a group of people participating in a weight loss 
programme which involve exercise intervention have shown a reduction in cortisol level 
after supplementing with E. longifolia, indicating a shift to an anabolic hormone state and 
the subsequent improvement in certain psychological mood states (Talbott et al., 2006; 
Talbot et al., 2013). Although there are a strong validity and reliability reported by Terry 
et al. (1999) and it is suitable to be used for adolescent and adults (Terry et al., 1999; 
Terry et al., 2003), a pilot test to check on the reliability was not performed in the current 
study. The BRUMS questionnaire was generated from data collected using the response 
time frame, “How do you feel right now?” may not be relevant to data collected using 
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other response timeframes (Terry et al., 1999).  The current study did not personally meet 
the participants to monitor the process of filling up the BRUMS and was asked to fill up 
the forms independently. Hence, they could have been affected by situational differences, 
such as various stress or lifestyle factors, such as diet, exercise or sleep patterns while 
participating in the studies. These factors could affect the study’s outcome for the whole 
duration of the study. The current study did not project a positive mood profile suggested 
by Morgan (1980), and the improvement may not be entirely due to the supplementation 
of E. longifolia.   
 
The current study utilised young men who have normal testosterone concentration 
levels and may not be suffering any decline in testosterone levels. They reported a higher 
baseline score in all the negative mood domains. Hence, the effect on young participants 
was less evident in the current short and long-term supplementation period study and may 
require longer supplementation duration beyond eight weeks. Nevertheless, any 
improvement in the psychological domains in both the short and long-term 
supplementation period that did take place do not seem to have any possible association 
between E. longifolia’s testosterone-enhancing ability with psychological mood state 
among young, healthy male participants due to the lack of changes in the testosterone 
presented in Chapter 4. Hence, the improvement may be due to various confounding 
factors such as participating in physical activity, dietary and other environmental factors. 
However, based on the present findings, E. longifolia demonstrate adaptogen effects and 
could be an alternative to improving psychological mood, but better control towards the 




5.5.2 Sexual function 
 
Eurycoma longifolia is commonly used for the treatment of sexual dysfunction and the 
improvement of sexual functions. Numerous studies have been carried out using in vivo 
animal models (Ang & Ngai, 2001; Ang & Lee, 2002; Ang et al., 2003a; Ang et al., 
2003b; Ang et al., 2004). Only a limited number of human clinical trials have examined 
the impact of E. longifolia in managing sexual dysfunction (Tambi, 2009; Tambi and 
Imran, 2010; Muhammad et al., 2010; Tambi et al., 2012; Tambi et al., 2012; Udani et 
al., 2014). Supplementation of E. longifolia exhibited improvement within EL in the 
ejaculation domain during the short-term period and improved ejaculation, erection, and 
overall satisfaction domains in the long-term supplementation period. Current findings 
concur with the view that E. longifolia does have a beneficial effect on male sexual 
function, as has been shown in previous human clinical trials examining sexual health 
and sexual disorder (Ang et al., 2000; Tambi, 2009; Bhat & Karim, 2010; Tambi et al., 
2012). However, data reported no significant difference between EL and PLA, 
demonstrating that the improvement in certain sexual function domains may not entirely 
due to the supplementation of E. longifolia. 
 
Evidence from the current study using the BSFI for the first time to examine E. 
longifolia supplementation for two and eight weeks found significant improvement in 
certain sexual function domains, i.e., ejaculation, erection and overall satisfaction. In 
addition, the E. longifolia treated group scored better but not significantly in most sexual 
function domains compared to PLA, in either interim or post-supplementation. Based on 
the data, the improvement in the domains of the sexual functions observed in the current 
study may indicate that E. longifolia can exhibit aphrodisiac effects in humans 
(Sambandan et al., 2006; Asiah et al., 2007; Tambi and Imran, 2010). However, a closer 
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evaluation of Figure 5.4 and 5.5 shows that the difference between EL and PLA is 
minimal. The improvement in EL may not be entirely due to supplementation but may be 
affected by other confounding factors that are not measured in the current study, i.e. 
resistance exercise and cortisol. The improvement may also be due to the improvement 
in certain mood state domains shown in Figure 5.2 and 5.3.  Although the precise 
mechanism is postulated based on animal studies, some human clinical trials were 
performed to examine the effects of E. longifolia on sexual functions. One study 
demonstrated the efficacy of E. longifolia on men’s sexual health by its ability to reduce 
the stress hormone profile, which is correlated with male sexual performance (Tambi, 
2006).  
 
Eurypeptides in E. longifolia have been shown to exert and enhance an effect on the 
biosynthesis of androgens. Eurypeptides activate the CYP17 (17 α - hydroxylase/17, 20 
lyase) enzyme to enhance the metabolism of progesterone and 17 - OH - progesterone to 
androstenedione and testosterone (Ali and Saad, 1993). The increase in testosterone levels 
was thought to be a factor in the improvement of sexual function. The dosage of 600 mg 
E. longifolia used in the current study was the highest compared to all previous studies 
(Ismail et al. 2012; Tambi et al., 2012; Talbott et al., 2013; Henkel et al., 2014; Udani et 
al., 2014; Chen et al., 2014; George et al., 2018; Chen et al., 2019) but did not 
demonstrate changes in testosterone level. The dosage between 200 to 400 mg of E. 
longifolia improved testosterone levels in older participant age between 30 to 72 years 
old (Tambi et al., 2012; Ismail et al., 2012; Talbott et al., 2013; Henkel et al., 2014; Udani 
et al., 2014; George et al., 2018). However, the same dosage did not increase testosterone 
levels in young participants (Chen et al., 2014; Chen et al., 2019). 
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Previous studies reported improved sexual activity and wellbeing (Talbott et al., 2013), 
sexual performance, sexual libido (Tambi et al., 2012; Udani et al.,2014; George & 
Henkel, 2014; Henkel et al., 2014), sexual intercourse performance, the concentration of 
male sex hormone, overall sexual wellbeing (Udani et al.,2014), erectile function, sexual 
intercourse performance and penile hardness (Tambi et al., 2012), with an improvement 
in testosterone level. However, the investigation was performed mostly on elderly 
individuals with a history of erectile dysfunction, LOH and idiopathic infertility.   George 
and Henkel (2014) suggested that the possibility of E. longifolia improving male sex 
libido is higher in 60-year old patients having 40 to 50% lower testosterone levels than 
young individuals. Testosterone levels remained in the normal range level among healthy 
young adults presented in Chapter 4. It is speculated that E. longifolia acts as a maintainer 
of normal testosterone levels (Talbott et al. 2013), and because of this, the present 
findings did not present vast differences in the sexual function domain between the young 
adults in EL and PLA. While data showed improvement in some sexual functions, the 
finding does not demonstrate any possible association between E. longifolia 
supplementation with sexual function. The current findings can only be compared with 
previous studies that mainly recruited elderly participants diagnosed with LOH and 
sexual dysfunction. Hence, explaining the positive findings of significant efficacy in 
young adults is challenging.  
 
The Brief Sexual Function Inventory (BSFI) was designed to be brief, self-
administered, and clinically useful in assessing current sexual functioning. MyKletun et 
al. (2005) examined male sexual function using the BSFI and found that mean levels of 
sexual drive, erection, ejaculation, problem assessment, and overall satisfaction decreases 
from age 20 to 29 years to 40 to 49 years, followed by a more substantial decline among 
participants aged 70 to 79 years. This investigation may be the first study investigating 
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the extract's effect on young participants who did not suffer from LOH. However, being 
healthy, young, and having a sexual partner (MyKletun et al., 2005) may affect the higher 
scores of the BSFI domains reported in the current study. Also, the low participation rate 
due to this study’s nature, which required parrticipants to disclose information such as 
testosterone levels and sexual ability, may affect the study’s outcome. Despite this, the 
findings in the current study demonstrate E. longifolia having some influence in managing 
male sexual function among young males but may not be the main contributor to the 




At present, the improvement in mood and sexual function is claimed to be associated 
with E. longifolia’s ability to increase the testosterone level in the human body and reduce 
the stress hormone known as cortisol. The consumption of E. longifolia for two and eight 
weeks has exhibited significant improvement in specific mood states, and sexual function 
domains following short and long-term supplementation corroborate E. 
longifolia's adaptogen and aphrodisiac properties. However, considering that the 
participants recruited are healthy, young, and possibly having a sexual partner may 
confound the outcome, not necessarily due to E. longifolia alone. The precise mechanism 
behind the increase in testosterone is still unknown in humans, and evidence of the 
association between E. longifolia with mood and sexual function is still limited and not 
shown in the current study. Nevertheless, the current study has highlighted the role of E. 
longifolia as a potential herbal supplement against various negative mood states, such as 
anxiety, depression, anger and fatigue, and male sexual health disorders, such as sexual 
desire, erection, ejaculation and problem assessment functioning.  However, further 
clinical investigations into stress hormones, male infertility (i.e., quality and quantity of 
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sperm) among young males, and considering possible confounding factors are needed to 
determine the impact and association of E. longifolia on mood and sexual function. 
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CHAPTER 6: THE EFFECTS OF EURYCOMA LONGIFOLIA ON BODY 




 Individuals involved in sports and exercise are constantly looking for effective ways 
to enhance their performance. Many athletes and non-athletes believe that herbal 
supplements can improve sport and exercise by increasing energy levels, inducing weight 
loss, promoting muscle growth and strength or even inducing other physiological or 
metabolic responses. (Herbold et al., 2004; Williams, 2006; Sellami et al., 2018).  
 
 To study such effects, many scientific investigations with controlled clinical trials have 
been carried out. Various herbal supplements, including, but not limited to, E. longifolia, 
are believed to have medicinal and ergogenic effects (William, 2006; Rogerson et al., 
2007; Poole et al., 2010). Although some have shown evidence and putative effects in 
improving health and wellbeing, the investigation into quality and safety remains limited. 
Furthermore, the mechanisms concerning how the supplements enhance physical 
performance are not clearly understood (Yavuz & Őzkum, 2014).  
 
 In the context of exercise performance, an increase in muscle mass and strength is 
associated with E longifolia supplementation (Hamzah & Yusof, 2003; Henkel et al., 
2013; Chen et al., 2019). It has been observed in physically active individuals (Hamzah et 
al.,2003; Henkel et al., 2013; Chen et al., 2019) and healthy young (Sarina et al., 2009; 
George et al., 2013) and older adult populations.  
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 E. longifolia is said to increase testosterone levels (Tambi et al., 2012; Talbott et al., 
2013; Henkel et al., 2013; Udani et al., 2013). It is expected to act similarly to exogenous 
testosterone in increasing strength.  Indeed, improving physical performance, such as 
muscular strength and anaerobic power, is important for athletes and those involved in 
bodybuilding wanting to enhance muscle mass and strength (Bhat & Karim, 2010; 
George et al., 2013). However, the potential ergogenic effects of  E.longifolia remain 
inconclusive, with some demonstrating an increase in testosterone (Tambi et al., 2012; 
Talbott et al., 2013; Henkel et al., 2013; Udani et al., 2014) and others not (Ismail et al., 
2012; Chen et al., 2014).  
 
 Furthermore, exercise intervention in most studies carried out along with E 
longifolia supplementation in young men may have contributed significantly to the 
strength improvement. Several studies have shown that a combination of E. longifolia 
with exercise improves muscular strength. So, it is unknown whether E longifolia alone 
can improve strength in young, healthy adults.  
 
6.2 Literature Review 
  
The ergogenic effects of E. longifolia supplementation have been studied in both athletic 
endurance and muscular strength performance. Preliminary evidence suggests a lack of 
effect of E. longifolia on endurance in humans (Ooi et al., 2001; Ooi et al., 2003; 
Muhamad et al., 2010) but positive findings in muscular strength (Hamzah & Yusof, 
2003; Sarina et al., 2009; Henkel et al., 2013; George et al., 2013). The increase in 
testosterone levels following E. longifolia supplementation with or without exercise, 
reported in several studies (Tambi et al., 2012; Talbott et al., 2013; Low et al., 2013a & 
2013b; Henkel et al., 2013; Udani et al., 2014) is often linked to the increase in muscle 
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mass and strength. However, only one study (Henkel et al., 2013) reported that the 
administration of E. longifolia increased testosterone levels and, subsequently, improved 
muscular strength. At the same time, other studies have demonstrated an improvement in 
strength post-E. longifolia administration, these studies did not measure testosterone 
levels (Hamzah & Yusof, 2003; Sarina et al., 2009; Ooi et al., 2015).  Hence, published 
clinical research associating testosterone and muscular strength when supplemented 
with E. longifolia remains inconclusive.   
 
6.2.1 Effect of E. longifolia on Muscular Strength  
  
Six studies shown in Table 6.1 have investigated the effect of E. 
longifolia supplementation on muscular strength. All reported an increase in muscular 
strength and muscle size after a period of E. longifolia supplementation (5 to 12 weeks). 
The combination of E. longifolia with resistance training may have contributed to 
muscular strength improvement (Hamzah & Yusof, 2003; Sarina et al., 2009; Henkel et 
al., 2013; Ooi et al., 2015; Chen et al., 2019). From the six studies, four investigated the 
effect of E. longifolia by combining E. longifolia supplementation (100 mg) with 
resistance training for 5 to 12 weeks (Hamzah & Yusof, 2003; Sarina et al., 2009; Ooi et 
al., 2015; Chen et al., 2019). The participants were male in Hamzah and Yusof (2003), 
Ooi et al. (2015), and Chen et al. (2019), while in Sarina et al. (2009), the participants 
were middle-aged women. All the studies demonstrated increases in muscle size and 
strength. However, only abstracts were published for studies by Hamzah & Yusof, 2003 
and Sarina et al., 2009 and, thus, the information they yielded was limited.  
 
 The testosterone to cortisol ratio is measured to determine the anabolic or catabolic 
status of a muscle during exercise (Hakkinen, 1989). According to Adlercreutz et al. 
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(1986), whenever an individual exercise, there is a change in the hormonal status from a 
catabolic state toward an anabolic state. The testosterone to cortisol ratio diminishes with 
increased training loads (Hoogeveen & Zonderland, 1996; Mujika et al., 1996), which 
indicates overtraining and fatigue (Adlercreutz et al., 1986; Hakkinen & Pakarinen, 
1991). Henkel et al. (2013) reported higher testosterone values to cortisol ratio in men 
after E. longifolia administration, indicating E. longifolia increases the body's anabolic 
status (Henkel et al., 2013). Sedentary males and physically active males and females 
were recruited in George et al. (2013), and Henkel et al. (2013) and an increase in 
muscular strength was found, even though strength training was not performed. Henkel et 
al. (2013) reported an increase in muscle force production, and this finding was associated 
with a significant increase in total and free testosterone concentrations due to E. 
longifolia. Hence, it is suggested that E. longifolia, with an ability to enhance testosterone 
with or without resistance training, might increase muscle size and strength in males.  
  
 Administration of exogenous testosterone is associated with increases in muscle mass 
and strength (Blazevich & Giorgi, 2001). Also, the use of exogenous testosterone in 
conjunction with heavy resistance training has shown strength gains (Bhasin et al., 1996). 
Heavy resistance training increases muscle pennation and muscle size, and the 
administration of supraphysiological doses of testosterone may have hastened the gain of 
muscle mass and strength compared to individuals not performing any resistance training 
(Giorgi et al., 1999; Blazevich & Giorgi, 2001). While testosterone was not measured in 
Hamzah and Yusof (2003) and Ooi et al. (2015), Chen et al. (2019) reported no changes 
in the testosterone to epitestosterone ratio. These three studies demonstrated that the 
combination of E. longifolia with resistance training increases muscle size and strength 
compared to control groups. On the other hand, in studies without performing any 
resistance training and involving just the consumption of E. longifolia, an improvement 
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in muscle mass and strength has been identified (Sarina et al., 2009; Henkel et al., 2013; 
George et al. 2013), indicating the increase in circulating testosterone may have 
contributed to the improvement.   
  
However, George et al. (2013), in their randomised, double-blind, placebo-controlled 
trial, examined 40 men aged between 30 to 55 years supplemented with E. longifolia for 
12 weeks. Although testosterone is known to affect muscles (Herbst & Bhasin, 2004), E. 
longifolia may not be restricted to enhancing testosterone. The study showed no increase 
in testosterone levels but, surprisingly, reported an increase in muscular strength, 
indicating the increase in strength may not be related to the testosterone hormone. The 
increase in strength may be due to E. longifolia being a natural adaptogenic energiser in 
healthy ageing in men with suboptimal testosterone levels (George et al., 2013). As men 
age, they encounter a decrease in muscle mass and subsequent decrease in strength and 
physical function due to lower testosterone production (Harman et al., 2001; Feldman et 
al., 2002; Standworth & Jones, 2008). It is suggested that the supplementation of E. 
longifolia may not generally increase testosterone levels but modulate it to optimal levels 
based on the individual’s present hormonal level status (Henkel et al., 2013; George et 




Table 6.1: Studies on the effect of E. longifolia in exercise and sports. 
 
Studies Participants Dosage & 
Duration 
Test Findings 
Hamzah & Yusof 
(2003) 
14 healthy men (age) 100 mg  
 5 weeks 
Body composition, arm circumference, 
1RM, (sEMG)  
Strength training intervention 
Increased FFM, reduced BF, and 
increased muscle strength and 
size. T not measured 




Handgrip test, muscle circumference 
measured  
Increased handgrip strength and 
bigger quadriceps muscle. 
Henkel et al. (2013) 13 male and 12 
physically active 
female 57 - 72 years 
400 mg 
5 weeks 
Handgrip test  
Standard hematological parameters 
Increased in T and FT  
Enhanced muscle force.  
George et al. (2013) 40  men  
30 - 55 years 
300 mg  
12 weeks 
sit and reach, handgrip, back, and leg 
strength, sit up, push up, and body 
composition.  
The ratio of T:E was analyzed 
Ratio T:E did not change  
Muscular strength improved 
significantly in the back and leg.  
Ooi et al. (2015) 40 male 
35 to 55 years 
400 mg 
8 weeks 
Isokinetic strength and power 
Circuit training 
Strength and power 
improvement 
T not measured 
Chen et al. (2019) 40 males  
19 to 25 years 
200 mg  
8 weeks 
Isokinetic muscular strength and power, 
anaerobic power 
Resistance training 
Muscular strength and peak 
power increased 
T:E ratio no change 
Note: Fat free mass (FMM); One repetition maximum (1RM) ; surface electromyography (sEMG); Testosterone (T); Epitestosterone (E); Free Testosterone (FT); Body Fat (BF) 
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Another reason for the increase in strength may be due to E. longifolia extract 
comprising of more than 22 percent protein and peptides, which could add to the 
ergogenic benefit, even without a significant increase of testosterone (Sambandan et al., 
2006). It is believed that protein may boost protein synthesis to assist in the repair and 
regeneration of skeletal muscle that has been damaged during resistance training, which 
may have an implication for the improvement of both muscle size and strength (Hoffman 
et al., 2006; Tarnopolsky et al., 1995; Roy et al., 2000; Ratamess et al., 2003; Kraemer 
et al., 2006). In addition, protein may influence the anabolic hormones involved in muscle 
regeneration and, subsequently, improve strength (Lemon et al., 1992; Chandler et al., 
1994; Volek et al., 1997). Future studies are necessary to examine the effects of proteins 
and peptides found in E. longifolia on muscles’ contractile properties. 
 
 Short or long-term consumption of E. longifolia has demonstrated its ability to 
promote strength gains (Table 6.1). Four studies recruited participants aged between 30 
to 72 years, and the remaining two studies recruited young participants between 19 to 25 
years. According to Travison et al. (2017), testosterone’s normal range in a healthy non-
obese population age between 19 to 39 years is between 264 to 916 ng/dL. Due to ageing, 
the older participants in Henkel et al. (2014) and George et al. (2013) reported suboptimal 
testosterone levels (384 ng/dL and 457.92 ng/dl) before the test. Owing to the putative 
effects of E. longifolia in increasing testosterone levels (442. Ng/dL and 483.29 ng/dL), 
the two studies demonstrated an increase in strength from week 5 to week 12 
(Henkel et al., 2013; George et al., 2013).  A dosage of 300 mg may be sufficient to 
induce strength gain, and the duration of supplementation to see improvement can be 
observed as early as week 5 in the older population.  
 
168 
 On the other hand, strength also improved in just five weeks of E. 
longifolia supplementation among young participants dosed with 100 mg of E. 
longifolia (Hamzah and Yusof, 2003). Chen et al. (2019) demonstrated an increase in 
strength when the participants were supplemented with 200 mg of E. longifolia for eight 
weeks. However, both studies included resistance training with the supplementation, and 
this combination may have amplified the improvement in strength. According to a study 
conducted by Ooi et al. (2015), their findings show an enhanced synergistic effect of E. 
longifolia supplementation combined with resistance training on isokinetic muscular 
strength and power compared to supplementation alone (Ooi et al., 2015). Thus, a 
combination of resistance training with supplementation of just 100 mg to 200 mg for 
five to eight weeks appears to be sufficient to demonstrate strength improvement. At 
present, a dosage ranging between 100 to 400 mg of E. longifolia shows improvement in 
strength within 5 to 12 weeks among participants aged 30 to 72 years. The improvement 
in strength among the young participants may be due to the resistance training and not 
entirely due to the E. longifolia supplementation. Hence, the appropriate dosage and 
duration of E. longifolia supplementation alone in young participants to see any 
improvement in strength is still unknown. 
 
 Based on this, the present study aimed to assess the following:  
To distinguish the potential ergogenic properties in relation to exercise performance 








A total of 21 males were recruited for the study aged between 18 to 30 years old, and 
their characteristics are tabulated in Table 4.3 and inclusion criteria is stated in Chapter 
4, page 93. The study was approved by the University Ethics Committee (14/SPS/013), 
and all participants provided informed consent.  
 
6.3.2 Experimental Design 
 
The study was a randomized, double-blind, placebo-controlled matched-paired design. 
Participants were assigned to E. longifolia (EL) (n=11) or placebo (PLA) (n=10) group 
using a matched-pairs design according to their body weight. The study was performed 
concurrently with the effect of long term consumption of E. longifolia on reproductive 
hormones regulation among collegiate men presented in Chapter 4. A total of three 
laboratory visits were scheduled: 1. Baseline performance, physiological, health, and 
well-being tests (week 0); 2. Interim performance, physiological, health, and well-being 
tests (week 4); and 3. Post-supplementation performance, physiological, health, and well-
being tests (week 8). Before baseline measures, participants visited the laboratory on two 
separate occasions for familiarisation with tests and equipment.  
 
6.3.3 Experimental Protocol  
 
Familiarisation sessions consisted of a health screen that incorporated measurements 
of resting heart rate and blood pressure and implementing a health-based PAR-Q to ensure 
that each participant fulfils the study criteria. Familiarisation also occurred to ensure valid 
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and reliable data collection, particularly concerning the performance tests that required 
some degree of participant training.  
 
 Each subsequent laboratory visits (visits 1 to 3) throughout the eight weeks testing 
period involved exercise performance tests in assessing quadriceps and hamstring muscle 
force production (Isokinetic dynamometry), anaerobic power (Wingate test and Vertical 
Jump test); health-related assessments, including anthropometric profiling (weight, 
height, body fat percentage, fat-free mass); cardiovascular measures (resting heart rate 
and blood pressure). Before the muscle strength and anaerobic power assessment, 
participants completed a warm-up exercise. The warm-up consisted of 5 minutes of 
dynamic exercise using a Monark 894E cycle ergometer (Monark Exercise AB, Vansbro, 
Sweden) maintained at 50 Watt, followed by stretching all major muscle groups.  
 
 A 24-hour recall concerning diet and physical activity was performed by each 
participant on each visit to the laboratory. The 24-hour recall questionnaire was used to 
identify whether the participants were consuming any other performance-enhancing 
supplements and involved in any high-intensity exercise and to enable replication of diet 
and physical activity before each visit. According to the group they were assigned to, 
participants were administered E. longifolia or placebo daily throughout the eight weeks 
period. Prior to each visit, all participants were asked to complete an overnight fast and 
refrain from alcohol and caffeine, strenuous activity, and sexual activity eight hours 





6.3.3.1 Anthropometric Measurements, Cardiovascular Measurements and Dietary 
Supplementation 
 
As mentioned in Chapter 4 general method, the participants recruited are the same. 
Hence the anthropometric and cardiovascular measurement is reported in Chapter 4, page 
93 and page 94. The supplementation of E. longifolia is also presented on page 94. 
  
6.3.3.2 Muscle Force Production Assessment 
 
Force production of the quadriceps and hamstring muscles was assessed using an 
isokinetic dynamometer (Biodex Medical Systems, New York, USA) on the dominant 
leg at two angular velocities (60 and 240°/sec). Participants were placed in a seated 
position with arms folded and secured according to the standard Biodex procedure using 
fixation girdle on the shin, thigh, pelvis, and upper torso. The axis of rotation of the 
dynamometer was aligned with the knee joint axis, defined as the most prominent point 
on the femur’s lateral epicondyle. The dynamometer’s shin brace was placed 2 cm above 
the medial malleolus while being tightly secured to the dynamometer lever arm, where a 
pad with 2 mm of high-density foam was secured tightly to the tibia to avoid any 
discomfort. The range of motion was fixed with participant’s maximum extension, and 
flexion movements are comfortable and without an excessive stretch of their hamstrings. 
Based on the individual, the most extended position was set to anatomical zero. Also, the 
gravity correction for limb weight was applied using the manufacturer protocol. Clear 
instructions and standardized verbal motivation were given to the participants to produce 
maximum muscular effort throughout the range of motion for both knee extensors and 
knee flexors, at a constant angular velocity of 60°/s and 240°/s.  The test was preceded 
by a warm-up involving six repetitions at 50 and 75% effort. Three to five submaximal 
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repetition was performed to familiarise participants with the test prior to the six maximal 
effort trial. Each test involved maximum concentric extension and flexion of the knee, 
and there was one-minute rest between each maximum concentric extension and flexion 
of the knee test. Test-retest reliability of the Biodex isokinetic mode for knee extension 
peak torque at 60/sec was r = 0.97, and at 240/sec was r = 0.95 (Feiring et al., 1990). 
 
6.3.3.3 Anaerobic Power Measurement 
 
Anaerobic power was assessed via the Wingate test (Ayalon et al., 1974) and the 
vertical jump test. Monark 894E cycle ergometer (Monark, Stockholm, Sweden) was used 
to perform the Wingate test with a suggested resistance of 0.075 kg per kg body mass 
applied to elicit the highest possible power output (Ayalon et al., 1974). The Wingate test 
duration was set at 30 seconds, and peak power, average peak power, relative peak power, 
and fatigue index were recorded. According to Bar-Or (1987), the correlation coefficients 
for Wingate tests performed under standardized environment condictions reported a 
ranged between 0.89 to 0.98  
 
 The vertical jump involves participants performing a countermovement jump on a 
force platform (Kisler Instrument Ltd, Winterthur, Switzerland). The participant was 
asked to keep their hands on their hips during the test, which involved push-off, flight and 
landing and ground reaction force was recorded. In a countermovement jump, the 
participant started from an upright standing position, bend downward by flexing at the 
knees and hips, and then immediately and vigorously extended the knees and hips again 
to jump vertically up off the ground. The platform recorded the force applied to it by the 
participants is called the ground reaction force. The vertical component of the jumper’s 
ground reaction force was sampled at 960 Hz and recorded by a computer. Data 
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acquisition and analysis of the jump were performed using a custom program that was 
written using Excel. The participant performed three countermovements jump forcefully 
upon instruction from the researcher, and max force and max power were recorded.   
 
6.3.4 Statistical Analysis   
 
All statistical analysis was conducted using the Statistical Package for the Social 
Sciences (SPSS) for Windows version 22.0 (SPSS Inc., Chicago, USA). Within-group 
differences to examine the time effect was analyzed using the repeated measurement 
ANCOVA and the baseline was used as a covariate. Assumption of normality, 
homogeneity of variances, compound symmetry, and homogeneity of regression was 
checked and fulfilled using the Shapiro Wilk test. Baseline data were also analyzed using 
the parametric (independent t-test) and non-parametric test (Mann Whitney test). All data 
in text, figures, and tables were presented as means ± SD or median (interquartile range) 




 A total of 22 participants with a mean age of 22.7 ± 3.7 years completed the 
experiment. This group of participants did not participate in the short term 
supplementation study. The mean body weight for EL (78.66 ± 8.30 kg) was statistically 
similar to PLA (76.89 ± 5.69 kg), (t19 = 0.565, p = 0.579). Both groups also were similar 
for body fat percentage (t19 = 0.304, p = 0.764) and lean body mass (t19 = 0.314, p = 
0.757).  Anthropometry measurement between groups and within 8 weeks of 
supplementation is shown in Figure 6.1. No significant main effect of time (F1.330, 23.947 = 
2.982, p = 0.087) and no significant main interaction between group and time (F1.330, 23.947 
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= 0.457, p = 0.560) observed in body weight (Figure 6.1A). In body fat assessment, no 
significant main effect of time (F1.630, 29.336 = 1.115, p = 0.331) and no significant main 
interaction between group and time (F1.630, 29.336 = 0.123,   p = 0.845) (Figure 6.1B). Also 
in lean body mass, no significant main effect of time (F1.332, 23.970 = 1.304, p = 0.277) and 
no significant main interaction between group and time (F1.332, 23.970 = 1.068,   p = 0.333) 
(Figure 6.1C). Pairwise comparison and independent t-test shows no significant 
differences within and between EL and PLA in body weight, body fat and lean body mass. 
 
6.4.1 Quadriceps peak torque and average quadriceps peak torque 60°/sec 
 
In quadriceps peak torque, no significant main effect of time (F1.427, 25.680 = 0.456, p = 
0.574) and no significant main interaction between group and time (F1.427, 25.680 = 0.015, p 
= 0.957) observed. In the pairwise comparison within groups, no significant changes but 
a decrease from baseline (206.26 ± 20.3Nm) to post-test (201.36 ± 37.7Nm) [MD = 
4.900Nm, 95% CI = -22.960, 32.760, p = 1.000] in EL and also in PLA from baseline 
(200.03 ± 23.8Nm) to post test (195.28 ± 22.0Nm) [MD = 4.75Nm, 95% CI = -3.390, 
12.890, p = 0.349). There are no significant differences between EL and PLA after 8 
weeks of supplementation at post-test (t19 = 0.661, 0.661).  
 
Also in average quadriceps peak torque, no significant main effect of time (F1.486, 26.746 
= 1.084, p = 0.335) and no significant main interaction between group and time (F1.486, 
26.746 = 0.022, p = 0.950). Similarly, no significant within and between EL and PLA (p > 









Figure 6.1: Anthropometric measurement between and within EL and PLA groups 
at baseline (Week 0), interim (Week 4) and Post (Week 8) 




































































6.4.2 Hamstring peak torque and average hamstring peak torque 60°/sec 
 
In hamstring peak torque, a significant main effect of time (F2, 36 = 10.719, p < 0.001) 
but no significant main interaction between group and time (F2, 36 = 0.711, p = 0.498). In 
the pairwise comparison within groups, there is no significant changes but a decrease 
from baseline (126.22 ± 24.4Nm) to post-test (120.27 ± 11.0Nm) [MD = 5.95Nm, 95% 
CI =-3.583, 15.473, p = 0.301] in EL and also in PLA from baseline (129.15 ± 23.3Nm) 
to post test (122.76 ± 17.6Nm) [MD = 6.39Nm, 95% CI = -0.312, 13.092, p = 0.062). 
There are no significant differences between EL and PLA after 8 weeks of 
supplementation at post test (t19 = -0.392, p = 0.699) (Figure 6.2B).  
 
In average hamstring peak torque, a significant main effect of time (F2, 36 = 4.697, p = 
0.015) but no significant main interaction between group and time (F2, 36 = 0.658, p = 
0.524). Pairwise comparison analysis shows no significant changes from baseline (114.69 
± 119.3Nm) to post test (109.6 ± 13.4Nm) in EL [MD = 5.10Nm, 95% CI = -4.905, 
15.105, p = 0.507] but a significant decrease in PLA from baseline (119.31 ± 24.1Nm) to 







   
Figure 6.2: Quadriceps (A) and hamstring (B) peak torque and average peak torque at 60°/s in E. longifolia and Placebo group to examine the 
time effect within-group and between-groups at baseline (Week 0), interim (Week 4) and Post (Week 8) 
Note: EL: E. Longifolia group; PLA: placebo group; Peak torque (PT); Average peak torque (APT) 
































































6.4.3 Quadriceps peak torque and average quadriceps peak torque 240°/sec 
 
In quadriceps peak torque, a significant main effect of time (F2, 36 = 7.347, p = 0.002) 
observed but no significant main interaction between group and time (F2,36 = 0.136, p = 
0.873). Pairwise comparison within groups shows no significant changes but a minimal 
increase from baseline (136.60 ± 23.1Nm) to post-test (139.18 ± 15.0Nm) [MD = -
2.58Nm, 95% CI = -11.331, 6.168, p = 1.000] in EL and also in PLA from baseline 
(127.46 ± 19.1Nm) to post test (133.04 ± 18.6Nm) [MD = -5.58Nm, 95% CI = -12.942, 
1.782, p = 0.155). There are no significant differences between EL and PLA after 8 weeks 
of supplementation at post test (t19 = 0.835, p = 0.414). Also in average quadriceps peak 
torque, no significant main interaction between group and time (F2, 36 = 2.475, p = 0.098) 
but significant main effect of time (F2,36 = 4.125, p = 0.024). Pairwise comparison show 
no significant change throughout the 8 weeks supplementation. Between group analysis 
saw a significant higher average peak torque in EL (131.42 ± 23.2Nm) compare to PLA 
(114.11 ± 7.2Nm) at interim (t19 = 2.259, p = 0.036) but no significant differences at post-
test (Figure 6.3A).  
 
6.4.4 Hamstring peak torque and average hamstring peak torque 240°/sec 
 
Hamstring peak torque, a significant main effect of time (F2, 36 = 8.158, p = 0.001) but 
no significant main interaction between group and time (F2,36 = 0.084, p = 0.919) 
observed. Pairwise comparison within groups shows no significant changes but a minimal 
increase from baseline (86.39 ± 11.7Nm) to post-test (89.92 ± 9.9Nm) [MD = -3.53Nm, 
95% CI = -12.354, 5.299, p = 0.814] in EL and also in PLA from baseline (90.82 ± 
11.8Nm) to post test (91.85 ± 11.2Nm) [MD = -1.03Nm, 95% CI = -10.406, 8.346, p = 
1.000). There are no significant differences between EL and PLA after 8 weeks of 
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supplementation at post test, (t19 = -0.420, p = 0.679). Also in average hamstring peak 
torque, significant main effect of time (F2,36 = 13.411, p < 0.001) but no significant main 
interaction between group and time (F2, 36 = 0.528, p = 0.595). Within group and between 
group analysis also did not show any significant differences (p > 0.05) throught the 
supplementation period (Figure 6.3B).  
 
6.4.5 Wingate 30 seconds anaerobic test (WAnT) 
 
In WanT peak power assessment, no significant main effect of time (F2, 36 = 0.187, p = 
0.830) observed and no significant main interaction between group and time (F2,36 = 
1.701, p = 0.197) and. Pairwise comparison within groups shows no significant changes 
but an increase from baseline (826.22 ± 144.87W) to post-test (840.11 ± 141.66W) [MD 
= -13.89W, 95% CI = -66.098, 38.318, p = 1.000] in EL and but PLA show a significant 
decrease from baseline (755.67 ± 68.22W) to interim (715.27 ± 46.49W) [MD = 40.40W, 
95% CI = 7.843, 72.949, p = 0.017) and increases back at post test (p > 0.05). Between 
group analysis saw a significant higher peak power in EL (844.08 ± 158.16W) compared 
to PLA (715.27 ± 46.49W), (t19 = 2.581, p = 0.024) at interim. However, no significant 
differences between EL and PLA at post-test (p > 0.05). 
 
Average peak power findings found significant main effect of time (F2,36 = 9.584, p < 
0.001) and significant main interaction between group and time (F2, 36 = 3.389, p = 0.045) 
was observed. Within-group analysis within EL and PLA did not find any significant 
changes over the 8 weeks supplementation. Between-group analysis shows significant 
higher average peak power (580.04 ± 63.06W) in EL compared to PLA (516.62 ± 41.3W), 
(t19 = 2.695, p = 0.014) after 4 weeks supplementation but no significant difference at 




Figure 6.3: Quadriceps (A) and hamstring (B) peak torque and average peak torque at 240°/s in E. longifolia and Placebo group to examine the 
time effect within-group and between-groups at baseline (Week 0), interim (Week 4) and Post (Week 8) 
Note: E. Longifolia group (EL); placebo (PLA); Peak torque (PT); Average peak torque (APT) 






































































Figure 6.4: Peak power and average peak power (30s Anaerobic Wingate Test) on 
E. longifolia and placebo group to examine the time effect within-group and 
between-groups at baseline (Week 0), interim (Week 4) and Post (Week 8) 
Note: E. Longifolia (EL); placebo (PLA); Peak power (PP); Average (A) 
* indicates that there is significant changes compare to baseline; † Denotes indicate significant differences 
between EL and PLA Peak Power; ¥ Denotes indicate significant difference between EL and PLA Average 
Peak Power. 
*,† Denotes level of significance was set at 0.05 (two-tailed) 
 
There is a significant main effect of time (F2, 36 = 8.979, p = 0.001) but no significant 
main interaction between group and time (F2,36 = 2.817, p = 0.073) in relative peak power. 
Pairwise comparison within groups shows no significant increased in relative peak power 
from baseline (10.85 ± 1.80 W/kg) to interim (10.70 ± 1.54 W/kg) [MD = 0.147 W/kg, 
95% CI = -1.14, 1.44, p = 1.000] and no significant increase from baseline to post-test 
(10.60 ± 1.28 W/kg) [MD = 0.250 W/kg, 95% CI = -0.772, 1.27, p = 1.000] in EL. PLA 
show significant decrease from baseline (9.87 ± 0.72 W/kg) to interim (9.31 ± 0.57 W/kg) 
[MD = 0.564 W/kg, 95% CI = 0.120, 1.00, p = 0.015) but no singnificant changes from 
baseline to to post-test (9.40 ± 0.89 W/kg) [MD = 0.477, 95% CI = -0.420, 1.37, p = 
0.442). Between group analysis saw a significant higher relative peak power in EL 
compared to PLA at interim (t19 = 2.688, p = 0.015) and in post-test (t19 = 2.477, p = 




























Figure 6.5: Relative peak power (30s Anaerobic Wingate Test) on E. longifolia and 
placebo group to examine the time effect within-group and between-groups at 
baseline (Week 0), interim (Week 4) and Post (Week 8) 
Note: E. Longifolia (EL); placebo (PLA) 
* indicates significant differences between EL and PLA 
*Denotes level of significance was set at 0.05 (two-tailed) 
 
In WanT, fatigue index was determined as well. There is a significant main effect of 
time (F2, 36 = 45.50, p = 0.000) and significant main interaction between group and time 
(F2,36 = 3.991, p = 0.027). Pairwise comparison within groups shows significant increased 
in fatigue index from baseline (59.93 ± 14.67 %) to interim (66.14 ± 5.63 %) [MD = -
6.216 %, 95% CI = -11.42, -1.05, p = 0.002] but no significant increase from baseline to 
post-test (62.55 ± 6.34 %) in EL. PLA show no significant changes from baseline (58.0 
± 12.9 %) to interim (58.1 ± 3.6 %) [MD = -0.063 %, 95% CI = -3.64, 3.51, p = 1.000) 
and also to post-test (57.6 ± 9.2 %) [MD = 0.445 %, 95% CI = -7.76, 8.65, p = 1.000) 
Between group analysis saw no significant fatigue index in EL (844.08 ± 158.16W) 

































Figure 6.6: Fatigue index (30s Anaerobic Wingate Test) on E. longifolia and placebo 
group at baseline (Week 0) and Post (Week 8) 
Note: E. Longifolia (EL); placebo (PLA)  
* indicates significant differences within EL  
*Denotes level of significance was set at 0.05 (two-tailed) 
 
6.4.6 Force generation via vertical jump test 
 
For baseline measurement, max force scores of EL (Median = 2075N) were not 
different than PLA (Median = 1892N). A Mann-Whitney test indicated that no 
statistically significant, U (EL = 11, PLA = 10) = 36.50, z = -1.303, p = 0.197. However, 
in max power, independent t-test shows significant difference between EL (4103.18 ± 
509.67N) and PLA (3555.9 ± 383.52N) in max power, (t19 = 2.757, p = 0.013). 
 
In max force, ANCOVA repeated measurement with baseline at the covariate shows 
no significant main effect of time (F1.356, 24.410 = 2.892, p = 0.091) and no significant main 
interaction between group and time (F1.356, 24.410 = 0.012, p = 0.959) was observed. 
Pairwise comparison within groups shows no significant changes but an increase from 
baseline (2141 ± 385N) to post-test (2154 ± 415N) [MD = -13.00N, 95% CI = -290.386, 



























(1936 ± 213N) [MD = -73.70, 95% CI = -234.124, 86.724, p = 0.610). Between group 
analysis shows no significant difference in max force between EL (2154 ± 415N) and 
PLA (1936 ± 213N) (t19 = 1.535, p = 0.145) at post-test (Figure 6.5A). 
 
In max power, ANCOVA repeated measurement shows no significant main effect of 
time (F2, 36 = 0.272, p = 0.764) but significant main interaction between group and time 
(F2, 36 = 3.650, p = 0.036) was observed. Pairwise comparison within groups shows no 
significant changes from baseline (4103 ± 510W) to post-test (4076 ± 585W) [MD = 
27.455, 95% CI = -128.955, 183.864, p = 1.000] in EL but there is significant increase in 
max power in PLA from baseline (3556 ± 384W) to post (3736.6 ± 421W) [MD = -
180.70W, 95% CI = -301.033, -60.367, p = 0.006). Between group analysis shows no 
significant difference in max power between EL (4076 ± 585W) and PLA (3736.6 ± 




Figure 6.7: Max force (A) and max power(B) (vertical jump on force platform) in E. longifolia and Placebo group to examine the time effect 
within-group and between-groups at baseline (Week 0), interim (Week 4) and Post (Week 8) 
 Note: E. Longifolia (EL) and placebo (PLA) 
*indicates that there is significant changes compare to baseline. 

























































The present results indicate that high dose supplementation (600 mg) alone does not 
significantly improve strength, anaerobic power or body composition in healthy young 
men.  An increase in testosterone was associated with increased skeletal muscle mass, 
strength and power (Storer et al., 2008). The testosterone level presented in Chapter 4 did 
not indicate any significant increase after E. longifolia supplementation.  Hence, the lack 
of strength, power and body composition improvement was observed.  
 
 While findings in the current study did not improve in strength or power after E. 
longifolia supplementation, several previous studies have shown improvements. Previous 
studies were performed on participants aged between 30 to 72 years old with a possibility 
of an age-related reduction in circulating testosterone levels (George et al., 2013; Henkel 
et al., 2014). Both studies demonstrated an increase in muscle strength after being 
supplemented with 100 mg and 400 mg of E. longifolia, respectively. However, only 
Henkel et al. (2014) found an increase in strength with testosterone levels elevated. It has 
been suggested that the improvement is due to the peptides found in E. longifolia which 
add additional ergogenic benefits (Sambandan et al., 2006). The peptides enhance protein 
synthesis to assist in the repair and regeneration of skeletal muscle fibres, which promote 
improvements in both muscle size and strength in the older population (Tarnopolsky et 
al., 1995; Roy et al., 2000; Ratamess et al., 2003; Hoffman et al., 2006; Kraemer et al., 
2006). However, the current long-term supplementation of 600 mg of E. longifolia did 
not improve strength and power. While E. longifolia exhibits greater changes in 
testosterone levels when initial levels are low (Talbott et al., 2013), baseline testosterone 
levels in the current study (Chapter 4) remain at the normal circulating levels. As a 
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consequence, the strength and power within the E. longifolia and placebo treated group 
remain unchanged.  
 
 The present study recruited adult males that do not participate in any physical 
activities. In order to determine whether supplementation of E. longifolia alone increases 
testosterone level and subsequently improves strength and power, resistance training 
intervention was not included in the study. However, without resistance training 
intervention, it may have a lesser effect in enhancing strength and power. The 
combination can elicit a greater effect in enhancing muscle strength and power than 
supplementation alone, considering exercise increases testosterone and results in higher 
testosterone to cortisol ratio values, which subsequently increase the individual’s anabolic 
status. It is suggested that the supplementation of E. longifolia during this anabolic state 
enhances muscle size and strength (Henkel et al., 2013; Adlercreutz et al., 1986). A 
combination of 400 mg per day of E. longifolia and circuit training for eight weeks has 
demonstrated better improvement than E. longifolia alone or exercise alone in increasing 
muscular strength and power (Ooi et al., 2015). An earlier pilot study found an intensive 
8-week strength training programme supplemented with 100 mg per day of E. 
longifolia exhibited a significant increase (6.78%) in strength compared to the placebo 
group (Hamzah & Yusof, 2003). Another study using 100 mg of E. longifolia, combined 
with strength training, found increased muscle strength and larger quadriceps muscles 
(Sarina et al., 2009). A more recent study, utilizing 40 males aged between 19 to 25 years, 
administered 200 mg per day of E. longifolia and, combined with resistance training, 
found significant muscular strength and power improvement. The improvement in 
muscular strength may be attributed to the resistance training acting as a stimulus to 
initiate muscular growth, and this growth, in turn, triggers protein signalling to activate 
and stimulate the synthesis of muscle protein, leading to increased muscle strength (Chen 
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et al., 2019). It is proven that strength can increase through performing resistance training 
(Brown and Wilmore, 1974; Anderson and Kearney, 1982; Morganti et al., 1995; 
Starkey et al., 1996; Chilibeck et al., 1998; Faigenbaum et al., 1999; Hagerman et al., 
2000). Previous studies have shown that the combination of E. longifolia and resistance 
training demonstrates a higher synergistic effect than E. longifolia alone in increasing 
muscular strength and power. Hence, the supplementation of E. longifolia alone in this 
study reported no improvement in strength.  
 
 Also, a high dose of E. longifolia (600 mg) supplemented in adult men did not elicit 
any increase in strength and anaerobic power.  Although there was a significantly higher 
relative peak power in EL than PLA, there were no significant changes within the EL. 
The significant difference could be due to the decrease of relative peak power in PLA, 
and most importantly, baseline relative peak power was higher in EL. Based on the fatigue 
index data, there is a higher decline in power output during the test in EL. According to 
Tambi (2005), 600 mg of E. longifolia is currently the highest dose tested on humans and 
is non-toxic. Thus, the current findings suggest that even a high dose of E. Longifolia will 
not produce a more beneficial effect on muscular strength among healthy young males; a 
combination of E. longifolia with resistance training may be needed. Although the 
participants were asked to perform two times of familiarization prior to the isokinetic 
dynamometer, Wingate and vertical jump test, there is a possibility that the muscular 
strength and power assessment may not obtain accurate and reliable measurements. 
According to Dias et al. (2005) and Vrbik et al. (2016), the familiarization of two to three 
familiarization sessions with previous experience of performing the testing activities is 
needed to measure strength and power accurately.  It is also suggested that one 
familiarization trial is sufficient to demonstrate excellent reproducibility for peak 
moment, average power and total work parameters. Also, one familiarization is 
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recommended prior to testing to reduce the effect of practice-based improvement (Nugent 
et al., 2015). Hence, a better assessment of familiarization is needed prior to testing future 
studies to obtain reliable measurements.  
 
 The present study did not significantly improve body weight, body fat percentage, and 
fat-free mass.  Hamzah and Yusof (2003) found that eight weeks of resistance training 
combined with E. longifolia exhibited a five percent increase in lean mass compared to 
the placebo group. The positive findings in lean mass improvement may have been due 
to the combination of intensive strength training and the supplementation of E. longifolia, 
which provides further evidence that a combination of E. longifolia and resistance training 
may significantly improve lean body mass. Thus, suggesting that this traditional remedy 
may be a practical approach to gaining lean body mass and, subsequently, losing body 
fat. However, the current study does not demonstrate this effect, and further research is 




  Administrating a high dose of E. longifolia for eight weeks did not elicit any effects in 
increasing isokinetic strength, anaerobic power or body composition among young men 
who had no previous health issues, including low testosterone levels. There are limitations 
in the current study, including the lack of exercise training in the experimental protocol, 
and participants might not have familiarized themselves with the exercise testing. Also, 
participants might have performed a certain amount of exercise throughout the trial 
period, which may confound the current findings. Biochemical markers, such as cortisol, 
growth hormone, dehydroepiandrosterone sulfate, total insulin-like growth factor-1, 
creatine kinase, can be measured to determine the anabolic or catabolic status after 
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consuming E. longifolia. Future studies involving muscle biopsies to assess the changes 
directly in the skeletal muscle tissues rather than indirectly through measures in the blood 
may provide substantial information such as skeletal muscle fiber hyperthrophy. The 
present study shows that the supplementation of E. longifolia alone, especially in young, 
healthy men, did not exhibit beneficial effects, despite long-term supplementation of high 
doses (600 mg). While it is suggested that a combination of resistance training and E. 
longifolia may augment muscular strength, anaerobic power or body composition, further 
studies are needed to confirm this. 
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This thesis has examined the efficacy of E. longifolia supplementation on exercise 
performance and wellbeing among male adults. This chapter provides a synthesis of the 
primary outcomes of the investigations presented in the thesis. Limitations and the future 
direction of research will also be discussed.  
The first objective is addressed in Chapter 3. The cytotoxicity effect of E. longifolia 
on C2C12 murine SMCs is assessed using the LDH assay. A concentration of 0.5 mg/ml 
and 1.0 mg/ml E. longifolia was administered to differentiated C2C12 cell lines (P13 and 
P26) throughout this cytotoxicity study. The findings reveal that P13 has a greater 
increase in myotube size compared to P26, with no cell death observed during the test 
period. While there is no cell death, the LDH cytotoxicity test demonstrated that the 
cytotoxicity level in the E. longifolia treated cells is lower than the cells treated with the 
differentiation medium (CON). The reduction in LDH activity indicates that E. longifolia 
reduces the rate of cytotoxicity or cell death. Also, there is increased cell viability in P13 
and P26 cells treated with 0.5 and 1.0 mg/ml of E. longifolia compared to the non treated 
control cells. However, the cell viability is lower than the P13 and P26 C2C12 cells 
treated with DM, demonstrating that there are more living cells in both P13 and P26 
treated with E. longifolia.  A higher dose is needed in P26 to induce higher cell viability. 
Findings suggest that E. longifolia, with its bioactive compounds, may have the ability to 
stimulate the myotube’s proliferation and differentiation. However, further studies are 
needed to identify which bioactive compounds are responsible for the current study 
outcome. 
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The second objective is addressed in Chapter 4. Two weeks of 600 mg of E. 
longifolia supplementation increased testosterone (11.1%), but this effect diminishes 
when the supplementation is extended to eight weeks. The increase in testosterone and 
free testosterone is thought to be due to an active ingredient known as eurycomanone. 
However, the prolonged administration of E. longifolia did not demonstrate any change 
in the reproductive hormones. While the current study shows that a high dose (600 mg) 
can increase short-term testosterone levels, the outcome may have been due to 
participants participating in exercise without the researcher’s knowledge. Also, other 
possible factors affecting the outcome such as dietary and supplementation intake, were 
not examined. Future investigations considering all the possible confounding factors are 
needed to allow a more reliable and accurate outcome.  
The current findings demonstrate that E. longifolia supplementation does not stimulate 
LH production nor reduce oestrogen levels. Instead, two weeks of E. 
longifolia supplementation shows a lower level in SHBG (1.3%) compared to placebo 
(16.5%). However, supplementation of E. longifolia for eight weeks demonstrated a 
significant increase in SHBG, and a reduction in free testosterone is observed. While a 
lower SHBG value was reported in EL than PLA in the short-term supplementation 
period, there are no significant changes from day 1 to day 14. Thus, demonstrating that 
E. longfolia did not influence SHBG to release free testosterone to circulate around the 
body.  The current study shows that E. longifolia did not boost testosterone in a healthy 
individual beyond the normal circulating levels and did not affect the LH, FSH, oestrogen 
and SHBG in the HPG axis.  
 
Chapter 5 addresses objective number three. The current study shows that participants 
supplemented with 600 mg of E. longifolia for either two or eight weeks do not 
demonstrate an optimal peak in vigour and low negative mood state above or below the 
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50% standard score, respectively. Hence, the present short and long-term 
supplementations of E. longifolia do not demonstrate a positive mood state profile among 
adult men. There is a significant reduction in the anger and confusion domains in the two-
week supplementation period, and all the negative domains demonstrate improvement 
after the long-term supplementation period, with tension and anger showing a significant 
decrease. Not all the psychological mood states are significantly increased in the current 
study; thus, the hypothesis is only partially accepted. Further research in this area, 
especially to examine the precise mechanism of E. longifolia in enhancing testosterone 
levels and reducing the cortisol level, is required. Although an improvement was observed 
in certain domains, the improvements within and between EL and PLA are too minimal 
to conclude the effectiveness of E. longifolia causes this outcome.  
Concerning sexual function, the E. longifolia supplemented group shows a significant 
increase only in the ejaculation domain and a non-significant increase in overall 
satisfaction after two weeks of supplementation. Alternatively, long-term 
supplementation demonstrates a significant increase in three sexual domains (erection, 
ejaculation, and overall satisfaction) and a higher increase in sexual desire and problem 
assessment than placebo. Although there is no indication that E. 
longifolia supplementation for two weeks contributes to sexual function improvement, 
there are improved sexual function in all domains over time compared to placebo. Similar 
to mood state, the improved sexual function may not be due to E. longifolia as testosterone 
level did not change significantly. However, the outcome may be affected due to 
confounding factors such as the participants recruited being healthy, young, and may have 
a sexual partner, and not directly related to E. longifolia.  
 The final objective is addressed in Chapter 6. E. longifolia supplementation (600 mg) 
alone does not demonstrate any significant improvement in strength, anaerobic power and 
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body composition in healthy young men. In order to improve muscular strength, 
anaerobic power and body composition, resistance training is needed. It has been shown 
in previous studies that the combination of E. longifolia and resistance training 
demonstrates a synergistic effect in increasing muscular strength and power compared to 
those that only participate in resistance training (Hamzah & Yusof, 2003; Sarina et al., 
2009; Henkel et al., 2013; George et al., 2013; Ooi et al., 2015; Chen et al. 2019). In 
addition, supplementation of E. longifolia with a dosage of 600 mg per day for eight 
weeks does not increase the testosterone levels in young adult participants with normal 
circulating levels. It should be noted that the human body constantly regulates 
testosterone levels to maintain homeostasis (O'Hara et al., 2015), and for this reason, 600 
mg of E. longifolia administered alone for a prolonged period may not be effective in 
increasing testosterone. Testosterone is perceived as a determining factor in enhancing 
strength. Hence, the lack of significant improvement in muscular strength, anaerobic 
power and body composition may be due to the lack of significant changes in testosterone 
level and the absence of resistance training. Further studies examining the synergistic 
effect of combined E. longifolia supplementation with resistance training on adult 
participants, and investigation into the possible perturbation of homeostasis due to the 




Figure 7.1 Summary of studies
E. longifolia Treatment
Human studies
To elucidate the 
changes in selected 
reproductive hormone
Short term 
Significant increase in 
testosterone (11.1%), No 
significant changes in Free 
testosterone, Estradiol, LH, 
FSH and SHBG
Long term 
No signicant increase in 
testosterone, free 
testosterone, estradiol, 
LH,FSH and SHBG 
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Cytotoxicity of 
E. longifolia on 
murine skeletal 
muscle cells
Lower cytotoxicity level 
in E. longifolia treated 
cells (P13 and P26) 
Increased in cell viability 
in cell treated with E. 
longifolia and DM. 
Therefore the treatment 
of E. longifolia not 
causing a cytotoxic 
impact. 
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7.2   Limitations of the Study 
 
Previous studies have mostly examined the cytotoxicity of E. longifolia in various 
cancer cell lines using various bioactive compounds isolated from E. longifolia.  In this 
study, the cytotoxicity test on SMCs is examined for the first time. Thus, there are no 
specific guidelines on the appropriate dose of E. longifolia to be used. The pilot test was 
conducted using various doses that were tested repeatedly on SMCs with different 
passage numbers to determine the most suitable dose and the cell passage number. While 
the current study shows lower cytotoxicity levels in murine SMCs compared to the control 
treatment, the reason behind the myotube growth observed after being treated with E. 
longifolia is unknown. This study is limited to cytotoxicity tests within cell culture 
models, and myotube size and gene expression were not performed to examine the muscle 
growth, hypertrophy post-E. longifolia treatment.  
Following the in vivo study, humans studies were conducted to examine the efficacy 
of E. longifolia, which is presented in Chapter 4 through to Chapter 6. The main obstacle 
faced during this in vitro study is the recruitment process. The participants’ recruitment 
is done in the United Kingdom, where E. longifolia is not widely used and was unfamiliar 
as a herbal supplement. Potential participants may not have been comfortable consuming 
the extract, thus hampering wider recruitment. In addition, the cost to purchase 
instruments (i.e. butterfly needles for phlebotomy, blood collection tube, assay kits for 
hormone analysis) also contribute to the smaller number of participants.   
 The study examining the possible mechanisms involved in E. longifolia 
supplementation in a human is performed for the first time. The current study is limited 
to analysing of the reproductive hormones, such as testosterone, free testosterone, the 
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luteinising hormones, FSH, oestrogen, and sexual hormone-binding globulin to determine 
whether E. longifolia influenced the HPG axis.  
 Chapter 4 demonstrate an increase and no change in testosterone levels after two and 
eight weeks of the supplementation period, respectively, with oestrogen levels remaining 
elevated. These findings suggest that aromatase is not inhibited after the E. longifolia 
supplementation period.  However, we cannot draw a well-founded conclusion that E. 
longifolia indeed does not inhibit aromatase since the aromatase activity is not examined. 
Therefore, the effect of E. longifolia on the aromatase activity warrants more 
investigation.  
 Testosterone levels in the body are regulated predominantly via the HPG axis and, to 
a lesser extent, the HPA axis. However, the current study can only speculate that the lack 
of a significant increase in testosterone levels in Chapter 4 may be due to a higher level 
of circulating cortisol hormones. The cortisol hormones play an important role in 
regulating testosterone in both the HPG and HPA axes. That their levels are not measured 
indicates another main limitation in the thesis. 
A combination of strength training and exogenous testosterone improves muscular 
strength significantly compared to participants who performed strength training alone. 
While a synergistic effect arising from the combined E. longifolia and resistance training 
regime on muscular strength and power, the exclusion of resistance training in the 
experimental protocol in Chapter 6 demonstrates another limitation in this study, and 
further research is needed to confirm the synergistic effects of the combination of E. 




7.3  Future Directions 
 
The present cytotoxicity study shows lower cytotoxicity levels in murine SMCs than 
the control treatment, and myotube growth is observed. The E. longifolia effects on 
skeletal muscle differentiation and hypertrophy are still unknown. Thus, future work 
examining the gene expression of MyoD, muscle regulatory factor 4 (MRF4), myogenic 
factor 5 (Myf5), and myogenin may provide a better understanding of skeletal muscle 
differentiation and hypertrophy post-administration of E. longifolia. Hence the adoption 
of muscle cells versus primary human culture through muscle biopsies to address cell 
behaviour via gene expression may facilitate a better understanding of skeletal muscle 
differentiation and hypertrophy. The ELISA kit used for human hormone measurements 
may need to be validated analytically (specificity, sensitivity, accuracy, precision, and 
parallelism of the dose-response relationship for the standard of the assay) and 
biologically (comparing changes in hormone levels) to ensure the accurate and reliable 
outcome. Also, studies investigating the claim ability in regulating signaling patways 
involved in proliferation, cell death and inflammation.  
At present, the effect of E. longifolia in increasing testosterone levels is based solely 
on the findings by Low et al. (2013a & 2013b), which demonstrated E. 
longifolia interfered with the HPG axis through the inhibition of aromatase enzymes and, 
thus, prevented the conversion of the testosterone to oestrogen. This mechanism allows 
more testosterone to stay in the system, and the inhibition of aromatase leads to a lower 
negative feedback signal to the hypothalamus. However, Chapter 4 suggests otherwise; 
hence, future work examining the aromatase activity in humans may provide a better 
mechanistic understanding of whether E. longifolia affects aromatase inhibition via 
humans’ HPG axis.  
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 E. longifolia at a 600 mg/day dosage was well-tolerated and considered safe for 
consumption by participants. However, this dosing regimen did not increase testosterone 
levels following eight weeks of supplementation, the levels remaining within the normal 
biological range. The present study did not measure cortisol levels, something which may 
provide valuable information about and understanding of the efficacy of E. longifolia in 
various stress domains and sexual function parameters.  Previous studies have shown a 
reduction in cortisol levels after supplementing with E. longifolia, indicating a shift to an 
anabolic hormone state.  Apart from the measurement of testosterone hormones, other 
biochemical markers, such as cortisol, growth hormones, dehydroepiandrosterone sulfate, 
total insulin-like growth factor-1 and creatine kinase, should be considered in future 
studies to determine the anabolic or catabolic status. Muscle biopsies could be an 
important future study direction to evaluate the skeletal muscle tissues’ modifications 
rather than using indirect measures in the blood. This may provide significant information 
regarding the effects of E. longifolia on muscle strength and hypertrophy. Also, studies 
investigating male fertility (semen volume, spermatozoa count, and motility) in human 
may provide better information regarding the aphrodisiac properties of E. longifolia. 
The current study does not demonstrate any muscular strength, anaerobic power or 
body composition improvement, even after participants had been supplemented with E. 
longifolia.  E. longifolia supplementation with exercise training may need to be conducted 
concurrently to demonstrate a possible synergistic effect on muscular strength and 
anaerobic power. Hence, future studies involving the combination of an exercise 
intervention with E. longifolia supplementation in young men with normal testosterone 






The LDH cytotoxicity test demonstrates that E. longifolia treatment displays low LDH 
activity in SMCs compared with the cells treated with differentiation medium, indicating 
E. longifolia treatment does not exhibit toxicity. Also, SMCs treated with E. longifolia 
demonstrate an increase in cell viability. This thesis also demonstrates that E. longifolia 
did not demonstrate efficacy in increasing the reproductive hormones, mood state, sexual 
function and exercise performance in the human study.  While the current findings show 
that E. longifolia does not interfere with the HPG axis to stimulate more testosterone 
production by affecting the LH and oestradiol, more work is needed to examine the HPG 
and HPA axes concurrently. This thesis also was the first to explore the reproductive 
hormones associated with the HPG axis. It is acknowledged that many confounding 
factors were unavoidable, and caution was needed in interpreting the findings to eliminate 
any bias toward E. longifolia supplementation.  Ultimately, the study’s outcome provides 
a new perspective on how E. longifolia could be conducted on murine skeletal muscle 
cells and a better understanding of the claim ability of E. longifolia in affecting the HPG 
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Appendix C: Certificate of analysis for E. longifolia by LGC laboratory accredidated 





Appendix D: Participation information sheet 
 
Title of Project:The effects of 12 Weeks Eurycoma longifolia (Tongkat Ali) ingestion on exercise 
performance, health and wellbeing 
 
Name of Researcher and School/Faculty: 
Kai Quin Chan 
School of Sport and Exercise Sciences, Faculty of Science 
 
Academic Supervisor: 
Dr Neil Chester 
School of Sport and Exercise Sciences, Faculty of Science 
 
“You are invited to take part in a sports science research project to examine the effects of 
a natural Asian herb, Eurycoma Longifolia (EL) on exercise performance, health and well-
being” 
I am looking for males aged 18 to 30 years old and 55 to 70 years old, free from musculoskeletal 
injury and are in good health.  You are not eligible to take part in this research project if you have 
diabetes mellitus, heart disease, liver disease and sleep apnoea. Also, if you smoke or take other 
recreational or prescription drug and have artificial pacemaker, you will not be eligible to 
participate in the research. 
 
The herb contains an ingredient, boldione, which is prohibited by the World Anti-Doping Agency 
and therefore those who may be subject to anti-doping tests (i.e. competitive athletes) are 
excluded from participating in the study. Whilst boldione is present in Tongkat Ali, the 
concentration/amount is extremely low and the dose administered as part of the study is within 
the range of 18 to 30 ng per day which is deemed to be innocuous from a health and safety 
perspective. 
 
Please, take the time to read the details of the project on this participant information sheet. 
Feel free to ask any questions you may have about the research and the processes 
involved. When you are ready you can decide whether you would like to take part in the 
research process or not. Thank you.”  
 
1. What is the purpose of the study? 
 
The purpose of this study is to assess the effects of the oral supplementation of a herb, 
Eurycoma longifolia (600mg/day) relative to placebo (maltodextrin) for 2 weeks, on health (heart 
rate and blood pressure; body composition; blood lipid profile i.e. cholesterol) and well-being 
(mood state and libido). The herb is considered to be a natural testosterone booster and therefore 
is reputed to increase testosterone levels in the human body. 
 
Testosterone is the predominant male sex hormone known for their androgenic (masculinizing) 
and anabolic (muscle-building) actions which create possible advantages to those engaged in 
sport. Eurycoma longifolia (EL) supplementation could increase testosterone levels and 
subsequently increase sports performance and effect health and wellbeing.  
 
2. Do I have to take part? 
 
Your participation in this process is completely voluntary. If you decide to take part in this study 
you will be asked to sign a volunteer consent form and will be given this information sheet. If at 
LIVERPOOL JOHN MOORES UNIVERSITY 
PARTICIPANT INFORMATION SHEET 
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any time during the study you would like to withdraw from the study you are free to do so without 
your rights, future treatment or service you receive being affected. Please ensure you read this 
and ask any question no matter how small a detail it may seem.  
 
3. What will happen to me if I take part? 
 
The duration of this study is 2 weeks and you will need to consume Eurycoma longifolia or 
placebo (maltodextrin) in capsule form throughout the duration (i.e. 600 mg per day). You will 
need to attend six (6) laboratory visits for blood sampling. Prior to each visit you will be asked 
to complete an overnight fast (8 hours), refrain from alcohol and caffeine, strenuous activity and 
sexual activity 24 hours prior to the blood collection day. 
 
The laboratory testing includes: 
1) Body composition will be determined by assessment of your height, and weight. In 
addition a technique known as ‘bioelectrical impedance analysis’ will be used to assess 
body composition. This technique involves the passage of a very low (unnoticeable) 
electrical current through the body to determine electrical resistance. This measurement 
corresponds with body composition. 
2) Heart rate and blood pressure will be assessed using a method involving an inflatable 
cuff around the upper arm.  
3) Measurement of haematological parameters and steroid and lipid profiles (i.e. 
cholesterol) will involve venepucture of a vein in the arm and the collection of a small 
sample of blood (15 ml divided into two separate tubes). 
4) Mood state will be assessed using a simple questionnaire involving the rating of your 
mood according to six states (i.e. vigour, depression, anger, confusion, fatigue and 
anxiety) 
5) Sexual function will be assessed by a simple questionnaire (11 questions) involving the 
rating of your sex drive. 
 
4. Are there any risks / benefits involved? 
 
Benefits 
Increases in testosterone level will provide potential benefits including: improvements in 
exercise performance (muscle strength and anaerobic power); health (heart rate and blood 




There are limited reported side effects following the supplementation with Eurycoma longifolia, 
however possible side effects include insomnia, anxiety, restlessness, and reduced blood 
glucose. Symptoms of low blood glucose are trembling or shakiness, fast heartbeat, sweating, 
anxiety, dizziness, feeling hungry, tiredness, blurred vision, confusion and difficulty concentrating.  
Subjects who experience such side-effects should report this to the researcher and may terminate 
their involvement in the study immediately. Men with breast cancer or prostate cancer, diabetes 
mellitus, heart disease, kidney disease, liver disease, sleep apnoea should avoid 
supplementation and will be excluded from the study via the pre-investigation health screen. The 
assessment of sexual function involves sensitive information and may cause 
distress/embarrassment to participants. Any distress will be alleviated through the completion of 
the questionnaire on-line, in a private room adjacent to the laboratory. The use of an on-line 
questionnaire will ensure the anonymity of the data since it will only be identifiable from a specific 
code number. The data will be encrypted and the computer will be password protected to ensure 
the data is not retrievable by a third party other than the researcher and supervisor.  
 
The Tongkat Ali administered contains a prohormone, boldione. Prohormones have the 
potential to adversely affect cholesterol levels if taken in high quantities. Research suggests that 
there are no effects in quantities of 100 mg  per day and therefore quantities in this study of within 
the range of 18 to 30 ng per day (greater than a million times less) is deemed to be innocuous 
from a health and safety perspective. Also, as boldione is currently prohibited by the World Anti-
Doping Agency (WADA) there is a risk of testing positive if an individual is a competitive athlete 
and is subject to anti-doping drug testing. For this reason competitive athletes are excluded from 
participating in this study. Also, those recruited to take part in this should not take part in any 
competitive athletic events that are subject to WADA regulations. 
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5. Will my taking part in the study be kept confidential? 
Should you choose to participate, your confidentiality will be assured in a number of ways. 
These include data encryption, secure file storage, and destruction of data after the valid period 
of use. 
 
This study has received ethical approval from LJMU’s Research Ethics Committee 
(14/SPS/013 – 23/4/2013) 
 
If you have any concerns regarding the research please contact the research or research 
supervisor: 
 
Contact Details of Researcher  
Kai Quin Chan 
k.q.chan@2013.ljmu.ac.uk 
 
Contact Details of Academic Supervisor  












































Appendix E: Consent form 
 
 
Project title: The effects of 12 Weeks Eurycoma longifolia (Tongkat Ali) ingestion on exercise 
performance, health and wellbeing 
Investigator : Kai Quin CHAN 
Supervisor : Dr Neil Chester 
School of Sport and Exercise Sciences, Faculty of Science 
 
Please initial the appropriate response for each of the following statements before 
signing the form:  
           
                                               Yes No 
1. I confirm that I have read and understand the information provided for the above 
study. I have had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without my medical care and my legal rights being affected.  
 
3. I understand that any personal information collected during the study will be 
anonymised and remain confidential 
 
4. I agree to take part in the above study (Ingestion of Eurycoma longifolia   
supplement or placebo and perform strength training programme) 
i.  
5. I understand that my results will be coded, stored and will not be possible to trace 
them back to me by individuals not associated with the project 
 
6. I consent to blood samples being collected and stored for biochemical analysis 
 
 
7. I understand that the blood samples are to be considered a gift as such, once 
the samples are analysed they will be destroyed. 
 
I, .......................................................................................... agree to take part in the above 
named project/procedure, the details of which have been fully explained to me and described 
in writing.  
 
Signed  ............................................ Date........................................... (Participant)  
 
I, .......................................................................................... certify that the details of this 
project/procedure have been fully explained and described in writing to the subject named 
above and have been understood by him/her.  
 
Signed ............................................ Date........................................... (Investigator)  
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I, .......................................................................................... certify that the details of this 
project/procedure have been fully explained and described in writing to the subject named 
above and have been understood by him/her.  
Signed ............................................ Date........................................... (Witness)  
 
Appendix F: Physical activity readiness questionnaire (PAR-Q) 
 
Physical Activity Readiness Questionnaire (PAR-Q) 
 
Title of Project: The effects of 12 Weeks Eurycoma longifolia (Tongkat Ali) ingestion on 
exercise performance, health and wellbeing. 
 
Name of Researcher (Student): Kai Quin Chan 
Academic Supervisors: Dr Neil Chester and Professor Claire Stewart 
School: Sport and Exercise Sciences, Faculty of Science 
Contact details : k.q.chan@2013.ljmu.ac.uk 
 
Many exercise performance assessment are associated with physical activity and completion of 
Physical Activity Readiness Questionnaire (PAR-Q) is important before participating in a 
physical activity laboratory testing. For most people physical activity should not pose any 
problem or hazard and the PAR-Q is designed to identify the small number of adults for whom 
physical activity might be inappropriate or those who should seek further advice from a doctor 
before participating in any exercise performance laboratory testing.  
  
Please read carefully and answer each one honestly. You are required to 
check YES or NO. 
YES NO 
1. Has your doctor ever said that you have a heart condition OR high/low 
blood pressure 
  
2. Do you feel pain in your chest at rest, during your daily activities of living, 
OR when you do physical activity? 
  
3. Do you lose balance because of dizziness OR have you lost consciousness 
in the last 12 months? Please answer NO if your dizziness was associated 
with over-breathing (including during vigorous exercise). 
  
4. Do you have an artificial pacemaker implanted under your skin of your 
chest (below your collar bone) to help you heart muscle to pump blood 
regularly? 
  
5. Is there any history of Coronary Heart Disease in your family?   
6. Have you ever been diagnosed with another chronic medical condition 
(other than heart disease or high blood pressure)? 
  
7 Do you have Diabetes Mellitus or any other metabolic disease (liver 
disease, kidney diseases)? 
  
8. Has your doctor ever said you have raised cholesterol (serum level above 
6.2mmol/L)? 
  
9. Do you have sleep apnoea? (A type of sleep disorder characterized by 
pauses in breathing or instances of shallow or infrequent breathing during 
sleep). 
  
10. Have you been on medication for low testosterone (hypogonadism)?   
11. Are you currently taking prescribed drugs or medications for a chronic 
medical condition? 
  
12. Do you have a bone or joint problem that could be made worse by 
becoming more physically active? Please answer NO if you had a joint 
problem in the past, but it does not limit your current ability to be 
physically active. For example, knee, back, ankle, or hip. 
  






If you answered: 
 
YES to one or more questions: 
You should consult with your doctor to clarify that it is safe for you to participate in this research 
project at this current time and in in your current state of health. Inform your doctor what questions 
you answered YES to on PAR-Q or present your PAR-Q copy. 
 
No to all questions: 
If you answered PAR-Q accurately, you have reasonable assurance of your present suitability for 
the research project. 
 
I have read, understood and accurately completed this questionnaire. I confirm that I am 
voluntarily engaging in an acceptable level of physical activity. Any questions I had were 

































14. Have you ever suffered from unusual shortness of breath at rest or with 
mild exertion? 
  
15. Do you currently drink more than the recommended safe limit of alcohol 
per week (21 units; 1 unit = ½ pint of beer/cider/lager or 1 small glass of 
wine). 
  
16. Do you currently smoke?   
17 Do you know of any other reason why you should not participate in a 









Appendix G: The control of substances hazardous to health (COSHH) risk assessment form – 





























































































Appendix L: Presentation and abstracts 
 
Chan, K.Q., Stewart, C.S., Yusof, A., Hanim, S., and Chester, N. (2015). Effects of Eurycoma 
longifolia, a natural testosterone booster, on muscular force production and anaerobic power. Day 
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longifolia; a herbal supplement that interferes with testosterone negative feedback loop. In 










Appendix M: Project photos 
 
 
30 seconds Wingate Anaerobic test 
 
 













Cell culture project 
 
 
Preparation of E. 










Performing a venipuncture using a butterfly needle to collect blood sample 
